FRED HUTCHINSON CANCER CENTER
Cite this
Plain text FRED HUTCHINSON CANCER CENTER. furp.org, nonprofit organization profile, tax years 2009–2024. https://furp.org/org/fred-hutchinson-cancer-center-911935159. Retrieved 2026-11-03.
APA furp.org. (n.d.). FRED HUTCHINSON CANCER CENTER [Nonprofit organization profile; tax years 2009–2024]. Retrieved November 3, 2026, from https://furp.org/org/fred-hutchinson-cancer-center-911935159
MLA “FRED HUTCHINSON CANCER CENTER.” furp.org, tax years 2009–2024, https://furp.org/org/fred-hutchinson-cancer-center-911935159. Accessed 3 Nov. 2026.
Retrieved 2026-11-03; covers tax years 2009–2024. Data: furp.org, CC BY 4.0.
2024 · Form 990 · revenue $2.53B · expenses $2.41B · assets $3.60B
- Also known as
- Fred Hutch Cancer Center
- EIN
- 91-1935159
- Address
- 1100 FAIRVIEW AVE N, SEATTLE, WA 98109-4433
- Website
- HTTPS://WWW.FREDHUTCH.ORG
- NTEE code
- E240
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (corporation)
- Ruling date
- August 2000 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Hospital or medical research organization
- Cross-check
- ProPublica Nonprofit Explorer
Mission
FRED HUTCH CANCER CENTER ("FRED HUTCH") UNITES INNOVATIVE RESEARCH AND COMPASSIONATE CARE TO PREVENT AND ELIMINATE CANCER AND INFECTIOUS DISEASE. CONTINUED ON SCHEDULE O
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
99 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| Nancy Davidson Md | EVP, Clinical Affairs | 2016-2024 | $1,424,165 | $9,194,387 | 1 |
| Thomas J Lynch Md | President & Director | 2021-2024 | $2,598,413 | $6,953,646 | 1 |
| NICOLE C ROBINSON PhD | VP & Chief Operating Officer | 2015-2024 | $1,755,535 | $4,108,362 | 2 |
| Stephanie Mays | Former Officer | 2017-2024 | $532,884 | $3,805,593 | 1 |
| David Browdy | VP & Chief Financial Officer | 2021-2024 | $1,357,937 | $3,614,134 | 3 |
| Tom Purcell Md | VP & Chief Medical Officer | 2021-2024 | $1,304,414 | $3,603,428 | 1 |
| Michelle Hall | Former Key Employee | 2010-2024 | $317,842 | $3,519,464 | 1 |
| Bruce E Clurman Md Phd | EVP, Chief Sci. Officer & Deputy Director | 2016-2024 | $1,180,892 | $3,193,179 | 2 |
| Eric C Holland Md Phd | SVP & Director, Human Biology | 2022-2024 | $1,009,846 | $2,809,062 | 2 |
| Steven Haydon | Former Officer | 2021-2024 | $1,059,753 | $2,687,657 | 2 |
| Frederick Appelbaum Md | Executive Vice President | 2022-2024 | $958,897 | $2,681,565 | 2 |
| Timothy Ehling | Former Key Employee | 2015-2024 | $324,647 | $2,656,254 | 1 |
| Sara Hurvitz Md | SVP & Director, Clinical Research | 2023-2024 | $1,468,766 | $2,584,710 | 1 |
| Chad Hoggard | Former Key Employee | 2016-2024 | $268,483 | $2,565,814 | 1 |
| Kelly O'Brien | VP & Chief Philanthropy Officer | 2022-2024 | $934,006 | $2,325,973 | 2 |
| Brittany Mccreery Md | Former Key Employee | 2018-2024 | $485,712 | $2,255,585 | 1 |
| Nicki Nguyen-Colvin | Former Key Employee | 2018-2024 | $352,035 | $2,204,647 | 1 |
| Paul Helmuth | Former Key Employee | 2016-2024 | $286,638 | $2,135,276 | 1 |
| Gansuvd Balgansuren | Former Key Employee | 2015-2024 | $293,111 | $2,105,457 | 1 |
| Richard Lafrance | Former Key Employee | 2019-2024 | $400,565 | $2,040,341 | 1 |
| Matthew Mcsweyn | Former Key Employee | 2015-2024 | $269,924 | $1,947,170 | 1 |
| Geoffrey Hill Md | SVP & Director, Translational Sci | 2023-2024 | $916,834 | $1,772,528 | 1 |
| Jodi Burke | VP, Human Resources | 2023-2024 | $758,188 | $1,531,876 | 1 |
| Daniel Markus | Former Key Employee | 2021-2024 | $320,671 | $1,186,195 | 1 |
| Gerianne Sands | Corporate Secretary, VP & General Counsel | 2023-2024 | $642,019 | $1,070,741 | 1 |
| Chris Bundesmann | Corporate Controller | 2022-2024 | $371,001 | $1,068,067 | 3 |
| Herbert L Bone Iii | Corporate Treasurer | 2022-2024 | $342,109 | $990,197 | 2 |
| Nida Shekhani | VP & Chief Strategy Officer | 2024 | $965,527 | $965,527 | 1 |
| Andrew Jackson | Former Key Employee | 2021-2024 | $198,934 | $846,906 | 1 |
| Cindy Gist Mha | Former Key Employee | 2023-2024 | $396,331 | $838,707 | 1 |
| Warren T Phipps MD | Associate Professor | 2024 | $804,526 | $804,526 | 1 |
| Denene Prophet-Williams MBA MLA BSN | VP & Chief Nursing Officer - Beg 4/1/24 | 2024 | $530,352 | $530,352 | 1 |
| Norman Hubbard (former) | EXECUTIVE VP (THRU 4/19) | 2009-2019 | $758,677 | $8,199,812 | 3 |
| Deborah Gentzen (former) | VP, CHIEF STRATEGY OFC (THRU 5/20) | 2009-2020 | $1,047,469 | $6,067,715 | 1 |
| F Marc Stewart Md (former) | SVP, MEDICAL DIRECTOR (THRU 7/20) | 2009-2020 | $204,570 | $4,755,294 | 3 |
| Jonathan Tingstad (former) | VP & CFO (THRU 10/17) | 2009-2017 | $689,803 | $4,590,118 | 2 |
| Aaron Crane (former) | FORMER OFF/CHIEF CLINICAL OP | 2017-2022 | $1,590,986 | $4,509,468 | 1 |
| David Ackerson (former) | VP, CIO (THRU 7/19) | 2009-2019 | $438,723 | $4,332,584 | 1 |
| Barbara Jagels (former) | VP, CQV OFFICER THRU 01/21 | 2011-2021 | $260,256 | $3,985,914 | 1 |
| Theresa Mcdonnell Dnp (former) | VP & CHIEF NURSING OFFICER(THRU 9/23) | 2017-2023 | $671,676 | $3,627,541 | 1 |
| Gretchen Hanna (former) | DIR. CORPORATE FINANCE | 2011-2021 | $351,539 | $3,149,796 | 1 |
| Moreen Dudley (former) | VP, CHIEF PEOPLE OFFICER | 2010-2021 | $371,814 | $2,900,417 | 1 |
| Joseph Norton (former) | DIR. FINANCE (THRU 8/19) | 2009-2019 | $208,923 | $2,793,698 | 1 |
| Kristine Logan (former) | DIR. OPERATIONS | 2009-2020 | $295,238 | $2,692,667 | 1 |
| Kelly Patrick (former) | VP & CIO | 2019-2023 | $818,500 | $2,531,767 | 2 |
| Cheryl Wyman (former) | FORMER DIR. DIAG/THERAPY SVCS | 2009-2017 | $136,037 | $2,156,491 | 1 |
| Alphonso Emery (former) | DIR. REVENUE CYCLE MGT. (THRU 8/19) | 2010-2019 | $286,502 | $2,105,451 | 1 |
| Tami Deeb (former) | FORMER KEY EMPLOYEE | 2016-2023 | $228,294 | $2,077,345 | 1 |
| Madeline Buelt (former) | VP OPERATIONS/CHIEF NURSE | 2009-2013 | $396,604 | $2,015,075 | 2 |
| Fred Appelbaum Md (former) | EXECUTIVE DIRECTOR AND PRESIDENT | 2009-2015 | $328,857 | $2,010,206 | 2 |
| Traci Pranzini (former) | FORMER KEY EMPLOYEE | 2014-2021 | $146,485 | $1,740,737 | 1 |
| Ada Mohedano (former) | DIR. CLIN. ANALYTICS & BUS INTEL | 2015-2021 | $295,950 | $1,707,666 | 1 |
| Steven Huebner (former) | FORMER OFF/CFO | 2019-2022 | $340,470 | $1,679,813 | 1 |
| Aleana Waite (former) | DIR. RES INTEG/IMMUNO/CELL THERAPY | 2009-2015 | $240,244 | $1,547,191 | 1 |
| Carilla Wallin (former) | FORMER KEY EMPLOYEE | 2019-2023 | $266,059 | $1,225,035 | 1 |
| Zakaria Ramadan-Jradi (former) | DIR. CELL THERAP & CLIN LABS | 2010-2014 | $234,135 | $1,150,148 | 1 |
| Holly Rosenfeld (former) | DIR. MARKETING (THRU 2/20) | 2015-2019 | $250,898 | $1,111,954 | 1 |
| Shari Mcclure (former) | DIR. STRATEGY & BUS DEV (THRU 2/17) | 2011-2016 | $212,785 | $1,088,754 | 1 |
| Angelique Richard (former) | CHIEF NURSE EXEC. & VP (THRU 9/2/16) | 2014-2016 | $402,496 | $1,082,778 | 1 |
| Donna Kern (former) | REGISTERED NURSE | 2015-2019 | $226,930 | $1,050,668 | 1 |
| Susan Hammond (former) | DIR. PROGRAM MANAGEMENT | 2011-2015 | $224,064 | $1,035,782 | 1 |
| Camille Rapacz (former) | DIR. CPI (THRU 1/6/17) | 2012-2016 | $209,086 | $965,903 | 1 |
| Linda Lake (former) | DIR. CLIN INFO SYST & HIM | 2011-2015 | $210,551 | $963,982 | 1 |
| Deborah Stenhjem (former) | DIR. REV CYCLE MGMT | 2009-2015 | $179,201 | $936,595 | 1 |
| Margaret Owens (former) | CTP QUALITY SENIOR MANAGER | 2010-2014 | $187,761 | $915,884 | 1 |
| Cindy Gist (former) | FORMER KE/VP, PATIENT SVCS | 2020-2022 | $334,702 | $838,978 | 1 |
| Laura Esagui (former) | DOSIMETRIST III | 2019-2021 | $277,834 | $761,934 | 1 |
| Cecilia Zapata (former) | DIR. STRAT OUTREACH/CCA NETWORK | 2013-2016 | $206,325 | $723,242 | 1 |
| Scott Derouen (former) | DIR. ENTERPRISE PROJ MGT. | 2019-2021 | $245,672 | $705,316 | 1 |
| Fred Applebaum Md (former) | FORMER EXEC. DIR. & PRESIDENT | 2016-2017 | $162,147 | $684,573 | 1 |
| Steve Stadum (former) | EXEC VP & COOO | 2016-2022 | $673,237 | $673,237 | 2 |
| Theresa Mcdonell (former) | VP & CHIEF NURSING OFFICER | 2022 | $659,114 | $659,114 | 1 |
| Lori Bare (former) | ASSC DIR CLINICAL INFO SYSTEMS | 2015-2020 | $230,479 | $644,818 | 1 |
| Katie Colleen Ann Maletich (former) | DIR. QUALITY & SAFETY (THRU 1/20) | 2017-2019 | $227,946 | $639,437 | 1 |
| Claire Beck-Keeler (former) | DIRECTOR OF MARKETING | 2012-2014 | $238,034 | $578,258 | 1 |
| Tracy Wong (former) | FORMER KEY EMPLOYEE | 2018-2021 | $129,669 | $578,107 | 1 |
| Steven Johnson (former) | DIR. RESEARCH INTEGR. (THRU 10/20) | 2019-2020 | $301,665 | $560,912 | 1 |
| Marian Richardson (former) | ASSC DIR. CLINICAL OPS | 2016-2018 | $191,031 | $548,993 | 1 |
| Shannon Fernandez (former) | DIR. FINANCE OPS & REV CYCLE | 2020-2021 | $297,139 | $540,899 | 1 |
| Maria Gonzalez (former) | DIR. RESEARCH INT. (THRU 1/18) | 2016-2017 | $273,921 | $461,641 | 1 |
| Matthew Palmgren (former) | DIR. DIGITAL HEALTH (THRU 1/20) | 2018-2019 | $226,639 | $430,399 | 1 |
| Brandon Jones (former) | CHIEF TECHNOLOGY OFFICER | 2016-2017 | $209,151 | $417,539 | 1 |
| Avril Mcdowell (former) | DIR. CLINICAL OPS (THRU 7/17) | 2016-2017 | $210,302 | $416,710 | 1 |
| Ariam Zeresennai (former) | REGISTERED NURSE | 2016-2017 | $204,131 | $397,518 | 1 |
| Lisa Acomb (former) | DIR. BUS INTEL & ANALYTICS | 2019-2020 | $197,120 | $394,095 | 1 |
| Jan Watterson (former) | CONTROLLER | 2009-2010 | $176,129 | $347,216 | 1 |
| Karen Holloway (former) | RADIATION ONCOLOGY MGR | 2013-2014 | $156,671 | $320,474 | 1 |
| Anna Andrews (former) | INTERIM PROTON CTR TRANS LEAD | 2021 | $306,278 | $306,278 | 1 |
| Suni Elgar (former) | ASSC CHIEF NURSE | 2021 | $240,309 | $240,309 | 1 |
| Thomas Tsai Dir Clinical Ops (former) | DIAG/THERAPY SVCS (THRU 1/18) | 2017 | $227,910 | $227,910 | 1 |
| Maxine Ellis (former) | DIRECTOR DEI COACHING & CULTURE | 2021 | $225,833 | $225,833 | 1 |
| Madeline Grant (former) | DIR. PAYER CONTRACTING/STRATEGY | 2018 | $210,737 | $210,737 | 1 |
| Angela Rodriguez (former) | ASSC DIR CLINICAL OPS | 2020 | $209,710 | $209,710 | 1 |
| Roger Jansson (former) | ASSC GENERAL COUNSEL (THRU 09/18) | 2018 | $207,018 | $207,018 | 1 |
| Donna Lenderman (former) | REGISTERED NURSE | 2013 | $199,885 | $199,885 | 1 |
| Ann Raish (former) | DTR DIAG. & THERAPY | 2009 | $196,673 | $196,673 | 1 |
| Cecilia Zapata Dir Strat (former) | OUTREACH/CCA NETWORK (THRU 8/17) | 2017 | $182,596 | $182,596 | 1 |
| Debra Kirkley (former) | DIR. MAGNET PROGRAM (THRU 7/17) | 2017 | $172,071 | $172,071 | 1 |
| Marcie Headen (former) | SYSTEMS EDUCATOR (THRU 7/17/17) | 2016 | $158,160 | $158,160 | 1 |
Officers and directors, no compensation reported
66 people listed on the returns with $0 (or no amount) in every compensation column: current people first. Hours are as filed on the latest return each person appears on.
| Name | Latest title | Years | Hrs/wk (latest) | Compensation | Organizations |
|---|---|---|---|---|---|
| Leigh Morgan | Chair | 2021-2024 | 4 | $0 reported | 3 |
| Richard Anderson | Vice-Chair | 2023-2024 | 4 | $0 reported | 2 |
| Sean Boyle | Director | 2021-2024 | 2 | $0 reported | 2 |
| Julie Nordstrom | Secretary | 2021-2024 | 4 | $0 reported | 1 |
| Bradley Simmons | Director | 2023-2024 | 2 | $0 reported | 2 |
| Cheryl M Scott | Director | 2023-2024 | 2 | $0 reported | 1 |
| Joanne Harrell | Director | 2021-2024 | 2 | $0 reported | 1 |
| Kathy Surace-Smith | Director | 2021-2024 | 2 | $0 reported | 7 |
| Pete Shimer | Treasurer | 2023-2024 | 4 | $0 reported | 12 |
| Stephen Graham | Director | 2021-2024 | 2 | $0 reported | 5 |
| Timothy Dellit Md | Director | 2022-2024 | 2 | $0 reported | 4 |
| Eduardao Penalver | Director | 2022-2024 | 2 | $0 reported | 1 |
| James Lico | Director - Beg 6/18/25 | 2024 | 2 | $0 reported | 1 |
| Jeff Yurcisin | DIRECTOR - Beg 1/29/25 | 2024 | 2 | $0 reported | 1 |
| Michelle Seitz | Director | 2024 | 2 | $0 reported | 2 |
| Eduardo Penalver (former) | DIRECTOR | 2021-2023 | 2 | $0 reported | 6 |
| Kristianne Blake (former) | TREASURER | 2021-2023 | 4 | $0 reported | 1 |
| Cynthia Dold (former) | DIRECTOR(THRU 8/23) | 2022-2023 | 2 | $0 reported | 3 |
| Lisa Brandenburg (former) | EX-OFFICIO DIRECTOR (THRU 9/22) | 2011-2022 | 2 | $0 reported | 9 |
| Jeremy Jaech (former) | DIRECTOR (THRU 03/23) | 2021-2022 | 2 | $0 reported | 1 |
| Suzanne Beitel (former) | DIRECTOR THRU 03/22 | 2018-2021 | 1 | $0 reported | 5 |
| Christopher Bundesmann (former) | CORPORATE CONTROLLER | 2021 | 55 | $0 reported | 2 |
| Stewart Landefeld (former) | VICE CHAIR THRU 03/22 | 2017-2021 | 2 | $0 reported | 5 |
| Ruth Mahan (former) | DIRECTOR THRU 03/22 | 2009-2021 | 5 | $0 reported | 3 |
| Paul Ramsey Md (former) | EX OFFICIO DIRECTOR 04/22 | 2009-2021 | 2 | $0 reported | 4 |
| Paula Reynolds (former) | CHAIR THRU 03/22 | 2018-2021 | 2 | $0 reported | 2 |
| Mike Delman (former) | TREASURER THRU 03/22 | 2012-2021 | 2 | $0 reported | 1 |
| Kimberly Mcnally (former) | SECRETARY THRU 03/22 | 2011-2021 | 5 | $0 reported | 2 |
| Karen Glover (former) | IMM. PAST CHAIR THRU 03/22 | 2015-2021 | 3 | $0 reported | 2 |
| Gerald Grinstein (former) | DIRECTOR THRU 03/22 | 2015-2021 | 1 | $0 reported | 3 |
| Linda Mattox (former) | DIRECTOR THRU 03/22 | 2011-2021 | 0 | $0 reported | 1 |
| Richard Mccune (former) | DIRECTOR THRU 03/22 | 2015-2021 | 2 | $0 reported | 2 |
| Jeff Nitta (former) | DIRECTOR THRU 03/22 | 2019-2021 | 5 | $0 reported | 4 |
| Bruce Pym (former) | DIRECTOR THRU 03/22 | 2017-2021 | 2 | $0 reported | 1 |
| Russ Williams (former) | DIRECTOR THRU 03/22 | 2019-2021 | 2 | $0 reported | 1 |
| Alvin Winterroth (former) | DIRECTOR THRU 03/22 | 2017-2021 | 2 | $0 reported | 3 |
| Herbert Bone (former) | CORPORATE TREASURER | 2021 | 55 | $0 reported | 1 |
| Dr Thomas Lynch Jr (former) | DIRECTOR | 2019-2020 | 2 | $0 reported | 3 |
| Dr Sandy Melzer (former) | DIRECTOR (THRU 9/19) | 2016-2019 | 1 | $0 reported | 2 |
| Jacqueline Cabe (former) | DIRECTOR (THRU 11/18) | 2015-2018 | 1 | $0 reported | 5 |
| Robb Bakemeier (former) | DIRECTOR | 2009-2018 | 4 | $0 reported | 4 |
| Richard Yarmuth (former) | DIRECTOR | 2013-2018 | 3 | $0 reported | 1 |
| Carl Behnke (former) | IMMEDIATE PAST CHAIR | 2009-2017 | 2 | $0 reported | 11 |
| Deborah Haug (former) | DIRECTOR (THRU 2/18) | 2017 | 0 | $0 reported | 3 |
| Bruder Stapleton (former) | DIRECTOR | 2009-2017 | 1 | $0 reported | 3 |
| Brooks Ragen (former) | DIRECTOR (THRU 3/18) | 2009-2017 | 1 | $0 reported | 3 |
| Joann Taricani (former) | DIRECTOR | 2014-2016 | 1 | $0 reported | 2 |
| Bob Flowers (former) | DIRECTOR | 2014-2016 | 2 | $0 reported | 8 |
| Mark Groudine (former) | DIRECTOR (THRU 10/31/16) | 2009-2016 | 1 | $0 reported | 3 |
| Terry Mcdonnell (former) | CHIEF NURSE EXEC. & VP (FROM 01/17) | 2016 | 55 | $0 reported | 1 |
| Johnese Spisso (former) | DIRECTOR THRU 2/5/16 | 2009-2015 | 2 | $0 reported | 7 |
| Myra Tanita (former) | DIRECTOR THRU 12/11/15 | 2009-2015 | 2 | $0 reported | 2 |
| Rich Mccune (former) | VICE CHAIR | 2011-2014 | 2 | $0 reported | 1 |
| Kimberly Mcnally Mn Rn (former) | SECRETARY | 2012-2014 | 2 | $0 reported | 1 |
| Kari Glover (former) | DIRECTOR | 2014 | 1 | $0 reported | 1 |
| Shan Mullin (former) | DIRECTOR | 2009-2014 | 2 | $0 reported | 2 |
| Jonelle Johnson (former) | DIRECTOR | 2009-2013 | 2 | $0 reported | 2 |
| Rich Jones (former) | DIRECTOR | 2009-2013 | 3 | $0 reported | 2 |
| Rob Macaulay (former) | DIRECTOR | 2011-2013 | 3 | $0 reported | 1 |
| Bob Gerth (former) | TREASURER | 2009-2012 | 5 | $0 reported | 2 |
| Pat Hagan (former) | DIRECTOR THRU 1/31/12 | 2010-2011 | 1 | $0 reported | 2 |
| Kathy Randall (former) | DIRECTOR | 2009-2011 | 2 | $0 reported | 2 |
| Sue Albrecht (former) | DIRECTOR | 2009-2010 | 1 | $0 reported | 2 |
| Thomas Hansen Md (former) | MEMBER | 2009 | 2 | $0 reported | 4 |
| Pat Hagen (former) | DIRECTOR | 2009 | 2 | $0 reported | 1 |
| Lee Hartwell (former) | MEMBER | 2009 | 2 | $0 reported | 1 |
People by year
2024 · 47 people listed · 32 paid, $24.8M · 7,088 employees · 719 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| THOMAS J LYNCH MD | President & Director | 55 | $2,232,376 | $0 | $366,037 | $2,598,413 | 1 |
| NICOLE C ROBINSON PhD | VP & Chief Operating Officer | 55 | $1,587,507 | $0 | $168,028 | $1,755,535 | 2 |
| SARA HURVITZ MD | SVP & Director, Clinical Research | 55 | $1,271,572 | $0 | $197,194 | $1,468,766 | 1 |
| NANCY DAVIDSON MD | EVP, Clinical Affairs | 55 | $1,250,784 | $0 | $173,381 | $1,424,165 | 1 |
| DAVID BROWDY | VP & Chief Financial Officer | 54 | $1,186,790 | $0 | $171,147 | $1,357,937 | 3 |
| TOM PURCELL MD | VP & Chief Medical Officer | 55 | $1,150,671 | $0 | $153,743 | $1,304,414 | 1 |
| BRUCE E CLURMAN MD PHD | EVP, Chief Sci. Officer & Deputy Director | 55 | $1,019,199 | $0 | $161,693 | $1,180,892 | 2 |
| STEVEN HAYDON | Former Officer | 55 | $1,045,174 | $0 | $14,579 | $1,059,753 | 2 |
| ERIC C HOLLAND MD PHD | SVP & Director, Human Biology | 55 | $860,361 | $0 | $149,485 | $1,009,846 | 2 |
| Nida Shekhani | VP & Chief Strategy Officer | 55 | $805,373 | $0 | $160,154 | $965,527 | 1 |
| FREDERICK APPELBAUM MD | Executive Vice President | 55 | $811,307 | $0 | $147,590 | $958,897 | 2 |
| KELLY O'BRIEN | VP & Chief Philanthropy Officer | 55 | $786,916 | $0 | $147,090 | $934,006 | 2 |
| GEOFFREY HILL MD | SVP & Director, Translational Sci | 55 | $772,025 | $0 | $144,809 | $916,834 | 1 |
| Warren T Phipps MD | Associate Professor | 54 | $692,880 | $0 | $111,646 | $804,526 | 1 |
| JODI BURKE | VP, Human Resources | 55 | $615,767 | $0 | $142,421 | $758,188 | 1 |
| GERIANNE SANDS | Corporate Secretary, VP & General Counsel | 55 | $539,962 | $0 | $102,057 | $642,019 | 1 |
| STEPHANIE MAYS | Former Officer | 55 | $463,223 | $0 | $69,661 | $532,884 | 1 |
| Denene Prophet-Williams MBA MLA BSN | VP & Chief Nursing Officer - Beg 4/1/24 | 55 | $471,417 | $0 | $58,935 | $530,352 | 1 |
| BRITTANY MCCREERY MD | Former Key Employee | 55 | $373,473 | $0 | $112,239 | $485,712 | 1 |
| RICHARD LAFRANCE | Former Key Employee | 55 | $328,414 | $0 | $72,151 | $400,565 | 1 |
| CINDY GIST MHA | Former Key Employee | 55 | $312,580 | $0 | $83,751 | $396,331 | 1 |
| CHRIS BUNDESMANN | Corporate Controller | 54 | $317,546 | $0 | $53,455 | $371,001 | 3 |
| NICKI NGUYEN-COLVIN | Former Key Employee | 55 | $291,603 | $0 | $60,432 | $352,035 | 1 |
| HERBERT L BONE III | Corporate Treasurer | 55 | $284,408 | $0 | $57,701 | $342,109 | 2 |
| TIMOTHY EHLING | Former Key Employee | 55 | $262,659 | $0 | $61,988 | $324,647 | 1 |
| DANIEL MARKUS | Former Key Employee | 55 | $284,932 | $0 | $35,739 | $320,671 | 1 |
| MICHELLE HALL | Former Key Employee | 55 | $265,346 | $0 | $52,496 | $317,842 | 1 |
| GANSUVD BALGANSUREN | Former Key Employee | 55 | $243,187 | $0 | $49,924 | $293,111 | 1 |
| PAUL HELMUTH | Former Key Employee | 55 | $251,338 | $0 | $35,300 | $286,638 | 1 |
| MATTHEW MCSWEYN | Former Key Employee | 55 | $224,380 | $0 | $45,544 | $269,924 | 1 |
| CHAD HOGGARD | Former Key Employee | 55 | $238,527 | $0 | $29,956 | $268,483 | 1 |
| ANDREW JACKSON | Former Key Employee | 55 | $165,723 | $0 | $33,211 | $198,934 | 1 |
| Julie Nordstrom | Secretary | 4 | $0 | $0 | $0 | $0 | 1 |
| Leigh Morgan | Chair | 4 | $0 | $0 | $0 | $0 | 3 |
| Pete Shimer | Treasurer | 4 | $0 | $0 | $0 | $0 | 12 |
| Richard Anderson | Vice-Chair | 4 | $0 | $0 | $0 | $0 | 2 |
| Bradley Simmons | Director | 2 | $0 | $0 | $0 | $0 | 2 |
| Cheryl M Scott | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Eduardao Penalver | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| JAMES LICO | Director - Beg 6/18/25 | 2 | $0 | $0 | $0 | $0 | 1 |
| JEFF YURCISIN | DIRECTOR - Beg 1/29/25 | 2 | $0 | $0 | $0 | $0 | 1 |
| Joanne Harrell | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Kathy Surace-Smith | Director | 2 | $0 | $0 | $0 | $0 | 7 |
| MICHELLE SEITZ | Director | 2 | $0 | $0 | $0 | $0 | 2 |
| Sean Boyle | Director | 2 | $0 | $0 | $0 | $0 | 2 |
| Stephen Graham | Director | 2 | $0 | $0 | $0 | $0 | 5 |
| Timothy H Dellit MD | Director | 2 | $0 | $0 | $0 | $0 | 4 |
2023 · 47 people listed · 33 paid, $22.2M · 6,797 employees · 614 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| THOMAS J LYNCH MD | PRESIDENT & DIRECTOR | 55 | $2,028,077 | $0 | $364,136 | $2,392,213 | 1 |
| NANCY DAVIDSON MD | EVP, CLINICAL AFFAIRS | 55 | $1,198,547 | $0 | $159,901 | $1,358,448 | 1 |
| NICOLE C ROBINSON PHD | VP & COO | 55 | $1,153,027 | $0 | $162,054 | $1,315,081 | 2 |
| DAVID BROWDY | VP & CFO | 54 | $1,115,822 | $0 | $171,675 | $1,287,497 | 3 |
| SARA HURVITZ MD | SVP & DIRECTOR, CLINICAL RESEARCH | 55 | $1,057,788 | $0 | $58,156 | $1,115,944 | 1 |
| BRUCE E CLURMAN MD PHD | EVP, CHIEF SCI. OFFICER & DEPUTY DIRECTOR | 55 | $961,057 | $0 | $147,503 | $1,108,560 | 2 |
| ERIC C HOLLAND MD PHD | SVP & DIRECTOR, HUMAN BIOLOGY | 55 | $803,616 | $0 | $144,143 | $947,759 | 2 |
| FREDERICK APPELBAUM MD | EXECUTIVE VICE PRESIDENT | 55 | $771,543 | $0 | $141,975 | $913,518 | 2 |
| STEVEN HAYDON | VP & GENERAL COUNSEL(THRU 2/24) | 55 | $812,745 | $0 | $73,528 | $886,273 | 2 |
| GEOFFREY HILL MD | SVP & DIRECTOR, TRANSLATIONAL SCI | 55 | $718,444 | $0 | $137,250 | $855,694 | 1 |
| KELLY PATRICK | VP & CIO | 55 | $761,873 | $0 | $56,627 | $818,500 | 2 |
| TOM PURCELL MD | VP & CHIEF MEDICAL OFFICER | 55 | $661,932 | $0 | $137,970 | $799,902 | 1 |
| JODI BURKE | VP, HUMAN RESOURCES | 55 | $640,821 | $0 | $132,867 | $773,688 | 1 |
| KELLY O'BRIEN | VP & CHIEF PHILANTHROPY OFFICER | 55 | $621,488 | $0 | $136,478 | $757,966 | 2 |
| THERESA MCDONNELL DNP | VP & CHIEF NURSING OFFICER(THRU 9/23) | 55 | $608,583 | $0 | $63,093 | $671,676 | 1 |
| STEPHANIE MAYS | FORMER OFFICER | 55 | $512,712 | $0 | $68,204 | $580,916 | 1 |
| CINDY GIST MHA | FORMER KEY EMPLOYEE | 55 | $354,803 | $0 | $87,573 | $442,376 | 1 |
| CHAD HOGGARD | FORMER KEY EMPLOYEE | 55 | $368,825 | $0 | $70,387 | $439,212 | 1 |
| GERIANNE SANDS | CORP SEC., VP&GEN. COUNSEL(BEG 2/24) | 55 | $365,941 | $0 | $62,781 | $428,722 | 1 |
| BRITTANY MCCREERY MD | FORMER KEY EMPLOYEE | 55 | $320,868 | $0 | $107,709 | $428,577 | 1 |
| NICKI NGUYEN-COLVIN | FORMER KEY EMPLOYEE | 55 | $327,282 | $0 | $64,843 | $392,125 | 1 |
| RICHARD LAFRANCE | FORMER KEY EMPLOYEE | 55 | $276,203 | $0 | $65,984 | $342,187 | 1 |
| CHRIS BUNDESMANN | CORPORATE CONTROLLER | 54 | $288,955 | $0 | $50,244 | $339,199 | 3 |
| HERBERT L BONE III | CORPORATE TREASURER | 55 | $258,649 | $0 | $57,304 | $315,953 | 2 |
| TIMOTHY EHLING | FORMER KEY EMPLOYEE | 55 | $252,017 | $0 | $60,849 | $312,866 | 1 |
| MICHELLE HALL | FORMER KEY EMPLOYEE | 55 | $258,875 | $0 | $52,093 | $310,968 | 1 |
| DANIEL MARKUS | FORMER KEY EMPLOYEE | 55 | $270,742 | $0 | $33,752 | $304,494 | 1 |
| GANSUVD BALGANSUREN | FORMER KEY EMPLOYEE | 55 | $233,728 | $0 | $49,429 | $283,157 | 1 |
| PAUL HELMUTH | FORMER KEY EMPLOYEE | 55 | $240,299 | $0 | $34,345 | $274,644 | 1 |
| MATTHEW MCSWEYN | FORMER KEY EMPLOYEE | 55 | $227,577 | $0 | $45,212 | $272,789 | 1 |
| CARILLA WALLIN | FORMER KEY EMPLOYEE | 55 | $216,323 | $0 | $49,736 | $266,059 | 1 |
| TAMI DEEB | FORMER KEY EMPLOYEE | 55 | $205,480 | $0 | $22,814 | $228,294 | 1 |
| ANDREW JACKSON | FORMER KEY EMPLOYEE | 55 | $163,218 | $0 | $31,001 | $194,219 | 1 |
| LEIGH MORGAN | CHAIR | 4 | $0 | $0 | $0 | $0 | 3 |
| RICHARD ANDERSON | VICE-CHAIR(FROM 1/24) | 4 | $0 | $0 | $0 | $0 | 2 |
| SEAN BOYLE | VICE-CHAIR(THRU 1/24), DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| KRISTIANNE BLAKE | TREASURER | 4 | $0 | $0 | $0 | $0 | 1 |
| JULIE NORDSTROM | SECRETARY | 4 | $0 | $0 | $0 | $0 | 1 |
| BRADLEY SIMMONS | DIRECTOR(FROM 8/23) | 2 | $0 | $0 | $0 | $0 | 2 |
| CHERYL M SCOTT | DIRECTOR (BEG 4/24) | 2 | $0 | $0 | $0 | $0 | 1 |
| CYNTHIA DOLD | DIRECTOR(THRU 8/23) | 2 | $0 | $0 | $0 | $0 | 3 |
| EDUARDO PENALVER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 6 |
| JOANNE HARRELL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KATHY SURACE-SMITH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 7 |
| PETE SHIMER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 12 |
| STEPHEN GRAHAM | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 5 |
| TIMOTHY H DELLIT MD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 4 |
2022 · 43 people listed · 31 paid, $19.5M · 6,568 employees · 965 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| THOMAS LYNCH | PRESIDENT & DIRECTOR | 55 | $1,877,400 | $0 | $85,620 | $1,963,020 | 1 |
| NANCY DAVIDSON MD | EVP CLINICAL AFFAIRS | 55 | $1,545,412 | $0 | $50,466 | $1,595,878 | 1 |
| AARON CRANE | FORMER OFF/CHIEF CLINICAL OP | 55 | $1,546,465 | $0 | $44,521 | $1,590,986 | 1 |
| NICOLE C ROBINSON | VP & DEPUTY COO | 55 | $960,946 | $0 | $76,800 | $1,037,746 | 2 |
| DAVID HARLAN BROWDY | VP & CHIEF FINANCIAL OFFICER | 55 | $902,580 | $0 | $66,120 | $968,700 | 3 |
| BRUCE E CLURMAN | EXEC VP & DEPUTY DIR, FHCC | 40 | $842,773 | $0 | $60,954 | $903,727 | 2 |
| TOM PURCELL | VP & CHIEF MEDICAL OFFICER | 55 | $825,503 | $0 | $59,288 | $884,791 | 1 |
| ERIC C HOLLAND | NE MDO STAFF | 40 | $775,665 | $0 | $75,792 | $851,457 | 2 |
| FREDERICK R APPELBAUM | EXEC VP & DEPUTY DIR, EXT AFFR | 40 | $749,598 | $0 | $59,552 | $809,150 | 2 |
| STEVEN HAYDON | VP, GENERAL COUNSEL | 55 | $661,179 | $0 | $80,452 | $741,631 | 2 |
| STEVE STADUM | EXEC VP & COOO | 20 | $592,831 | $0 | $80,406 | $673,237 | 2 |
| THERESA MCDONELL | VP & CHIEF NURSING OFFICER | 55 | $595,290 | $0 | $63,824 | $659,114 | 1 |
| KELLY PATRICK | FORMER OFF/VP | 55 | $603,285 | $0 | $52,191 | $655,476 | 2 |
| KELLY O'BRIEN | VP PHILANTHROPY | 55 | $573,513 | $0 | $60,488 | $634,001 | 2 |
| STEPHANIE MAYS | FORMER OFF/AVP & DEPUTY GEN. | 55 | $475,128 | $0 | $66,941 | $542,069 | 1 |
| BRITTANY MCCREERY | FORMER KE/VP | 55 | $330,621 | $0 | $56,206 | $386,827 | 1 |
| RICHARD LAFRANCE | FORMER KE/DIR. PHARMACY | 55 | $307,586 | $0 | $57,109 | $364,695 | 1 |
| CHRIS BUNDESMANN | CORPORATE CONTROLLER | 55 | $311,642 | $0 | $46,225 | $357,867 | 3 |
| CHAD HOGGARD | FORMER KE/CHIEF INFO SEC. OFF | 55 | $294,876 | $0 | $56,680 | $351,556 | 1 |
| STEVEN HUEBNER | FORMER OFF/CFO | 55 | $340,470 | $0 | $0 | $340,470 | 1 |
| NICKI NGUYEN-COLVIN | FORMER KE/DIR. STRATEGY | 55 | $281,392 | $0 | $53,337 | $334,729 | 1 |
| CINDY GIST | FORMER KE/VP, PATIENT SVCS | 55 | $286,843 | $0 | $47,859 | $334,702 | 1 |
| HERBERT L BONE III | CORPORATE TREASURER | 55 | $280,088 | $0 | $52,047 | $332,135 | 2 |
| DANIEL MARKUS | FORMER KE/DIR. SUPPLY CHAIN | 55 | $295,010 | $0 | $28,063 | $323,073 | 1 |
| TIMOTHY EHLING | FORMER KE/DIR. NURSING | 55 | $253,545 | $0 | $50,073 | $303,618 | 1 |
| MATTHEW MCSWEYN | FORMER KE/DIR. INFRA & OPS. | 55 | $250,600 | $0 | $43,190 | $293,790 | 1 |
| MICHELLE HALL | FORMER KE/DIR. IT OPS | 55 | $248,584 | $0 | $44,064 | $292,648 | 1 |
| PAUL HELMUTH | FORMER KE/DIR. CLIN BUS OPS | 55 | $241,622 | $0 | $31,470 | $273,092 | 1 |
| GANSUVD BALGANSUREN | FORMER KE/DIR. CI LABS | 55 | $224,007 | $0 | $41,634 | $265,641 | 1 |
| CARILLA WALLIN | FORMER KE/DIR. STRAT OUTREACH | 55 | $209,028 | $0 | $46,000 | $255,028 | 1 |
| ANDREW JACKSON | FORMER KE/ASSOC. DIR. ENTER. | 55 | $191,839 | $0 | $32,882 | $224,721 | 1 |
| KATHY SURACE-SMITH | CHAIR | 4 | $0 | $0 | $0 | $0 | 7 |
| LEIGH MORGAN | VICE CHAIR | 4 | $0 | $0 | $0 | $0 | 3 |
| SEAN BOYLE | TREASURER | 4 | $0 | $0 | $0 | $0 | 2 |
| JULIE NORDSTROM | SECRETARY | 2 | $0 | $0 | $0 | $0 | 1 |
| KRISTIANNE BLAKE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| STEPHEN GRAHAM | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 5 |
| JOANNE HARRELL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| CYNTHIA DOLD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| EDUARDAO PENALVER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TIMOTHY DELLIT | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 4 |
| JEREMY JAECH | DIRECTOR (THRU 03/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| LISA BRANDENBURG | EX-OFFICIO DIRECTOR (THRU 9/22) | 2 | $0 | $0 | $0 | $0 | 9 |
2021 · 65 people listed · 33 paid, $12.3M · 2,549 employees · 250 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| AARON CRANE | EXECUTIVE VICE PRESIDENT | 55 | $790,366 | $0 | $191,393 | $981,759 | 1 |
| NANCY DAVIDSON MD | EVP CLINICAL AFFAIRS, DIR EFF 4/22 | 37 | $861,197 | $0 | $43,744 | $904,941 | 1 |
| THERESA MCDONNELL | SVP, CHIEF NURSING OFFICER | 55 | $615,786 | $0 | $184,120 | $799,906 | 1 |
| STEVEN HUEBNER | VP, CHIEF FINANCIAL OFFICER | 55 | $652,598 | $0 | $0 | $652,598 | 1 |
| TOM PURCELL MD | CHIEF MEDICAL OFFICER | 55 | $608,783 | $0 | $5,538 | $614,321 | 1 |
| KELLY PATRICK | VP, CHIEF INFORMATION OFFICER | 55 | $497,929 | $0 | $80,713 | $578,642 | 2 |
| STEPHANIE MAYS | VP, CHIEF LEGAL OFFICER | 55 | $436,413 | $0 | $98,451 | $534,864 | 1 |
| TAMI DEEB | VP, CHIEF STRATEGY OFFICER | 55 | $399,220 | $0 | $77,557 | $476,777 | 1 |
| MOREEN DUDLEY | VP, CHIEF PEOPLE OFFICER | 55 | $317,320 | $0 | $54,494 | $371,814 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $296,607 | $0 | $54,932 | $351,539 | 1 |
| RICHARD LAFRANCE | DIR. PHARMACY | 55 | $257,844 | $0 | $65,184 | $323,028 | 1 |
| CHAD HOGGARD | CHIEF INFO SECURITY OFFICER | 55 | $250,640 | $0 | $58,639 | $309,279 | 1 |
| ANNA ANDREWS | INTERIM PROTON CTR TRANS LEAD | 55 | $306,278 | $0 | $0 | $306,278 | 1 |
| NICKI NGUYEN-COLVIN | DIR. STRATEGY & BUS DEV | 55 | $242,214 | $0 | $56,065 | $298,279 | 1 |
| TIMOTHY EHLING | DIR. NURSING & CLIN. OPS INTEG. | 55 | $239,583 | $0 | $58,408 | $297,991 | 1 |
| SHANNON FERNANDEZ | DIR. FINANCE OPS & REV CYCLE | 55 | $249,324 | $0 | $47,815 | $297,139 | 1 |
| ADA MOHEDANO | DIR. CLIN. ANALYTICS & BUS INTEL | 55 | $258,213 | $0 | $37,737 | $295,950 | 1 |
| MICHELLE HALL | DIR. IT OPERATIONS | 55 | $238,514 | $0 | $53,038 | $291,552 | 1 |
| CINDY GIST | VP, PATIENT SVCS & CLIN. LABS | 55 | $238,986 | $0 | $44,478 | $283,464 | 1 |
| BRITTANY MCCREERY | VP, CHIEF QUALITY & VALUE OFFICER | 55 | $231,847 | $0 | $46,776 | $278,623 | 1 |
| LAURA ESAGUI | DOSIMETRIST III | 55 | $227,006 | $0 | $50,828 | $277,834 | 1 |
| GANSUVD BALGANSUREN | DIRECTOR CI LABS | 55 | $213,773 | $0 | $46,826 | $260,599 | 1 |
| BARBARA JAGELS | VP, CQV OFFICER THRU 01/21 | 55 | $245,719 | $0 | $14,537 | $260,256 | 1 |
| MATTHEW MCSWEYN | DIR. INFRASTRUCTURE & OPS. | 55 | $207,040 | $0 | $51,125 | $258,165 | 1 |
| PAUL HELMUTH | DIR. CLIN BUS OPS, COMMUNITY SITES | 55 | $223,272 | $0 | $33,164 | $256,436 | 1 |
| CARILLA WALLIN | DIR. STRAT OUTREACH/CCA NETWORK | 55 | $202,614 | $0 | $51,974 | $254,588 | 1 |
| SCOTT DEROUEN | DIR. ENTERPRISE PROJ MGT. | 55 | $196,821 | $0 | $48,851 | $245,672 | 1 |
| SUNI ELGAR | ASSC CHIEF NURSE | 55 | $190,332 | $0 | $49,977 | $240,309 | 1 |
| DANIEL MARKUS | DIR. SUPPLY CHAIN | 55 | $236,060 | $0 | $1,897 | $237,957 | 1 |
| ANDREW JACKSON | ASSC DIR ENTERPRISE APPS | 55 | $186,687 | $0 | $42,345 | $229,032 | 1 |
| MAXINE ELLIS | DIRECTOR DEI COACHING & CULTURE | 55 | $200,979 | $0 | $24,854 | $225,833 | 1 |
| TRACI PRANZINI | FORMER KEY EMPLOYEE | 55 | $131,743 | $0 | $14,742 | $146,485 | 1 |
| TRACY WONG | FORMER KEY EMPLOYEE | 55 | $121,492 | $0 | $8,177 | $129,669 | 1 |
| THOMAS LYNCH | PRESIDENT & DIRECTOR | 55 | $0 | $0 | $0 | $0 | 1 |
| PAULA REYNOLDS | CHAIR THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 2 |
| STEWART LANDEFELD | VICE CHAIR THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 5 |
| MIKE DELMAN | TREASURER THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | SECRETARY THRU 03/22 | 5 | $0 | $0 | $0 | $0 | 2 |
| KAREN GLOVER | IMM. PAST CHAIR THRU 03/22 | 3 | $0 | $0 | $0 | $0 | 2 |
| SUZANNE BEITEL | DIRECTOR THRU 03/22 | 1 | $0 | $0 | $0 | $0 | 5 |
| GERALD GRINSTEIN | DIRECTOR THRU 03/22 | 1 | $0 | $0 | $0 | $0 | 3 |
| RUTH MAHAN | DIRECTOR THRU 03/22 | 5 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR THRU 03/22 | 0 | $0 | $0 | $0 | $0 | 1 |
| RICHARD MCCUNE | DIRECTOR THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 2 |
| JEFF NITTA | DIRECTOR THRU 03/22 | 5 | $0 | $0 | $0 | $0 | 4 |
| BRUCE PYM | DIRECTOR THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| STEVE STADUM | DIRECTOR THRU 03/22 | 1 | $0 | $0 | $0 | $0 | 2 |
| RUSS WILLIAMS | DIRECTOR THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| ALVIN WINTERROTH | DIRECTOR THRU 03/22 | 2 | $0 | $0 | $0 | $0 | 3 |
| KATHY SURACE-SMITH | CHAIR FROM 04/22 | 4 | $0 | $0 | $0 | $0 | 7 |
| LEIGH MORGAN | VICE CHAIR FROM 04/22 | 3 | $0 | $0 | $0 | $0 | 3 |
| SEAN BOYLE | TREASURER FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 2 |
| JULIE NORDSTROM | SECRETARY FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| KRISTIANNE BLAKE | DIRECTOR FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| STEPHEN GRAHAM | DIRECTOR FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 5 |
| JOANNE HARRELL | DIRECTOR FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| JEREMY JAECH | DIRECTOR FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 1 |
| EDUARDO PENALVER | DIRECTOR FROM 04/22 | 2 | $0 | $0 | $0 | $0 | 6 |
| PAUL RAMSEY MD | EX OFFICIO DIRECTOR 04/22 | 2 | $0 | $0 | $0 | $0 | 4 |
| LISA BRANDENBURG | EX-OFFICIO DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| HERBERT BONE | CORPORATE TREASURER | 55 | $0 | $0 | $0 | $0 | 1 |
| DAVID BROWDY | VICE PRESIDENT & CFO | 55 | $0 | $0 | $0 | $0 | 3 |
| CHRISTOPHER BUNDESMANN | CORPORATE CONTROLLER | 55 | $0 | $0 | $0 | $0 | 2 |
| STEVEN HAYDON | VP & GC, CORPORATE SECRETARY | 55 | $0 | $0 | $0 | $0 | 2 |
| NICOLE ROBINSON | VP & CHIEF ADMIN. OFFICER | 55 | $0 | $0 | $0 | $0 | 2 |
2020 · 51 people listed · 34 paid, $12.2M · 2,189 employees · 198 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEBORAH GENTZEN | VP, CHIEF STRATEGY OFC (THRU 5/20) | 55 | $1,016,486 | $0 | $30,983 | $1,047,469 | 1 |
| AARON CRANE | EXECUTIVE VICE PRESIDENT | 55 | $721,479 | $0 | $174,523 | $896,002 | 1 |
| NANCY DAVIDSON MD | EXECUTIVE DIRECTOR AND PRESIDENT | 37 | $771,644 | $0 | $31,470 | $803,114 | 1 |
| THERESA MCDONNELL | SVP, CHIEF NURSING OFFICER | 55 | $447,693 | $0 | $159,460 | $607,153 | 1 |
| BARBARA JAGELS | VP, CHIEF QUALITY & VALUE OFC | 55 | $406,239 | $0 | $154,815 | $561,054 | 1 |
| STEPHANIE MAYS | VP, CHIEF LEGAL OFFICER | 55 | $415,592 | $0 | $95,567 | $511,159 | 1 |
| STEVEN HUEBNER | CHIEF FINANCIAL OFFICER | 55 | $491,745 | $0 | $0 | $491,745 | 1 |
| TAMI DEEB | VP, CHIEF STRATEGY OFFICER | 55 | $305,875 | $0 | $58,113 | $363,988 | 1 |
| MOREEN DUDLEY | VP, CHIEF PEOPLE OFFICER | 55 | $286,272 | $0 | $45,622 | $331,894 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $286,550 | $0 | $45,140 | $331,690 | 1 |
| RICHARD LAFRANCE | DIR. PHARMACY | 55 | $245,789 | $0 | $64,636 | $310,425 | 1 |
| KELLY PATRICK | VP, CHIEF INFORMATION OFFICER | 55 | $295,552 | $0 | $14,463 | $310,015 | 2 |
| STEVEN JOHNSON | DIR. RESEARCH INTEGR. (THRU 10/20) | 55 | $260,837 | $0 | $40,828 | $301,665 | 1 |
| ADA MOHEDANO | DIR. CLIN. ANALYTICS & BUS INTEL | 55 | $261,301 | $0 | $39,319 | $300,620 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $258,547 | $0 | $39,605 | $298,152 | 1 |
| KRISTINE LOGAN | DIR. OPERATIONS | 55 | $256,131 | $0 | $39,107 | $295,238 | 1 |
| CHAD HOGGARD | CHIEF INFO SECURITY OFFICER | 55 | $232,733 | $0 | $57,309 | $290,042 | 1 |
| NICKI NGUYEN-COLVIN | DIR. STRATEGY & BUS DEV | 55 | $228,881 | $0 | $56,299 | $285,180 | 1 |
| TIMOTHY EHLING | DIR. NURSING & CLIN. OPS INTEGR. | 55 | $224,054 | $0 | $58,333 | $282,387 | 1 |
| MICHELLE HALL | DIR. IT SERVICE MANAGEMENT | 55 | $232,067 | $0 | $48,670 | $280,737 | 1 |
| TRACY WONG | DIR. QUALITY & SAFETY | 55 | $242,049 | $0 | $24,218 | $266,267 | 1 |
| LAURA ESAGUI | DOSIMETRIST III | 55 | $211,137 | $0 | $49,596 | $260,733 | 1 |
| GANSUVD BALGANSUREN | DIR. CIL | 55 | $202,390 | $0 | $46,160 | $248,550 | 1 |
| BRITTANY MCCREERY | DIR. MED STAFF SVCS/PHYS PRACT | 55 | $203,753 | $0 | $44,197 | $247,950 | 1 |
| PAUL HELMUTH | DIR. CLIN OPS, COMMUNITY SITES | 55 | $214,194 | $0 | $32,963 | $247,157 | 1 |
| SHANNON FERNANDEZ | DIR FINANCE OPS & REV CYCLE | 55 | $228,741 | $0 | $15,019 | $243,760 | 1 |
| MATTHEW MCSWEYN | DIR. IT SERVICES | 55 | $190,947 | $0 | $49,851 | $240,798 | 1 |
| SCOTT DEROUEN | DIR. ENTERPRISE PROJ MGT | 55 | $186,212 | $0 | $51,501 | $237,713 | 1 |
| LORI BARE | ASSC DIR CLINICAL INFO SYSTEMS | 55 | $187,573 | $0 | $42,906 | $230,479 | 1 |
| CARILLA WALLIN | DIR. STRAT OUTREACH/CCA NETWORK | 55 | $188,938 | $0 | $39,323 | $228,261 | 1 |
| CINDY GIST | DIR. CLIN OPS | 55 | $188,200 | $0 | $32,612 | $220,812 | 1 |
| ANGELA RODRIGUEZ | ASSC DIR CLINICAL OPS | 55 | $182,909 | $0 | $26,801 | $209,710 | 1 |
| F MARC STEWART MD | SVP, MEDICAL DIRECTOR (THRU 7/20) | 45 | $179,643 | $0 | $24,927 | $204,570 | 3 |
| LISA ACOMB | DIR. BUS INTEL & ANALYTICS | 55 | $179,864 | $0 | $17,256 | $197,120 | 1 |
| ALVIN WINTERROTH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| BRUCE PYM | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GERALD GRINSTEIN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| JEFF NITTA | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 4 |
| KAREN GLOVER | IMMEDIATE PAST CHAIR | 3 | $0 | $0 | $0 | $0 | 2 |
| KIMBERLY MCNALLY | SECRETARY | 5 | $0 | $0 | $0 | $0 | 2 |
| LINDA MATTOX | DIRECTOR | 0 | $0 | $0 | $0 | $0 | 1 |
| LISA BRANDENBURG | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| MIKE DELMAN | TREASURER | 2 | $0 | $0 | $0 | $0 | 1 |
| PAULA REYNOLDS | CHAIR | 2 | $0 | $0 | $0 | $0 | 2 |
| RICHARD MCCUNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| RUSS WILLIAMS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RUTH MAHAN | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 3 |
| STEVE STADUM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| STEWART LANDEFELD | VICE CHAIR | 2 | $0 | $0 | $0 | $0 | 5 |
| SUZANNE BEITEL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 5 |
| THOMAS LYNCH JR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
2019 · 56 people listed · 37 paid, $12.4M · 2,069 employees · 225 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NANCY DAVIDSON MD | EXECUTIVE DIRECTOR AND PRESIDENT | 37 | $810,563 | $0 | $32,227 | $842,790 | 1 |
| NORMAN HUBBARD | EXECUTIVE VP (THRU 4/19) | 55 | $725,046 | $0 | $33,631 | $758,677 | 3 |
| AARON CRANE | EXECUTIVE VICE PRESIDENT | 55 | $586,077 | $0 | $137,313 | $723,390 | 1 |
| DEBORAH GENTZEN | VP, CHIEF STRATEGY OFFC (THRU 5/20) | 55 | $531,479 | $0 | $163,569 | $695,048 | 1 |
| THERESA MCDONNELL | CHIEF NURSE EXEC, VP-CLIN OPS | 55 | $456,248 | $0 | $151,903 | $608,151 | 1 |
| BARBARA JAGELS | VP, CHIEF QUALITY & VALUE OFFC | 55 | $451,520 | $0 | $153,158 | $604,678 | 1 |
| STEPHANIE MAYS | VP, GENERAL COUNSEL | 55 | $391,417 | $0 | $73,709 | $465,126 | 1 |
| DAVID ACKERSON | VP, CIO (THRU 7/19) | 55 | $394,176 | $0 | $44,547 | $438,723 | 1 |
| F MARC STEWART MD | VP, MEDICAL DIRECTOR | 30 | $293,665 | $0 | $33,512 | $327,177 | 3 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $274,862 | $0 | $44,029 | $318,891 | 1 |
| MOREEN DUDLEY | DIR. CLINIC OPERATIONS | 55 | $268,266 | $0 | $43,759 | $312,025 | 1 |
| TAMI DEEB | VP, CHIEF STRATEGY OFFICER | 55 | $259,808 | $0 | $48,153 | $307,961 | 1 |
| RICHARD LAFRANCE | DIR. PHARMACY | 55 | $236,018 | $0 | $63,423 | $299,441 | 1 |
| ALPHONSO EMERY | DIR. REVENUE CYCLE MGT. (THRU 8/19) | 55 | $263,548 | $0 | $22,954 | $286,502 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $245,181 | $0 | $37,923 | $283,104 | 1 |
| NICKI NGUYEN-COLVIN | DIR. STRATEGY & BUS DEV | 55 | $222,062 | $0 | $54,364 | $276,426 | 1 |
| KRISTINE LOGAN | DIR. OPERATIONS | 55 | $239,064 | $0 | $37,091 | $276,155 | 1 |
| ADA MOHEDANO | DIR. CLIN. ANALYTICS & BUS INTEL | 55 | $237,405 | $0 | $36,532 | $273,937 | 1 |
| TIMOTHY EHLING | DIR. NURSING & CLIN. OPS INTEG. | 55 | $216,272 | $0 | $56,109 | $272,381 | 1 |
| MICHELLE HALL | DIR. PERFORMANCE EXCELLENCE | 55 | $220,714 | $0 | $47,078 | $267,792 | 1 |
| CHAD HOGGARD | CHIEF INFO SECURITY OFFICER | 55 | $209,666 | $0 | $53,286 | $262,952 | 1 |
| STEVEN JOHNSON | DIR. RESEARCH INTEGRATION | 55 | $205,988 | $0 | $53,259 | $259,247 | 1 |
| HOLLY ROSENFELD | DIR. MARKETING (THRU 2/20) | 55 | $198,066 | $0 | $52,832 | $250,898 | 1 |
| KATIE COLLEEN ANN MALETICH | DIR. QUALITY & SAFETY (THRU 1/20) | 55 | $178,488 | $0 | $49,458 | $227,946 | 1 |
| BRITTANY MCCREERY | DIR. MED STAFF SVCS/PHYS PRACT | 55 | $186,018 | $0 | $41,527 | $227,545 | 1 |
| DONNA KERN | REGISTERED NURSE | 55 | $178,134 | $0 | $48,796 | $226,930 | 1 |
| MATTHEW PALMGREN | DIR. DIGITAL HEALTH (THRU 1/20) | 55 | $176,823 | $0 | $49,816 | $226,639 | 1 |
| MATTHEW MCSWEYN | DIR. IT SERVICES | 55 | $179,462 | $0 | $47,158 | $226,620 | 1 |
| LAURA ESAGUI | DOSIMETRIST III | 55 | $181,715 | $0 | $41,652 | $223,367 | 1 |
| SCOTT DEROUEN | DIR. ENTERPRISE PROJ MGT | 55 | $175,814 | $0 | $46,117 | $221,931 | 1 |
| CARILLA WALLIN | DIR. STRAT OUTREACH/CCA NETWORK | 55 | $182,958 | $0 | $38,141 | $221,099 | 1 |
| LORI BARE | ASSC DIR CLINICAL INFO SYSTEMS | 55 | $177,378 | $0 | $40,859 | $218,237 | 1 |
| PAUL HELMUTH | DIR. CLIN OPS, COMMUNITY SITES | 55 | $181,249 | $0 | $29,410 | $210,659 | 1 |
| JOSEPH NORTON | DIR. FINANCE (THRU 8/19) | 55 | $180,667 | $0 | $28,256 | $208,923 | 1 |
| LISA ACOMB | DIR. BUS INTEL & ANALYTICS | 55 | $179,248 | $0 | $17,727 | $196,975 | 1 |
| STEVEN HUEBNER | CFO, INTERIM (FROM 4/19) | 55 | $195,000 | $0 | $0 | $195,000 | 1 |
| KELLY PATRICK | VP, CIO (FROM 9/19) | 55 | $169,134 | $0 | $0 | $169,134 | 2 |
| KAREN GLOVER | CHAIR | 5 | $0 | $0 | $0 | $0 | 2 |
| BRUCE PYM | VICE CHAIR | 1 | $0 | $0 | $0 | $0 | 1 |
| MIKE DELMAN | TREASURER | 1 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | SECRETARY | 1 | $0 | $0 | $0 | $0 | 2 |
| RICHARD MCCUNE | IMMEDIATE PAST CHAIR | 1 | $0 | $0 | $0 | $0 | 2 |
| SUZANNE BEITEL | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 5 |
| LISA BRANDENBURG | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 9 |
| BRUCE CLURMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| GERALD GRINSTEIN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| STEWART LANDEFELD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 5 |
| THOMAS LYNCH JR | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| RUTH MAHAN | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SANDY MELZER | DIRECTOR (THRU 9/19) | 1 | $0 | $0 | $0 | $0 | 2 |
| JEFF NITTA | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 4 |
| PAULA REYNOLDS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| STEVE STADUM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| RUSS WILLIAMS | DIRECTOR (FROM 10/19) | 1 | $0 | $0 | $0 | $0 | 1 |
| ALVIN WINTERROTH | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
2018 · 52 people listed · 33 paid, $11.4M · 1,917 employees · 245 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VP (THRU 4/19) | 55 | $932,837 | $0 | $231,024 | $1,163,861 | 3 |
| NANCY DAVIDSON MD | EXECUTIVE DIRECTOR AND PRESIDENT | 45 | $929,406 | $0 | $0 | $929,406 | 1 |
| DEBORAH GENTZEN | VP, CHIEF STRATEGY OFFICER | 55 | $505,671 | $0 | $152,782 | $658,453 | 1 |
| DAVID ACKERSON | VP, CHIEF INFORMATION OFFICER | 55 | $449,578 | $0 | $132,922 | $582,500 | 1 |
| F MARC STEWART MD | VP, MEDICAL DIRECTOR | 30 | $556,519 | $0 | $0 | $556,519 | 3 |
| BARBARA JAGELS | VP, CHIEF QUALITY & VALUE OFFC | 55 | $405,660 | $0 | $140,585 | $546,245 | 1 |
| THERESA MCDONNELL | CHIEF NURSE EXEC, VP-CLIN OPS | 55 | $405,596 | $0 | $135,994 | $541,590 | 1 |
| STEPHANIE MAYS | GENERAL COUNSEL | 55 | $375,051 | $0 | $59,807 | $434,858 | 1 |
| AARON CRANE | INTERIM EXEC VP (FROM 4/19) & CFO | 55 | $279,676 | $0 | $37,655 | $317,331 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $272,735 | $0 | $38,329 | $311,064 | 1 |
| TAMI DEEB | DIR. SERVICE LINES | 55 | $255,762 | $0 | $42,026 | $297,788 | 1 |
| JOSEPH NORTON | DIR. FINANCE | 55 | $254,996 | $0 | $41,674 | $296,670 | 1 |
| MOREEN DUDLEY | DIR. CLIN. OPS, SUPPORTIVE SVCS | 55 | $246,007 | $0 | $34,803 | $280,810 | 1 |
| KRISTINE LOGAN | DIR. OPERATIONS | 55 | $236,101 | $0 | $32,436 | $268,537 | 1 |
| NICKI NGUYEN-COLVIN | DIR. STRATEGY & BUS DEV | 55 | $226,082 | $0 | $39,791 | $265,873 | 1 |
| TIMOTHY EHLING | DIR. NURSING & CLIN. OPS INTEG. | 55 | $214,598 | $0 | $43,810 | $258,408 | 1 |
| MICHELLE HALL | DIR. PERFORMANCE EXCELLENCE | 55 | $218,753 | $0 | $39,017 | $257,770 | 1 |
| ALPHONSO EMERY | DIR. REVENUE CYCLE MGT. | 55 | $219,386 | $0 | $30,548 | $249,934 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $215,510 | $0 | $30,905 | $246,415 | 1 |
| HOLLY ROSENFELD | DIR. MARKETING | 55 | $197,271 | $0 | $42,224 | $239,495 | 1 |
| CHAD HOGGARD | CHIEF INFO SECURITY OFFICER | 55 | $195,196 | $0 | $42,015 | $237,211 | 1 |
| ADA MOHEDANO | DIR. CLIN. ANALYTICS & BUS INTEL | 55 | $203,383 | $0 | $29,266 | $232,649 | 1 |
| DONNA KERN | REGISTERED NURSE | 55 | $191,896 | $0 | $40,515 | $232,411 | 1 |
| KATIE COLLEEN ANN MALETICH | DIR. QUALITY & SAFETY | 55 | $178,110 | $0 | $39,549 | $217,659 | 1 |
| MADELINE GRANT | DIR. PAYER CONTRACTING/STRATEGY | 55 | $179,371 | $0 | $31,366 | $210,737 | 1 |
| ROGER JANSSON | ASSC GENERAL COUNSEL (THRU 09/18) | 55 | $198,100 | $0 | $8,918 | $207,018 | 1 |
| PAUL HELMUTH | DIR. CLIN OPS, COMMUNITY SITES | 55 | $179,885 | $0 | $26,024 | $205,909 | 1 |
| MATTHEW MCSWEYN | DIR. IT SERVICES | 55 | $167,699 | $0 | $37,299 | $204,998 | 1 |
| MATTHEW PALMGREN | DIR. DIGITAL HEALTH | 55 | $165,485 | $0 | $38,275 | $203,760 | 1 |
| BRITTANY MCCREERY | DIR. MED STAFF SVCS/PHYS PRACT | 55 | $168,256 | $0 | $32,095 | $200,351 | 1 |
| GANSUVD BALGANSUREN | DIR. CLINICAL IMMUNOGENETICS LAB | 55 | $167,586 | $0 | $32,713 | $200,299 | 1 |
| MARIAN RICHARDSON | ASSC DIR. CLINICAL OPS | 55 | $166,778 | $0 | $24,253 | $191,031 | 1 |
| TRACY WONG | DIR. VALUE & PATIENT EXP | 55 | $166,990 | $0 | $15,181 | $182,171 | 1 |
| KAREN GLOVER | CHAIR | 5 | $0 | $0 | $0 | $0 | 2 |
| BRUCE PYM | VICE CHAIR | 5 | $0 | $0 | $0 | $0 | 1 |
| MIKE DELMAN | TREASURER | 4 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | SECRETARY | 3 | $0 | $0 | $0 | $0 | 2 |
| RICHARD MCCUNE | IMMEDIATE PAST CHAIR | 3 | $0 | $0 | $0 | $0 | 2 |
| ROBB BAKEMEIER | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 4 |
| SUZANNE BEITEL | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 5 |
| LISA BRANDENBURG | DIRECTOR (FROM 11/18) | 3 | $0 | $0 | $0 | $0 | 9 |
| JACQUELINE CABE | DIRECTOR (THRU 11/18) | 1 | $0 | $0 | $0 | $0 | 5 |
| BRUCE CLURMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| GERALD GRINSTEIN | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 3 |
| STEWART LANDEFELD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 5 |
| RUTH MAHAN | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SANDY MELZER | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| PAULA REYNOLDS | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| STEVE STADUM | DIRECTOR | 8 | $0 | $0 | $0 | $0 | 2 |
| ALVIN WINTERROTH | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| RICHARD YARMUTH | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 1 |
2017 · 56 people listed · 35 paid, $11.2M · 1,811 employees · 249 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NANCY DAVIDSON MD | EXECUTIVE DIRECTOR AND PRESIDENT | 45 | $1,273,027 | $0 | $0 | $1,273,027 | 1 |
| NORMAN HUBBARD | EXECUTIVE VP | 55 | $948,024 | $0 | $165,779 | $1,113,803 | 3 |
| JONATHAN TINGSTAD | VP & CFO (THRU 10/17) | 55 | $634,441 | $0 | $55,362 | $689,803 | 2 |
| DEBORAH GENTZEN | VP, CHIEF STRATEGY OFFICER | 55 | $423,869 | $0 | $111,983 | $535,852 | 1 |
| F MARC STEWART MD | VP, MEDICAL DIRECTOR | 55 | $515,591 | $0 | $0 | $515,591 | 3 |
| DAVID ACKERSON | VP, CHIEF INFORMATION OFFICER | 55 | $389,833 | $0 | $94,009 | $483,842 | 1 |
| BARBARA JAGELS | VP, CHIEF QUALITY & VALUE OFFC | 55 | $353,516 | $0 | $101,199 | $454,715 | 1 |
| THERESA MCDONNELL | CHIEF NURSE EXEC, VP-CLIN OPS | 55 | $348,640 | $0 | $50,425 | $399,065 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $255,771 | $0 | $35,490 | $291,261 | 1 |
| JOSEPH NORTON | DIR. FINANCE | 55 | $239,040 | $0 | $38,582 | $277,622 | 1 |
| MARIA GONZALEZ | DIR. RESEARCH INT. (THRU 1/18) | 55 | $234,607 | $0 | $39,314 | $273,921 | 1 |
| KRISTINE LOGAN | DIR. OPERATIONS | 55 | $209,309 | $0 | $28,447 | $237,756 | 1 |
| MOREEN DUDLEY | DIR. CLIN. OPS, SUPPORTIVE SVCS | 55 | $204,837 | $0 | $30,195 | $235,032 | 1 |
| ALPHONSO EMERY | DIR. REVENUE CYCLE MGT | 55 | $204,542 | $0 | $28,045 | $232,587 | 1 |
| TAMI DEEB | DIR. SERVICE LINES | 55 | $201,208 | $0 | $27,304 | $228,512 | 1 |
| THOMAS TSAI DIR CLINICAL OPS | DIAG/THERAPY SVCS (THRU 1/18) | 55 | $207,209 | $0 | $20,701 | $227,910 | 1 |
| HOLLY ROSENFELD | DIR. MARKETING | 55 | $183,795 | $0 | $38,761 | $222,556 | 1 |
| TIMOTHY EHLING | DIR. NURSING & CLIN. OPS INTEG. | 55 | $183,884 | $0 | $38,503 | $222,387 | 1 |
| MICHELLE HALL | DIR. PERFORMANCE EXCELLENCE | 55 | $187,794 | $0 | $33,408 | $221,202 | 1 |
| ADA MOHEDANO | DIR. CLIN. ANALYTICS & BUS INTEL | 55 | $188,599 | $0 | $26,732 | $215,331 | 1 |
| DONNA KERN | REGISTERED NURSE | 55 | $179,044 | $0 | $34,647 | $213,691 | 1 |
| CHAD HOGGARD | DIR. IT SECURITY | 55 | $176,175 | $0 | $37,275 | $213,450 | 1 |
| AVRIL MCDOWELL | DIR. CLINICAL OPS (THRU 7/17) | 55 | $195,822 | $0 | $14,480 | $210,302 | 1 |
| BRANDON JONES | CHIEF TECHNOLOGY OFFICER | 55 | $183,079 | $0 | $26,072 | $209,151 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $180,562 | $0 | $25,795 | $206,357 | 1 |
| ARIAM ZERESENNAI | REGISTERED NURSE | 55 | $168,272 | $0 | $35,859 | $204,131 | 1 |
| STEPHANIE MAYS | GENERAL COUNSEL | 55 | $189,375 | $0 | $14,342 | $203,717 | 1 |
| KATIE COLLEEN ANN MALETICH | DIR. QUALITY & SAFETY | 55 | $165,741 | $0 | $28,091 | $193,832 | 1 |
| GANSUVD BALGANSUREN | CIL DIR. | 55 | $162,731 | $0 | $30,730 | $193,461 | 1 |
| PAUL HELMUTH | DIR. CLINICAL OPERATIONS | 55 | $169,203 | $0 | $24,011 | $193,214 | 1 |
| CECILIA ZAPATA DIR STRAT | OUTREACH/CCA NETWORK (THRU 8/17) | 55 | $168,315 | $0 | $14,281 | $182,596 | 1 |
| MARIAN RICHARDSON | ASSC. DIR. CLINICAL OPS | 55 | $159,854 | $0 | $22,590 | $182,444 | 1 |
| DEBRA KIRKLEY | DIR. MAGNET PROGRAM (THRU 7/17) | 55 | $160,866 | $0 | $11,205 | $172,071 | 1 |
| FRED APPLEBAUM MD | FORMER EXEC. DIR. & PRESIDENT | 12 | $162,147 | $0 | $0 | $162,147 | 1 |
| CHERYL WYMAN | FORMER DIR. DIAG/THERAPY SVCS | 0 | $136,037 | $0 | $0 | $136,037 | 1 |
| RICHARD MCCUNE | CHAIR | 5 | $0 | $0 | $0 | $0 | 2 |
| KAREN GLOVER | VICE CHAIR | 2 | $0 | $0 | $0 | $0 | 2 |
| MIKE DELMAN | TREASURER | 3 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
| CARL BEHNKE | IMMEDIATE PAST CHAIR | 2 | $0 | $0 | $0 | $0 | 11 |
| ROBB BAKEMEIER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 4 |
| JACQUELINE CABE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 5 |
| BRUCE CLURMAN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| GERALD GRINSTEIN | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 3 |
| DEBORAH HAUG | DIRECTOR (THRU 2/18) | 0 | $0 | $0 | $0 | $0 | 3 |
| STEWART LANDEFELD | DIRECTOR (FROM 4/18) | 4 | $0 | $0 | $0 | $0 | 5 |
| RUTH MAHAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 0 | $0 | $0 | $0 | $0 | 1 |
| SANDY MELZER | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| BRUCE PYM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| BROOKS RAGEN | DIRECTOR (THRU 3/18) | 1 | $0 | $0 | $0 | $0 | 3 |
| STEVE STADUM | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| BRUDER STAPLETON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| ALVIN WINTERROTH | DIRECTOR (FROM 3/18) | 1 | $0 | $0 | $0 | $0 | 3 |
| RICHARD YARMUTH | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 1 |
| AARON CRANE | VP & CFO (FROM 5/18) | 55 | $0 | $0 | $0 | $0 | 1 |
2016 · 55 people listed · 34 paid, $9.9M · 1,681 employees · 241 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $802,143 | $0 | $129,991 | $932,134 | 3 |
| F MARC STEWART MD | MEDICAL DIRECTOR & VP | 55 | $661,296 | $0 | $0 | $661,296 | 3 |
| JONATHAN TINGSTAD | CHIEF FINANCIAL OFFICER & VP | 55 | $518,209 | $0 | $92,231 | $610,440 | 2 |
| DEBORAH GENTZEN | CHIEF STRATEGY OFFICER & VP | 55 | $469,970 | $0 | $86,135 | $556,105 | 1 |
| FRED APPLEBAUM MD | EXEC. DIR. & PRESIDENT (THRU 11/16) | 12 | $522,426 | $0 | $0 | $522,426 | 1 |
| DAVID ACKERSON | CHIEF INFORMATION OFFICER & VP | 55 | $429,383 | $0 | $68,063 | $497,446 | 1 |
| BARBARA JAGELS | CHIEF QUALITY OFFICER & VP | 55 | $375,126 | $0 | $75,329 | $450,455 | 1 |
| ANGELIQUE RICHARD | CHIEF NURSE EXEC. & VP (THRU 9/2/16) | 55 | $355,996 | $0 | $46,500 | $402,496 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $252,679 | $0 | $35,807 | $288,486 | 1 |
| JOSEPH NORTON | DIRECTOR FINANCE | 55 | $237,653 | $0 | $39,108 | $276,761 | 1 |
| CHERYL WYMAN | DIR. DIAG./THERAP. SVCS (THRU 5/16) | 55 | $236,656 | $0 | $27,770 | $264,426 | 1 |
| KRISTINE LOGAN | DIR. PT ACCESS & FACILITIES | 55 | $206,201 | $0 | $28,604 | $234,805 | 1 |
| MOREEN DUDLEY | DIR. CLIN OPS, SUPPORTIVE SVCS | 55 | $197,297 | $0 | $33,835 | $231,132 | 1 |
| ALPHONSO EMERY | DIR. REVENUE CYCLE MGMT | 55 | $191,437 | $0 | $27,072 | $218,509 | 1 |
| HOLLY ROSENFELD | DIR. MARKETING | 55 | $176,181 | $0 | $38,257 | $214,438 | 1 |
| SHARI MCCLURE | DIR. STRATEGY & BUS DEV (THRU 2/17) | 55 | $185,847 | $0 | $26,938 | $212,785 | 1 |
| MICHELLE HALL | DIR. IT SERVICES | 55 | $178,543 | $0 | $32,732 | $211,275 | 1 |
| CAMILLE RAPACZ | DIR. CPI (THRU 1/6/17) | 55 | $175,847 | $0 | $33,239 | $209,086 | 1 |
| BRANDON JONES | CHIEF TECHNOLOGY OFFICER | 55 | $181,930 | $0 | $26,458 | $208,388 | 1 |
| ADA MOHEDANO | DIR. CLIN ANALYTICS & BUS INTEL | 55 | $181,452 | $0 | $26,363 | $207,815 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $180,535 | $0 | $26,387 | $206,922 | 1 |
| AVRIL MCDOWELL | DIR. CLIN OPS (THRU 7/13/17) | 55 | $196,082 | $0 | $10,326 | $206,408 | 1 |
| CECILIA ZAPATA | DIR. STRAT OUTREACH/CCA NETWORK | 55 | $180,057 | $0 | $26,268 | $206,325 | 1 |
| DONNA KERN | REGISTERED NURSE | 55 | $167,297 | $0 | $31,843 | $199,140 | 1 |
| TIMOTHY EHLING | DIR. CLINICAL OPS INTEGRATION | 55 | $157,396 | $0 | $36,281 | $193,677 | 1 |
| CHAD HOGGARD | DIR. IT SECURITY | 55 | $162,552 | $0 | $31,077 | $193,629 | 1 |
| ARIAM ZERESENNAI | REGISTERED NURSE | 55 | $157,863 | $0 | $35,524 | $193,387 | 1 |
| GANSUVD BALGANSUREN | DIR. CLINICAL IMMUNOGETICS LABS | 55 | $157,853 | $0 | $31,002 | $188,855 | 1 |
| MARIA GONZALEZ | DIR. RESEARCH INTEGRATION | 55 | $173,538 | $0 | $14,182 | $187,720 | 1 |
| PAUL HELMUTH | DIR. CLINICAL OPERATIONS | 55 | $163,572 | $0 | $23,955 | $187,527 | 1 |
| MARIAN RICHARDSON | ASSOC DIR. CLINICAL OPS | 55 | $153,103 | $0 | $22,415 | $175,518 | 1 |
| TAMI DEEB | DIR. SERVICE LINES | 55 | $162,919 | $0 | $11,106 | $174,025 | 1 |
| MARCIE HEADEN | SYSTEMS EDUCATOR (THRU 7/17/17) | 55 | $158,160 | $0 | $0 | $158,160 | 1 |
| NANCY DAVIDSON MD | EXEC. DIR. & PRESIDENT (FROM 12/16) | 20 | $62,618 | $0 | $0 | $62,618 | 1 |
| RICHARD MCCUNE | CHAIR | 4 | $0 | $0 | $0 | $0 | 2 |
| MIKE DELMAN | VICE CHAIR & TREASURER | 2 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
| CARL BEHNKE | IMMEDIATE PAST CHAIR | 3 | $0 | $0 | $0 | $0 | 11 |
| ROBB BAKEMEIER | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 4 |
| LISA BRANDENBURG | DIRECTOR (THRU 9/30/16) | 2 | $0 | $0 | $0 | $0 | 9 |
| JACQUELINE CABE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 5 |
| BRUCE CLURMAN | DIRECTOR (FROM 11/01/16) | 1 | $0 | $0 | $0 | $0 | 2 |
| BOB FLOWERS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 8 |
| KAREN GLOVER | VICE CHAIR | 2 | $0 | $0 | $0 | $0 | 2 |
| GERALD GRINSTEIN | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 3 |
| MARK GROUDINE | DIRECTOR (THRU 10/31/16) | 1 | $0 | $0 | $0 | $0 | 3 |
| RUTH MAHAN | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SANDY MELZER | DIRECTOR (FROM 10/10/16) | 1 | $0 | $0 | $0 | $0 | 2 |
| BROOKS RAGEN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| STEVE STADUM | DIRECTOR (FROM 07/05/17) | 2 | $0 | $0 | $0 | $0 | 2 |
| BRUDER STAPLETON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| JOANN TARICANI | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| RICHARD YARMUTH | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 1 |
| TERRY MCDONNELL | CHIEF NURSE EXEC. & VP (FROM 01/17) | 55 | $0 | $0 | $0 | $0 | 1 |
2015 · 50 people listed · 30 paid, $8.4M · 1,559 employees · 234 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $693,720 | $0 | $94,741 | $788,461 | 3 |
| JONATHAN TINGSTAD | CHIEF FINANCIAL OFFICER AND VP | 55 | $480,508 | $0 | $67,461 | $547,969 | 2 |
| F MARC STEWART MD | MEDICAL DIRECTOR AND VICE PRESIDENT | 30 | $510,701 | $0 | $0 | $510,701 | 3 |
| DEBORAH GENTZEN | CHIEF STRATEGY OFFICER AND VP | 55 | $435,136 | $0 | $61,898 | $497,034 | 1 |
| ANGELIQUE RICHARD | CHIEF NURSE EXECUTIVE AND VP | 55 | $425,974 | $0 | $42,386 | $468,360 | 1 |
| DAVID ACKERSON | CHIEF INFORMATION OFFICER AND VP | 55 | $395,284 | $0 | $45,231 | $440,515 | 1 |
| FRED APPELBAUM MD | EXECUTIVE DIRECTOR AND PRESIDENT | 12 | $328,857 | $0 | $0 | $328,857 | 2 |
| BARBARA JAGELS | CHIEF QUALITY OFFICER AND VP | 55 | $247,562 | $0 | $54,199 | $301,761 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $234,793 | $0 | $33,030 | $267,823 | 1 |
| JOSEPH NORTON | DIRECTOR FINANCE | 55 | $228,723 | $0 | $37,102 | $265,825 | 1 |
| CHERYL WYMAN | DIR. DIAGNOSTIC & THERAPEUTIC SVCS | 55 | $221,773 | $0 | $37,503 | $259,276 | 1 |
| ALEANA WAITE | DIR. RES INTEG/IMMUNO/CELL THERAPY | 55 | $204,801 | $0 | $35,443 | $240,244 | 1 |
| SUSAN HAMMOND | DIR. PROGRAM MANAGEMENT | 55 | $190,977 | $0 | $33,087 | $224,064 | 1 |
| KRISTINE LOGAN | DIR. PT ACCESS & FACILITIES | 55 | $195,274 | $0 | $26,880 | $222,154 | 1 |
| MOREEN DUDLEY | DIR. SPPT CARE/RAD SVC/SPC CLIN | 55 | $185,428 | $0 | $31,380 | $216,808 | 1 |
| LINDA LAKE | DIR. CLIN INFO SYST & HIM | 55 | $184,667 | $0 | $25,884 | $210,551 | 1 |
| ALPHONSO EMERY | DIR. DIVERSITY EFFORTS | 55 | $179,051 | $0 | $25,101 | $204,152 | 1 |
| MICHELLE HALL | DIR. IT SERVICES | 55 | $172,751 | $0 | $31,292 | $204,043 | 1 |
| CAMILLE RAPACZ | DIR. STRAT OUTREACH/CCA NETWORK | 55 | $167,945 | $0 | $31,079 | $199,024 | 1 |
| LORI BARE | IT INFRASTRUCTURE MGR | 55 | $196,102 | $0 | $0 | $196,102 | 1 |
| SHARI MCCLURE | DIR. STRATEGY & BUS DEV | 55 | $171,052 | $0 | $24,567 | $195,619 | 1 |
| CECILIA ZAPATA | DIR. STRAT OUTREACH/CCA NETWORK | 55 | $166,148 | $0 | $23,955 | $190,103 | 1 |
| TIMOTHY EHLING | ASSOC DIR. OPERATIONS | 55 | $153,686 | $0 | $34,206 | $187,892 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $161,583 | $0 | $23,435 | $185,018 | 1 |
| HOLLY ROSENFELD | DIR. MARKETING | 55 | $162,069 | $0 | $22,498 | $184,567 | 1 |
| ADA MOHEDANO | DIR. CLIN ANALYTICS & BUS INTEL | 55 | $158,364 | $0 | $23,000 | $181,364 | 1 |
| MATTHEW MCSWEYN | ASSC DIR. ENTERPRISE APPS | 55 | $147,805 | $0 | $32,281 | $180,086 | 1 |
| DEBORAH STENHJEM | DIR. REV CYCLE MGMT | 32 | $145,890 | $0 | $33,311 | $179,201 | 1 |
| DONNA KERN | RN | 55 | $150,401 | $0 | $28,095 | $178,496 | 1 |
| GANSUVD BALGANSUREN | DIR. CLINICAL IMMUNOGENETICS LABS | 55 | $153,100 | $0 | $18,684 | $171,784 | 1 |
| RICHARD MCCUNE | CHAIR | 2 | $0 | $0 | $0 | $0 | 2 |
| MIKE DELMAN | VICE CHAIR & TREASURER | 4 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
| BOB FLOWERS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 8 |
| BROOKS RAGEN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| BRUDER STAPLETON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| CARL BEHNKE | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 11 |
| GERALD GRINSTEIN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| JACQUELINE CABE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 5 |
| JOANN TARICANI | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| JOHNESE SPISSO | DIRECTOR THRU 2/5/16 | 2 | $0 | $0 | $0 | $0 | 7 |
| KAREN GLOVER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| LISA BRANDENBURG | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| MARK GROUDINE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| MYRA TANITA | DIRECTOR THRU 12/11/15 | 2 | $0 | $0 | $0 | $0 | 2 |
| NICOLE ROBINSON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| RICHARD YARMUTH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBB BAKEMEIER | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 4 |
| RUTH MAHAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
2014 · 45 people listed · 27 paid, $7.3M · 1,517 employees · 236 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $611,438 | $0 | $82,733 | $694,171 | 3 |
| JONATHAN TINGSTAD | VP CHIEF FINANCIAL OFFICER | 55 | $447,065 | $0 | $62,997 | $510,062 | 2 |
| F MARC STEWART MD | MEDICAL DIRECTOR/VP CLINIC & LAB OPS | 30 | $469,480 | $0 | $0 | $469,480 | 3 |
| DEBORAH GENTZEN | VP CHIEF STRATEGY OFFICER | 55 | $405,911 | $0 | $57,501 | $463,412 | 1 |
| DAVID ACKERSON | VP CHIEF INFORMATION OFFICER | 55 | $373,201 | $0 | $43,864 | $417,065 | 1 |
| FRED APPELBAUM MD | PRESIDENT AND EXECUTIVE DIRECTOR | 12 | $339,496 | $0 | $0 | $339,496 | 2 |
| CHERYL WYMAN | DIR. DIAGNOSTIC & THERAPY SVCS | 55 | $258,124 | $0 | $40,190 | $298,314 | 1 |
| BARBARA JAGELS | VP QUALITY SAFETY AND VALUE | 55 | $216,499 | $0 | $45,074 | $261,573 | 1 |
| JOSEPH NORTON | DIRECTOR OF FINANCE | 55 | $217,395 | $0 | $40,265 | $257,660 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $224,668 | $0 | $31,103 | $255,771 | 1 |
| CLAIRE BECK-KEELER | DIRECTOR OF MARKETING | 55 | $218,076 | $0 | $19,958 | $238,034 | 1 |
| ALEANA WAITE | DIR. RES INTEG, IMMUNO, CELL THRPY | 55 | $200,919 | $0 | $33,520 | $234,439 | 1 |
| ZAKARIA RAMADAN-JRADI | DIR. CELL THERAP & CLIN LABS | 55 | $198,411 | $0 | $35,724 | $234,135 | 1 |
| SUSAN HAMMOND | DIR. PROGRAM MANAGEMENT | 55 | $184,056 | $0 | $30,874 | $214,930 | 1 |
| KRISTINE LOGAN | DIR. PT ACCESS & FACILITIES | 55 | $186,954 | $0 | $25,287 | $212,241 | 1 |
| ANGELIQUE RICHARD PHD RN | CNE/VP CLINICAL OPERATIONS | 55 | $206,263 | $0 | $5,659 | $211,922 | 1 |
| MOREEN DUDLEY | DIR. SUPPORT CARE/SPEC CLINICS | 55 | $171,729 | $0 | $28,460 | $200,189 | 1 |
| LINDA LAKE | DIR. CLIN INFO SYST & HIM | 55 | $175,365 | $0 | $24,098 | $199,463 | 1 |
| ALPHONSO EMERY | DIR DIVERSITY EFFORTS | 55 | $172,398 | $0 | $23,197 | $195,595 | 1 |
| CAMILLE RAPACZ | DIRECTOR OF CPI | 55 | $161,250 | $0 | $28,786 | $190,036 | 1 |
| MARGARET OWENS | CTP QUALITY SENIOR MANAGER | 65 | $172,659 | $0 | $15,102 | $187,761 | 1 |
| SHARI MCCLURE | DIR. MEDICAL STAFF SERVICES | 55 | $159,729 | $0 | $22,514 | $182,243 | 1 |
| MICHELLE HALL | DIRECTOR OF IT SERVICES | 55 | $153,220 | $0 | $27,664 | $180,884 | 1 |
| DEBORAH STENHJEM | DIR. REVENUE CYCLE MGMT | 55 | $139,307 | $0 | $30,471 | $169,778 | 1 |
| TRACI PRANZINI | CORPORATE INTEGRITY OFFICER | 55 | $147,344 | $0 | $20,940 | $168,284 | 1 |
| CECILIA ZAPATA | DIR. REGIONAL & GLOBAL NETWORK | 55 | $143,636 | $0 | $20,427 | $164,063 | 1 |
| KAREN HOLLOWAY | RADIATION ONCOLOGY MGR | 55 | $136,857 | $0 | $19,814 | $156,671 | 1 |
| CARL BEHNKE | CHAIRMAN | 10 | $0 | $0 | $0 | $0 | 11 |
| RICH MCCUNE | VICE CHAIR | 2 | $0 | $0 | $0 | $0 | 1 |
| MIKE DELMAN | TREASURER | 3 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY MN RN | SECRETARY | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBB BAKEMEIER | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 4 |
| LISA BRANDENBURG | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| BOB FLOWERS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 8 |
| KARI GLOVER | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK GROUDINE MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| RUTH MAHAN | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHAN MULLIN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| BROOKS RAGEN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| JOHNESE SPISSO | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 7 |
| BRUDER STAPLETON MD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| MYRA TANITA | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| JOANN TARICANI | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| RICHARD YARMUTH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2013 · 44 people listed · 26 paid, $7.0M · 1,390 employees · 232 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $575,586 | $0 | $47,950 | $623,536 | 3 |
| JONATHAN TINGSTAD | VP/CFO | 55 | $428,186 | $0 | $52,588 | $480,774 | 2 |
| DEBORAH GENTZEN | VP/CHIEF STRATEGY OFFICER | 55 | $388,076 | $0 | $52,364 | $440,440 | 1 |
| F MARC STEWART MD | VP/MEDICAL DIRECTOR | 36 | $431,220 | $0 | $0 | $431,220 | 3 |
| DAVID ACKERSON | VP/CHIEF INFO OFFICER | 55 | $357,691 | $0 | $42,962 | $400,653 | 1 |
| MADELINE BUELT | VP OPERATIONS/CHIEF NURSE | 55 | $347,742 | $0 | $48,862 | $396,604 | 2 |
| FRED APPELBAUM MD | EXECUTIVE DIRECTOR/PRESIDENT | 12 | $322,262 | $0 | $0 | $322,262 | 2 |
| CHERYL WYMAN | DIR. DIAGNOSIS THERAPY SVCS | 55 | $220,469 | $0 | $36,527 | $256,996 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $221,662 | $0 | $34,175 | $255,837 | 1 |
| JOSEPH NORTON | DIRECTOR OF FINANCE | 55 | $214,595 | $0 | $37,765 | $252,360 | 1 |
| ZAKARIA RAMADAN-JRADI | DIR. CELL THRPY & CLIN LAB | 55 | $209,348 | $0 | $36,994 | $246,342 | 1 |
| ALEANA WAITE | DIR. RES INTEG, IMMUNO, CELL THRPY | 55 | $191,029 | $0 | $32,295 | $223,324 | 1 |
| SUSAN HAMMOND | DIRECTOR PROGRAM MANAGEMENT | 55 | $182,908 | $0 | $31,299 | $214,207 | 1 |
| KRISTINE LOGAN | DIRECTOR PT ACCESS & FACILITIES | 55 | $184,201 | $0 | $24,857 | $209,058 | 1 |
| LINDA LAKE | DIR. CLIN INFO SYST & HIM | 55 | $176,590 | $0 | $24,152 | $200,742 | 1 |
| DONNA LENDERMAN | REGISTERED NURSE | 65 | $179,992 | $0 | $19,893 | $199,885 | 1 |
| ALPHONSO EMERY | DIR. DIVERSITY EFFORTS | 55 | $171,681 | $0 | $21,969 | $193,650 | 1 |
| BARBARA JAGELS | VP/QUALITY SAFETY AND VALUE | 55 | $159,144 | $0 | $32,440 | $191,584 | 1 |
| MOREEN DUDLEY | DIR. SUPPORT CARE/SPEC CLINICS | 55 | $164,241 | $0 | $27,204 | $191,445 | 1 |
| CAMILLE RAPACZ | DIRECTOR CPI | 55 | $160,100 | $0 | $28,341 | $188,441 | 1 |
| MARGARET OWENS | CTP QUALITY SENIOR MANAGER | 55 | $169,237 | $0 | $16,183 | $185,420 | 1 |
| MICHELLE HALL | DIRECTOR OF IT SERVICES | 55 | $150,492 | $0 | $27,002 | $177,494 | 1 |
| SHARI MCCLURE | DIR. MEDICAL STAFF SERVICES | 55 | $154,519 | $0 | $21,483 | $176,002 | 1 |
| CLAIRE BECK-KEELER | DIRECTOR OF MARKETING | 55 | $142,738 | $0 | $30,203 | $172,941 | 1 |
| KAREN HOLLOWAY | RADIATION ONCOLOGY MANAGER | 55 | $143,372 | $0 | $20,431 | $163,803 | 1 |
| CECILIA ZAPATA | DIR. REGIONAL GLOBAL NETWORK | 55 | $142,533 | $0 | $20,218 | $162,751 | 1 |
| ROBB BAKEMEIER | CHAIRMAN | 10 | $0 | $0 | $0 | $0 | 4 |
| CARL BEHNKE | VICE CHAIR | 6 | $0 | $0 | $0 | $0 | 11 |
| RICH MCCUNE | TREASURER | 1 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY MN RN | SECRETARY | 3 | $0 | $0 | $0 | $0 | 1 |
| LISA BRANDENBURG | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 9 |
| MIKE DELMAN | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 1 |
| MARK GROUDINE MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| JONELLE JOHNSON | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| RICH JONES | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| ROB MACAULAY | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 1 |
| RUTH MAHAN | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHAN MULLIN | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 2 |
| BROOKS RAGEN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| JOHNESE SPISSO | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 7 |
| BRUDER STAPLETON MD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| MYRA TANITA | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| RICHARD YARMUTH | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 1 |
2012 · 41 people listed · 23 paid, $6.2M · 1,330 employees · 340 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $550,514 | $0 | $47,334 | $597,848 | 3 |
| JONATHAN TINGSTAD | CFO/VICE PRESIDENT | 55 | $399,261 | $0 | $52,154 | $451,415 | 2 |
| FRED APPELBAUM MD | EXECUTIVE DIRECTOR/PRESIDENT | 14 | $446,442 | $0 | $0 | $446,442 | 2 |
| DEBORAH GENTZEN | VP/CHIEF STRATEGY OFFICER | 55 | $357,484 | $0 | $51,436 | $408,920 | 1 |
| MADELINE BUELT | VP OPERATIONS/CHIEF NURSE | 55 | $342,412 | $0 | $51,929 | $394,341 | 2 |
| DAVID ACKERSON | VP/CHIEF INFO OFFICER | 55 | $328,723 | $0 | $42,148 | $370,871 | 1 |
| F MARC STEWART MD | MEDICAL DIRECTOR/VICE PRESIDENT | 28 | $367,348 | $0 | $0 | $367,348 | 3 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $209,183 | $0 | $35,135 | $244,318 | 1 |
| CHERYL WYMAN | DIR. DIAGNOSIS THERAPIC SVCS | 55 | $206,690 | $0 | $35,252 | $241,942 | 1 |
| JOSEPH NORTON | DIRECTOR OF FINANCE | 55 | $202,485 | $0 | $37,923 | $240,408 | 1 |
| ZAKARIA RAMADAN-JRADI | DIR. CELL THRPY & CLIN LAB | 55 | $196,818 | $0 | $37,359 | $234,177 | 1 |
| ALEANA WAITE | DIR. BMT, IMMUNO & RESEARCH INTEG. | 55 | $188,218 | $0 | $32,271 | $220,489 | 1 |
| SUSAN HAMMOND | DIRECTOR PROGRAM MANAGEMENT | 55 | $172,646 | $0 | $30,254 | $202,900 | 1 |
| KRISTINE LOGAN | DIRECTOR PT ACCESS & FACILITIES | 55 | $168,475 | $0 | $23,140 | $191,615 | 1 |
| LINDA LAKE | DIR. CLIN INFO SYST & HIM | 55 | $167,552 | $0 | $23,312 | $190,864 | 1 |
| ALPHONSO EMERY | DIRECTOR PATIENT ACCTG | 55 | $163,766 | $0 | $21,749 | $185,515 | 1 |
| MARGARET OWENS | CTP QUALITY SENIOR MANAGER | 55 | $165,626 | $0 | $15,892 | $181,518 | 1 |
| MOREEN DUDLEY | DIR. SUPPORT CARE/SPEC CLINICS | 55 | $153,854 | $0 | $26,265 | $180,119 | 1 |
| CAMILLE RAPACZ | DIRECTOR CPI | 55 | $151,677 | $0 | $27,639 | $179,316 | 1 |
| BARBARA JAGELS | DIR. CLINICAL EXCELLENCE | 55 | $144,516 | $0 | $31,068 | $175,584 | 1 |
| MICHELLE HALL | DIRECTOR OF IT SERVICES | 55 | $142,581 | $0 | $26,367 | $168,948 | 1 |
| CLAIRE BECK KEELER | DIRECTOR OF MARKETING | 55 | $137,470 | $0 | $29,813 | $167,283 | 1 |
| SHARI MCCLURE | DIR. MEDICAL STAFF SVCS | 55 | $140,989 | $0 | $19,725 | $160,714 | 1 |
| ROBB BAKEMEIER | CHAIRMAN | 8 | $0 | $0 | $0 | $0 | 4 |
| CARL BEHNKE | VICE CHAIR | 5 | $0 | $0 | $0 | $0 | 11 |
| KIMBERLY MCNALLY MN RN | SECRETARY | 2 | $0 | $0 | $0 | $0 | 1 |
| BOB GERTH | TREASURER | 5 | $0 | $0 | $0 | $0 | 2 |
| MARK GROUDINE MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| LISA BRANDENBURG | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| MIKE DELMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| JONELLE JOHNSON | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 2 |
| RICH JONES | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| ROB MACAULAY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RUTH MAHAN | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| RICH MCCUNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SHAN MULLIN | DIRECTOR | 4 | $0 | $0 | $0 | $0 | 2 |
| BROOKS RAGEN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| JOHNESE SPISSO | DIRECTOR | 5 | $0 | $0 | $0 | $0 | 7 |
| BRUDER STAPLETON MD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| MYRA TANITA | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
2011 · 41 people listed · 22 paid, $5.5M · 1,284 employees · 261 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $497,015 | $0 | $47,052 | $544,067 | 3 |
| JONATHAN TINGSTAD | CFO/VICE PRESIDENT | 55 | $394,532 | $0 | $52,814 | $447,346 | 2 |
| MADELINE BUELT | VP OPERATIONS/CHIEF NURSE | 55 | $351,011 | $0 | $52,805 | $403,816 | 2 |
| FRED APPELBAUM MD | EXEC DIRECTOR/PRESIDENT | 9 | $312,533 | $0 | $0 | $312,533 | 2 |
| DEBORAH GENTZEN | VP/CHIEF STRATEGY OFFICER | 55 | $258,113 | $0 | $44,480 | $302,593 | 1 |
| F MARC STEWART MD | MEDICAL DIRECTOR/VP | 20 | $274,720 | $0 | $0 | $274,720 | 3 |
| DAVID ACKERSON | VP/CHIEF INFO OFFICER | 55 | $232,121 | $0 | $33,290 | $265,411 | 1 |
| JOSEPH NORTON | DIRECTOR OF FINANCE | 55 | $203,243 | $0 | $40,394 | $243,637 | 1 |
| CHERYL WYMAN | DIR. DIAG. & THRPY. SVCS. | 55 | $208,064 | $0 | $34,668 | $242,732 | 1 |
| ZAKARIA RAMADAN-JRADI | DIR. CELL THRPY & CLIN LAB | 55 | $197,644 | $0 | $39,107 | $236,751 | 1 |
| GRETCHEN HANNA | DIR. CORPORATE FINANCE | 55 | $206,634 | $0 | $26,482 | $233,116 | 1 |
| ALEANA WAITE | DIR. BMT IMMUNO & RESEARCH | 55 | $186,815 | $0 | $33,183 | $219,998 | 1 |
| DEBORAH STENHJEM | DIR. REVENUE CYCLE MGMT | 55 | $174,505 | $0 | $31,703 | $206,208 | 1 |
| KRISTINE LOGAN | DIRECTOR OF FACILITIES | 55 | $164,835 | $0 | $24,045 | $188,880 | 1 |
| MOREEN DUDLEY | DIR. SUPPORT CARE/SPEC | 55 | $154,056 | $0 | $27,445 | $181,501 | 1 |
| SUSAN HAMMOND | DIR. PROGRAM MGMT | 55 | $163,603 | $0 | $16,078 | $179,681 | 1 |
| MARGARET OWENS | SR MGR CCP QUALITY | 55 | $160,214 | $0 | $18,048 | $178,262 | 1 |
| BARBARA JAGELS | DIR. CLINICAL EXCELLENCE | 55 | $145,374 | $0 | $32,635 | $178,009 | 1 |
| ALPHONSO EMERY | DIRECTOR PATIENT ACCTG | 55 | $154,042 | $0 | $21,462 | $175,504 | 1 |
| MICHELLE HALL | DIR. IT TECH SERVICES | 55 | $143,568 | $0 | $27,635 | $171,203 | 1 |
| LINDA LAKE | DIR. CLIN INFO SYST & HIM | 55 | $147,472 | $0 | $14,890 | $162,362 | 1 |
| SHARI MCCLURE | DIR. MEDICAL STAFF SVCS | 55 | $141,643 | $0 | $19,748 | $161,391 | 1 |
| BROOKS RAGEN | CHAIRMAN | 8 | $0 | $0 | $0 | $0 | 3 |
| ROBB BAKEMEIER | VICE CHAIR | 6 | $0 | $0 | $0 | $0 | 4 |
| CARL BEHNKE | SECRETARY | 5 | $0 | $0 | $0 | $0 | 11 |
| BOB GERTH | TREASURER | 5 | $0 | $0 | $0 | $0 | 2 |
| MARK GROUDINE MD PHD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| PAT HAGAN | DIRECTOR THRU 1/31/12 | 1 | $0 | $0 | $0 | $0 | 2 |
| LISA BRANDENBURG | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| JONELLE JOHNSON | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| RICH JONES | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| ROB MACAULAY | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 1 |
| RUTH MAHAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| LINDA MATTOX | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| RICH MCCUNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KIMBERLY MCNALLY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| SHAN MULLIN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| KATHY RANDALL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| JOHNESE SPISSO | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 7 |
| BRUDER STAPLETON MD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
| MYRA TANITA | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
2010 · 33 people listed · 18 paid, $4.3M · 1,168 employees · 250 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 40 | $438,652 | $0 | $47,263 | $485,915 | 3 |
| JONATHAN TINGSTAD | CFO/VICE PRESIDENT | 40 | $376,449 | $0 | $53,191 | $429,640 | 2 |
| MADELINE BUELT | VP OPERATIONS/CHIEF NURSE EXEC. | 40 | $359,536 | $0 | $53,220 | $412,756 | 2 |
| F MARC STEWART MD | MEDICAL DIRECTOR/VP | 20 | $253,900 | $0 | $0 | $253,900 | 3 |
| JOSEPH NORTON | DIRECTOR OF FINANCE | 40 | $199,553 | $0 | $40,026 | $239,579 | 1 |
| DEBORAH GENTZEN | DIR. STRAT. & BUS DEVEL | 40 | $195,406 | $0 | $40,083 | $235,489 | 1 |
| CHERYL WYMAN | DIR. DIAG. & TERP. SVCS | 40 | $198,815 | $0 | $32,584 | $231,399 | 1 |
| DAVID ACKERSON | CHIEF INFORMATION OFFCR | 40 | $195,699 | $0 | $28,665 | $224,364 | 1 |
| ALEANA WAITE | DIR. BMT IMMUNO & RESEARCH | 40 | $177,526 | $0 | $31,997 | $209,523 | 1 |
| ZAKARIA RAMADAN-JRADI | DIR. CELL THRPY & CLIN LABS | 40 | $173,919 | $0 | $24,824 | $198,743 | 1 |
| DEBORAH STENHJEM | DIR. REVENUE CYCLE MGMT | 40 | $163,314 | $0 | $30,296 | $193,610 | 1 |
| MARGARET OWENS | SR MGR CCP QUALITY | 40 | $149,832 | $0 | $33,091 | $182,923 | 1 |
| KRISTINE LOGAN | DIRECTOR OF FACILITIES | 40 | $156,020 | $0 | $23,300 | $179,320 | 1 |
| JAN WATTERSON | CONTROLLER | 40 | $148,894 | $0 | $27,235 | $176,129 | 1 |
| MOREEN DUDLEY | DIR. SUPPORT CARE/SPEC | 40 | $141,778 | $0 | $25,870 | $167,648 | 1 |
| MICHELLE HALL | DIR. IT TECH SERVICES | 40 | $137,965 | $0 | $27,141 | $165,106 | 1 |
| ALPHONSO EMERY | DIRECTOR PATIENT ACCTG | 40 | $143,739 | $0 | $19,764 | $163,503 | 1 |
| FRED APPELBAUM MD | EXEC DIRECTOR/PRESIDENT | 6 | $152,640 | $0 | $0 | $152,640 | 2 |
| RICH JONES | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| SUE ALBRECHT | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| BOB GERTH | TREASURER | 6 | $0 | $0 | $0 | $0 | 2 |
| SHAN MULLIN | SECRETARY | 3 | $0 | $0 | $0 | $0 | 2 |
| CARL BEHNKE | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 11 |
| MARK GROUDINE MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| MYRA TANITA | DIRECTOR | 3 | $0 | $0 | $0 | $0 | 2 |
| JONELLE JOHNSON | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| RUTH MAHAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| BROOKS RAGEN | DIRECTOR/CHAIR | 7 | $0 | $0 | $0 | $0 | 3 |
| KATHY RANDALL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| ROBB BAKEMEIER | DIRECTOR/VICE CHAIR | 6 | $0 | $0 | $0 | $0 | 4 |
| PAT HAGAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| JOHNESE SPISSO | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 7 |
| BRUDER STAPLETON MD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 3 |
2009 · 32 people listed · 14 paid, $3.4M · 1,045 employees · 200 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| NORMAN HUBBARD | EXECUTIVE VICE PRESIDENT | 55 | $450,280 | $0 | $47,059 | $497,339 | 3 |
| JONATHAN TINGSTAD | CFO AND VICE PRESIDENT | 55 | $370,029 | $0 | $52,640 | $422,669 | 2 |
| MADELINE BUELT | CHIEF NURSE EXEC AND VP | 55 | $354,894 | $0 | $52,664 | $407,558 | 2 |
| JOSEPH T NORTON | DIRECTOR BUS. INTEGRATION | 55 | $195,641 | $0 | $38,612 | $234,253 | 1 |
| DEBORAH GENTZEN | DIRECTOR BUS. DEVELOPMENT | 55 | $200,722 | $0 | $26,178 | $226,900 | 1 |
| CHERYL WYMAN | DTR.DIAG. & THERP. SVCS | 55 | $193,315 | $0 | $32,054 | $225,369 | 1 |
| DAVID ACKERSON | CHIEF INFORMATION OFFCR | 55 | $184,273 | $0 | $26,921 | $211,194 | 1 |
| ALEANA WAITE | DTR BLOOD & MARROW TRANS. | 55 | $173,900 | $0 | $25,274 | $199,174 | 1 |
| ANN RAISH | DTR DIAG. & THERAPY | 55 | $162,720 | $0 | $33,953 | $196,673 | 1 |
| DEBORAH STENHJEM | DTR REV. CYCLE & PAYOR | 55 | $158,704 | $0 | $29,094 | $187,798 | 1 |
| F MARC STEWART MD | CHIEF MEDICAL DIRECTOR | 28 | $182,772 | $0 | $0 | $182,772 | 3 |
| KRISTINE LOGAN | DTR FACILITIES | 55 | $152,309 | $0 | $24,599 | $176,908 | 1 |
| JAN WATTERSON | CONTROLLER | 55 | $148,512 | $0 | $22,575 | $171,087 | 1 |
| FRED APPELBAUM MD | EXE DIR AND PRESIDENT | 9 | $107,976 | $0 | $0 | $107,976 | 2 |
| CARL BEHNKE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 11 |
| BOB GERTH | TREASURER | 2 | $0 | $0 | $0 | $0 | 2 |
| MARK GROUDINE MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| RICH JONES | DIRECTOR/CHAIR | 2 | $0 | $0 | $0 | $0 | 2 |
| MYRA TANITA | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| JONELLE JOHNSON | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| RUTH MAHAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| SHAN MULLIN | DIRECTOR/SECRETARY | 2 | $0 | $0 | $0 | $0 | 2 |
| BROOKS RAGEN | DIRECTOR/VICE CHAIR | 2 | $0 | $0 | $0 | $0 | 3 |
| JOHNESE SPISSO | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 7 |
| SUE ALBRECHT | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| ROBB BAKEMEIER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 4 |
| PAT HAGEN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KATHY RANDALL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| BRUDER STAPLETON MD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| LEE HARTWELL | MEMBER | 2 | $0 | $0 | $0 | $0 | 1 |
| THOMAS HANSEN | MEMBER | 2 | $0 | $0 | $0 | $0 | 4 |
| PAUL RAMSEY | MEMBER | 2 | $0 | $0 | $0 | $0 | 4 |
Highest-paid independent contractors
2024 · 5 contractors · $179.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE SERVICES | $137,036,236 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | BONE MARROW TRANSPLANT SERVICES | $16,149,180 |
| LEASE CRUTCHER LEWIS | SEATTLE, WA | CONSTRUCTION SERVICES | $11,324,921 |
| IBA Proton Therapy Inc | Reston, VA | Proton Therapy Equipment Services | $8,869,296 |
| Allied Universal | Irvine, CA | Security Services | $6,132,156 |
2023 · 5 contractors · $225.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE SERVICES | $165,359,224 |
| GLY CONSTRUCTION INC | BELLEVUE, WA | CONSTRUCTION SERVICES | $27,432,116 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | BONE MARROW TRANSPLANT SERVICES | $17,191,214 |
| LEASE CRUTCHER LEWIS | SEATTLE, WA | CONSTRUCTION SERVICES | $8,722,862 |
| CLOUDMED SOLUTIONS LLC | PLANO, TX | DENIALS MANAGEMENT SERVICES | $6,510,276 |
2022 · 5 contractors · $286.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE SERVICES | $163,056,732 |
| GLY CONSTRUCTION INC | BELLEVUE, WA | CONSTRUCTION SERVICES | $92,084,358 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $13,734,600 |
| EMMES COMPANY | ROCKILLE, MD | RESEARCH SERVICES | $11,048,313 |
| LEASE CRUTCHER LEWIS | SEATTLE, WA | CONSTRUCTION SERVICES | $6,537,251 |
2021 · 5 contractors · $250.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES | $139,909,631 |
| GLY CONSTRUCTION INC | BELLEVUE, WA | CONSTRUCTION | $55,118,805 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULTING | $39,907,558 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $11,446,630 |
| LEASE CRUTCHER LEWIS | SEATTLE, WA | CONSTRUCTION | $4,065,963 |
2020 · 5 contractors · $247.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES | $149,778,956 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULT. | $43,768,814 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE, SERVICES | $25,579,316 |
| GLY CONSTRUCTION INC | BELLEVUE, WA | CONSTRUCTION | $17,451,549 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $11,172,257 |
2019 · 5 contractors · $278.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES | $189,989,747 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULT. | $40,161,744 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE, SERVICES | $26,012,177 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $13,962,071 |
| GLY CONSTRUCTION INC | BELLEVUE, WA | CONSTRUCTION | $8,797,141 |
2018 · 5 contractors · $308.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES | $231,830,300 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULT. | $38,417,306 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE, SERVICES | $19,712,389 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $13,628,732 |
| GLY CONSTRUCTION INC | BELLEVUE, WA | CONSTRUCTION | $4,913,134 |
2017 · 5 contractors · $270.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES | $195,754,182 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULT. | $35,543,947 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE, SERVICES | $23,070,660 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $11,288,352 |
| LEASE CRUTCHER LEWIS | SEATTLE, WA | CONSTRUCTION | $4,369,573 |
2016 · 5 contractors · $249.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES | $176,188,773 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULT. | $32,217,396 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE, SERVICES | $20,292,796 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $14,579,763 |
| LEASE CRUTCHER LEWIS | SEATTLE, WA | CONSTRUCTION | $5,986,039 |
2015 · 5 contractors · $180.7M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES, SUPPLIES | $115,141,690 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS, CONSULT. | $26,088,278 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE, SERVICES | $23,821,407 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $9,801,564 |
| PUGET SOUND BLOOD CENTER | SEATTLE, WA | BLOOD & TISSUE SERVICES | $5,850,203 |
2014 · 5 contractors · $266.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES, SUPPLIES | $208,360,837 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS CONSULT. | $27,085,795 |
| SEATTLE CHILDREN'S HOSPITAL | SEATTLE, WA | HEALTHCARE SERVICES | $16,183,072 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $9,594,232 |
| PUGET SOUND BLOOD CENTER | SEATTLE, WA | BLOOD & TISSUE SERVICES | $5,163,082 |
2013 · 5 contractors · $248.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERITY OF WASHINGTON | HEALTHCARE, SERVICES, SUPPLIES | $200,578,832 | |
| FRED HUTCHINSON CANCER RESEARCH CENTER | ADMIN, SUPPORT, SVCS CONSULT. | $19,864,971 | |
| SEATTLE CHILDREN'S HOSPITAL | HEALTHCARE SERVICES | $12,006,776 | |
| NATIONAL MARROW DONOR PROGRAM | MARROW TRANSPLANT SERVICES | $10,939,120 | |
| PUGET SOUND BLOOD CENTER | BLOOD & TISSUE SERVICES | $5,391,085 |
2012 · 5 contractors · $211.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES, SUPPLIES | $162,107,298 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, SVCS CONSULT. | $19,773,377 |
| SEATTLE CHILDRENS HOSPITAL | SEATTLE, WA | HEALTHCARE SERVICES | $14,832,944 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $9,279,161 |
| PUGET SOUND BLOOD CENTER | SEATTLE, WA | BLOOD & TISSUE SERVICES | $5,230,073 |
2011 · 5 contractors · $194.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES, SUPPLIES, ADMIN | $151,808,808 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, & SERVICES CONSULTING | $18,580,545 |
| SEATTLE CHILDRENS HOSPITAL | SEATTLE, WA | HEALTHCARE SERVICES | $10,975,428 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $8,558,513 |
| PUGET SOUND BLOOD CENTER | SEATTLE, WA | BLOOD & TISSUE SERVICES | $4,848,723 |
2010 · 5 contractors · $173.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES, SUPPLIES, ADMIN | $137,606,981 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, & SERVICES CONSULTING | $16,995,500 |
| SEATTLE CHILDRENS HOSPITAL | SEATTLE, WA | HEALTHCARE SERVICES | $7,784,463 |
| NATIONAL MARROW DONOR PROGRAM | MINNEAPOLIS, MN | MARROW TRANSPLANT SERVICES | $6,965,988 |
| PUGET SOUND BLOOD CENTER | SEATTLE, WA | BLOOD & TISSUE SERVICES | $4,223,724 |
2009 · 5 contractors · $148.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | HEALTHCARE, SERVICES, SUPPLIES AND ADMIN | $125,922,606 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | SEATTLE, WA | ADMIN, SUPPORT, & SERVICES CONSULTING | $15,053,262 |
| TURNER CORPORATION | SEATTLE, WA | GENERAL CONTRACTOR | $4,394,799 |
| POINT B SOLUTIONS GROUP | SEATTLE, WA | HEALTHCARE CONSULTING | $2,254,737 |
| COPACINO AND FUJIKADO LLC | SEATTLE, WA | ADVERTISING CONSULTING | $987,043 |
Paid as a vendor by
Other organizations that listed this one among their highest-paid independent contractors. Contractor lists give no EIN, so these are matched on name and address; check the filing.
| Year | Paid by | Service | Paid | Filing |
|---|---|---|---|---|
| 2022 | EVERGREEN SOCIAL IMPACT | COVID-19 DATA RESEARCH PROJECT - CARE FU | $259,106 | view vendor page |
| 2021 | EVERGREEN SOCIAL IMPACT | COVID-19 DATA PROJECT | $591,666 | view vendor page |
| 2018 | FRED HUTCHINSON CANCER RESEARCH CENTER | PATIENT CARE SERVICES | $2,661,240 | view vendor page |
| 2017 | FRED HUTCHINSON CANCER RESEARCH CENTER | PATIENT CARE SERVICES | $1,904,354 | view vendor page |
| 2016 | FRED HUTCHINSON CANCER RESEARCH CENTER | PATIENT CARE SERVICES | $1,898,159 | view vendor page |
| 2015 | FRED HUTCHINSON CANCER RESEARCH CENTER | PATIENT CARE SERVICES | $1,720,284 | view vendor page |
| 2014 | FRED HUTCHINSON CANCER RESEARCH CENTER | PATIENT CARE SERVICES | $1,658,797 | view vendor page |
| 2012 | SEATTLE CHILDRENS HOSPITAL | PATIENT SUPPORT SERVICES | $4,184,040 | view vendor page |
| 2011 | FRED HUTCHINSON CANCER RESEARCH CENTER | PATIENT CARE SERVICES | $1,607,937 | view vendor page |
| 2010 | FRED HUTCHINSON CANCER RESEARCH CENTER | Patient care services | $3,520,670 | view vendor page |
Who the money went to
Grants this organization reported paying: Schedule I Part II of the Form 990, or the grants-paid list on the 990-PF. Open a year for every recipient. Recipients link to their own page when the grant names an EIN we have (990-PF grants list no EIN, so those link only on an exact, unique name and state). Grants to individuals are counted; their names are not shown.
2024 · 139 grants to organizations · $88.2M
Listed grants add up to $88,236,398; the return's “grants paid” expense line says $101,223,693. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2023 · 143 grants to organizations · $97.2M
Listed grants add up to $97,228,267; the return's “grants paid” expense line says $120,169,153. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2022 · 276 grants to organizations · $84.4M
Listed grants add up to $84,367,353; the return's “grants paid” expense line says $149,912,745. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2021 · 179 grants to organizations · $27.7M
Listed grants add up to $27,655,479; the return's “grants paid” expense line says $34,738,432. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2020 · 18 grants to organizations · $1.4M
Listed grants add up to $1,378,719; the return's “grants paid” expense line says $2,084,886. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2019 · 17 grants to organizations · $2.1M
Listed grants add up to $2,070,767; the return's “grants paid” expense line says $2,660,139. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2018 · 23 grants to organizations · $2.4M
Listed grants add up to $2,434,983; the return's “grants paid” expense line says $3,012,177. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2017 · 13 grants to organizations · $1.2M
Listed grants add up to $1,190,522; the return's “grants paid” expense line says $1,742,018. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2016 · 13 grants to organizations · $1.4M
Listed grants add up to $1,363,059; the return's “grants paid” expense line says $1,927,743. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2015 · 17 grants to organizations · $1.3M
Listed grants add up to $1,265,855; the return's “grants paid” expense line says $2,007,625. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2014 · 15 grants to organizations · $883K
Listed grants add up to $882,709; the return's “grants paid” expense line says $1,606,020. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2013 · 5 grants to organizations · $553K
Listed grants add up to $552,701; the return's “grants paid” expense line says $1,301,089. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2012 · 5 grants to organizations · $940K
Listed grants add up to $940,260; the return's “grants paid” expense line says $1,632,418. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2011 · 4 grants to organizations · $230K
Listed grants add up to $229,981; the return's “grants paid” expense line says $935,916. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2010 · 7 grants to organizations · $335K
Listed grants add up to $335,387; the return's “grants paid” expense line says $1,122,767. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2009 · 7 grants to organizations · $197K
Listed grants add up to $197,405; the return's “grants paid” expense line says $815,215. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
Negative amounts are returned or refunded grants; they are listed last and left out of the totals of grants paid.
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2024 · Form 990 | ||||||||
| $2,532,392,907 | $2,405,985,717 | $3,600,753,073 | $1,567,044,212 | $705,214,753 | $1,650,922,336 | $13,818,314 | 7,088 | 719 |
| 2023 · Form 990 | ||||||||
| $2,027,046,671 | $2,064,743,953 | $3,453,149,919 | $1,457,169,210 | $630,655,652 | $1,354,597,702 | $11,061,327 | 6,797 | 614 |
| 2022 · Form 990 | ||||||||
| $2,322,795,971 | $1,951,660,593 | $3,407,176,412 | $1,382,874,978 | $1,047,209,861 | $1,220,881,238 | $16,536,682 | 6,568 | 965 |
| 2021 · Form 990 | ||||||||
| $1,283,961,922 | $1,134,529,429 | $2,999,831,201 | $950,248,984 | $159,178,335 | $1,046,363,504 | $12,403,720 | 2,549 | 250 |
| 2020 · Form 990 | ||||||||
| $940,996,725 | $841,344,866 | $1,535,470,671 | $789,481,700 | $6,302,039 | $917,419,752 | $9,646,383 | 2,189 | 198 |
| 2019 · Form 990 | ||||||||
| $820,892,125 | $735,653,659 | $1,020,161,042 | $637,251,319 | $21,346,663 | $784,400,026 | $11,648,396 | 2,069 | 225 |
| 2018 · Form 990 | ||||||||
| $757,282,570 | $684,323,509 | $753,310,466 | $562,366,180 | $5,636,906 | $733,760,564 | $11,314,412 | 1,917 | 245 |
| 2017 · Form 990 | ||||||||
| $653,487,789 | $610,353,946 | $647,980,104 | $489,909,484 | $3,937,565 | $640,707,064 | $9,912,108 | 1,811 | 249 |
| 2016 · Form 990 | ||||||||
| $556,116,574 | $528,580,707 | $593,129,652 | $439,269,070 | $4,436,071 | $546,848,167 | $9,263,825 | 1,681 | 241 |
| 2015 · Form 990 | ||||||||
| $539,616,252 | $475,898,010 | $556,564,703 | $393,480,308 | $4,648,972 | $525,316,260 | $9,152,710 | 1,559 | 234 |
| 2015 · Form 990 | ||||||||
| $539,616,252 | $475,898,010 | $556,564,703 | $393,480,308 | $4,648,972 | $525,316,260 | $9,152,710 | 1,559 | 234 |
| 2014 · Form 990 | ||||||||
| $464,122,606 | $443,892,609 | $523,790,656 | $335,822,385 | $2,501,715 | $476,998,099 | $6,733,157 | 1,517 | 236 |
| 2014 · Form 990 | ||||||||
| $464,122,606 | $443,892,609 | $523,790,656 | $335,822,385 | $2,501,715 | $476,998,099 | $6,733,157 | 1,517 | 236 |
| 2013 · Form 990 | ||||||||
| $434,611,182 | $409,414,069 | $488,899,365 | $318,190,632 | $2,092,569 | $430,480,614 | $5,485,059 | 1,390 | 232 |
| 2012 · Form 990 | ||||||||
| $392,664,332 | $365,615,667 | $440,984,867 | $283,062,006 | $3,643,872 | $384,863,259 | $5,189,089 | 1,330 | 340 |
| 2011 · Form 990 | ||||||||
| $358,084,282 | $327,907,205 | $415,596,706 | $262,011,937 | $2,564,192 | $348,949,857 | $5,185,367 | 1,284 | 261 |
| 2010 · Form 990 | ||||||||
| $332,954,648 | $301,665,248 | $404,530,310 | $244,137,968 | $8,779,628 | $318,736,590 | $3,931,391 | 1,168 | 250 |
| 2009 · Form 990 | ||||||||
| $288,963,384 | $263,918,776 | $351,917,541 | $216,791,660 | $3,407,869 | $281,020,389 | $2,619,013 | 1,045 | 200 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- FRED HUTCHINSON CANCER RESEARCH CENTER Seattle, WA · 15 people in common (Bruce E Clurman Md Phd, Chris Bundesmann, David Browdy)
- ASSOCIATION OF UNIVERSITY PHYSICIANS Seattle, WA · 2 people in common (Bradley Simmons, Timothy Dellit Md)
- WASHINGTON ROUNDTABLE Seattle, WA · 2 people in common (Leigh Morgan, Michelle Seitz)
- UNIVERSITY OF WASHINGTON FOUNDATION Seattle, WA · 1 person in common (Pete Shimer)
- UW PHYSICIANS NETWORK Seattle, WA · 1 person in common (Timothy Dellit Md)
- PORTAGE BAY INSURANCE Seattle, WA · 1 person in common (Timothy Dellit Md)
- UNITED WAY OF KING COUNTY Seattle, WA · 1 person in common (Kathy Surace-Smith)
- YOUNG WOMENS CHRISTIAN ASSOCIATION OF SEATTLE-KING COUNTY-SNOHOMISH C Seattle, WA · 1 person in common (Kathy Surace-Smith)
- INSTITUTE FOR SYSTEMS BIOLOGY Seattle, WA · 1 person in common (Stephen Graham)
- PACIFIC SCIENCE CENTER FOUNDATION Seattle, WA · 1 person in common (David Browdy)
- SEATTLE INTERNATIONAL SOCCER LOCAL ORGANIZING COMMITTEE Seattle, WA · 1 person in common (Pete Shimer)
- TSF PROPERTIES Seattle, WA · 1 person in common (Pete Shimer)
- GREATER SEATTLE CHAMBER OF COMMERCE Seattle, WA · 1 person in common (Kathy Surace-Smith)
- LIFE SCIENCE WASHINGTON Seattle, WA · 1 person in common (Stephen Graham)
- JUNIOR ACHIEVEMENT USA Auburn, WA · 1 person in common (Pete Shimer)
- DRESS FOR SUCCESS SEATTLE Seattle, WA · 1 person in common (Kathy Surace-Smith)
- SEATTLE VACCINE RESEARCH FUND Seattle, WA · 1 person in common (Chris Bundesmann) · related organization (Schedule R)
- WINGS THE WASHINGTON TECHNOLOGY AN Seattle, WA · 1 person in common (Stephen Graham)
- YOUNG WOMENS SERVICE ASSOCIATION OF SEATTLE-KING COUNTY Seattle, WA · 1 person in common (Kathy Surace-Smith)
- TSF SERVICES Seattle, WA · 1 person in common (Pete Shimer)
Funders of this organization
249 grantors reported grants to this organization, $203,452,706 in all, tax years 2009 to 2025; the 25 largest shown (all 249). Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Type | Match | Years given | Grants | Total | Latest year | Latest year's amount | Grants |
|---|---|---|---|---|---|---|---|---|
| EMORY UNIVERSITY | Public charity | Exact | 2021-2024 | 4 | $28,558,540 | 2024 | $4,027,574 | show |
| GATES FOUNDATION | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2022-2024 | 20 | $26,453,840 | 2024 | $8,950,570 | show |
| FAMILY HEALTH INTERNATIONAL | Public charity | Exact | 2022-2024 | 3 | $13,689,792 | 2024 | $3,919,654 | show |
| VANGUARD CHARITABLE ENDOWMENT PROGRAM | DAF sponsor | Exact | 2020-2024 | 5 | $12,828,578 | 2024 | $1,535,650 | show |
| SEATTLE CHILDRENS HOSPITAL | DAF sponsor | Exact | 2010, 2021-2024 | 5 | $12,706,559 | 2024 | $2,165,165 | show |
| GS DONOR ADVISED PHILANTHROPY FUND FOR WEALTH MANAGEMENT INC | DAF sponsor | Exact | 2022-2024 | 3 | $8,962,250 | 2024 | $8,650,750 | show |
| DONOR ADVISED CHARITABLE GIVING | DAF sponsor | Exact | 2014-2024 | 11 | $8,633,054 | 2024 | $4,346,853 | show |
| FIDELITY INVESTMENTS CHARITABLE GIFT FUND | DAF sponsor | Exact | 2016-2024 | 9 | $8,048,333 | 2024 | $4,642,176 | show |
| LARRY BENAROYA FAMILY FOUNDATION | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2025 | 1 | $7,400,000 | 2025 | $7,400,000 | show |
| THE SEATTLE FOUNDATION | DAF sponsor | Exact | 2013-2014, 2016-2024 | 149 | $6,202,326 | 2024 | $2,493,235 | show |
| SWIM ACROSS AMERICA INC | Public charity | Exact | 2010-2025 | 16 | $5,095,000 | 2025 | $500,000 | show |
| THE V FOUNDATION | Public charity | Exact | 2021-2024 | 4 | $4,950,000 | 2024 | $3,100,000 | show |
| AMERICAN ONLINE GIVING FOUNDATION INC | DAF sponsor | Exact | 2019-2022, 2024-2025 | 6 | $3,272,068 | 2025 | $1,447,704 | show |
| WAYNE D KUNI AND JOAN E KUNI | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2022-2024 | 3 | $3,173,738 | 2024 | $898,738 | show |
| CHILDRENS CANCER RESEARCH FUND | Public charity | Exact | 2022-2024 | 4 | $2,625,096 | 2024 | $750,095 | show |
| LOPKER FAMILY FOUNDATION | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2023-2024 | 2 | $2,000,000 | 2024 | $1,000,000 | show |
| FUND FOR SCIENCE AND TECHNOLOGY | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2024 | 1 | $2,000,000 | 2024 | $2,000,000 | show |
| EUCALYPTUS FOUNDATION | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2022-2024 | 3 | $2,000,000 | 2024 | $1,000,000 | show |
| SCRIPPS RESEARCH INSTITUTE | Public charity | Exact | 2023-2024 | 2 | $1,954,804 | 2024 | $900,437 | show |
| MORGAN STANLEY GLOBAL IMPACT FUNDING TRUST INC | DAF sponsor | Exact | 2021-2024 | 11 | $1,882,660 | 2024 | $491,660 | show |
| G HAROLD AND LEILA MATHERS CHARITABLE FOUNDATION | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2010-2015, 2017-2020 | 12 | $1,725,000 | 2020 | $125,000 | show |
| UNIVERSITY OF SOUTHERN CALIFORNIA | DAF sponsor | Exact | 2023-2024 | 2 | $1,721,436 | 2024 | $861,338 | show |
| GERDIN CHARITABLE FOUNDATION | Private foundation | Fuzzy filed as “FRED HUTCHINSON CANCER CENTER” | 2023-2025 | 3 | $1,650,000 | 2025 | $550,000 | show |
| THE CHICAGO COMMUNITY TRUST | DAF sponsor | Exact | 2022-2024 | 3 | $1,501,000 | 2024 | $601,000 | show |
| SAN FRANCISCO FOUNDATION | DAF sponsor | Exact | 2024 | 1 | $1,500,000 | 2024 | $1,500,000 | show |
Nearby + Similar BETA
Organizations like this one: what they do and who they are linked to
Same category: NTEE code and revenue
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| SEATTLE CHILDRENS HOSPITAL | WA | E24 | $3,072,099,534 | $2,598,347,643 | FORMER OFFICER | $2,856,316 | Same NTEE code E24, revenue within 2x, same state |
| H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC | FL | E24 | $2,640,684,525 | $2,186,992,097 | FRM HOSPITAL PRES TO 10/2021 | $2,243,616 | Same NTEE code E24, revenue within 2x |
| CITY OF HOPE NATIONAL MEDICAL CENTER | CA | E24 | $3,432,349,751 | $3,288,442,084 | PRESIDENT & CEO | $7,115,860 | Same NTEE code E24, revenue within 2x |
| SHRINERS HOSPITALS FOR CHILDREN | FL | E24 | $1,582,506,437 | $1,193,256,330 | CHIEF OF STAFF | $2,387,804 | Same NTEE code E24, revenue within 2x, similar mission |
| CHILDRENS HOSPITAL MEDICAL CENTER | OH | E24 | $3,568,680,376 | $3,363,161,573 | DIV. DIR, CARDIOLOGY | $3,370,355 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HOSPITAL MEDICAL CENTER OF AKRON | OH | E24 | $1,540,288,244 | $1,353,888,762 | BOD/OFFICER-PRESIDENT AND CEO | $1,791,308 | Same NTEE code E24, revenue within 2x |
| COOK CHILDRENS MEDICAL CENTER | TX | E24 | $2,268,395,631 | $1,746,134,010 | CEO | $3,598,135 | Same NTEE code E24, revenue within 2x |
| ST JUDE CHILDRENS RESEARCH HOSPITAL INC | TN | E24 | $2,208,853,162 | $1,897,571,834 | PRESIDENT/CEO | $1,713,883 | Same NTEE code E24, revenue within 2x |
| CHILDRENS MERCY HOSPITAL | MO | E24 | $2,340,991,656 | $2,006,474,542 | Director; President & CEO; End 1/2/25 | $1,803,068 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HOSPITAL COLORADO | CO | E24 | $2,014,273,578 | $1,968,035,328 | Chief Executive Officer | $4,286,194 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HOSPITAL LOS ANGELES | CA | E24 | $1,816,852,966 | $1,930,797,327 | Director, CEO | $1,888,151 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HOSPITAL CORPORATION | MA | E24 | $3,588,588,824 | $3,527,089,859 | Chief Executive Officer | $3,490,323 | Same NTEE code E24, revenue within 2x |
| TEXAS CHILDRENS HOSPITAL | TX | E24 | $4,436,955,658 | $4,105,997,047 | BOARD MEMBER, CHAIR & CEO THROUGH 10/4/24 | $13,338,019 | Same NTEE code E24, revenue within 2x |
| RADY CHILDRENS HOSPITAL SAN DIEGO | CA | E24 | $1,762,087,501 | $1,717,147,159 | PRESIDENT & CEO | $2,563,540 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HEALTH SYSTEM OF TEXAS | TX | E24 | $2,662,618,681 | $2,449,136,918 | President CEO | $4,345,262 | Same NTEE code E24, revenue within 2x |
| NEW YORK SOCIETY FOR THE RELIEF OF RUPTURED & CRIPPLED MAINTAINING | NY | E24 | $1,756,859,714 | $1,642,543,258 | President & CEO | $5,329,588 | Same NTEE code E24, revenue within 2x |
| LUCILE SALTER PACKARD CHILDRENS HOSPITAL AT STANFORD | CA | E24 | $2,890,101,302 | $2,734,866,795 | DIRECTOR | $5,385,633 | Same NTEE code E24, revenue within 2x |
| DRISCOLL CHILDRENS HOSPITAL | TX | E24 | $1,456,858,271 | $916,288,284 | EXECUTIVE VICE PRESIDENT & COO | $2,429,480 | Same NTEE code E24, revenue within 2x |
| THE NEMOURS FOUNDATION | FL | E24 | $2,357,991,833 | $2,111,711,586 | President and CEO | $3,081,278 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HOSPITAL | DC | E24 | $1,872,813,787 | $1,777,542,451 | FORMER CHIEF OPERATING OFFICER | $3,140,501 | Same NTEE code E24, revenue within 2x |
| PHOENIX CHILDRENS HOSPITAL | AZ | E24 | $1,736,932,091 | $1,538,377,122 | DIRECTOR/PRESIDENT & CEO | $3,558,771 | Same NTEE code E24, revenue within 2x |
| CHILDRENS HOSPITAL OF ORANGE COUNTY | CA | E24 | $1,687,593,095 | $1,470,505,641 | PRESIDENT & CEO | $2,563,540 | Same NTEE code E24, revenue within 2x |
| THE CHILDRENS HOSPITAL OF PHILADELPHIA | PA | E24 | $4,165,576,231 | $3,837,536,215 | PRESIDENT, CEO & TRUSTEE | $5,479,580 | Same NTEE code E24, revenue within 2x |
| ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO | IL | E24 | $1,726,489,572 | $1,477,118,547 | Ex-Officio Director/President & CEO LCH | $2,617,499 | Same NTEE code E24, revenue within 2x |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NY | E24 | $8,499,234,483 | $7,913,348,443 | Board member, President & CEO | $6,979,162 | Same NTEE code E24, revenue within 5x |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2024 · Form 990 · $2,405,985,717 spent · pay $853,703,548 · grants $101,223,693 · events $6,266,573
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | Medical & Research Supplies | $754,870,116 | $754,870,116 | - | - | 31.4% |
| Other salaries and wages | $654,299,492 | $527,532,817 | $112,031,737 | $14,734,938 | 27.2% | |
| Fees: other services | $275,123,584 | $238,828,298 | $32,870,587 | $3,424,699 | 11.4% | |
| Other employee benefits | $91,267,501 | $91,610,039 | -$2,148,574 | $1,806,036 | 3.8% | |
| Grants to US organizations and governments | $88,367,993 | $88,367,993 | - | - | 3.7% | |
| Other (as described) | Collaborative Agreement | $78,943,217 | $78,943,217 | - | - | 3.3% |
| Depreciation and depletion | $75,810,261 | $59,765,853 | $15,876,768 | $167,640 | 3.2% | |
| Information technology | $55,911,496 | $8,921,760 | $46,977,952 | $11,784 | 2.3% | |
| Payroll taxes | $48,233,558 | $39,027,144 | $8,183,319 | $1,023,095 | 2.0% | |
| Interest | $46,832,691 | $43,963,789 | $2,693,397 | $175,505 | 1.9% | |
| Pension plan contributions | $40,299,606 | $33,233,104 | $6,109,403 | $957,099 | 1.7% | |
| Occupancy | $39,484,850 | $27,495,613 | $11,983,614 | $5,623 | 1.6% | |
| Other (as described) | Equipment Rental & Maintenance | $27,856,352 | $27,294,202 | $559,197 | $2,953 | 1.2% |
| All other expenses | $23,416,602 | $17,292,465 | $3,116,301 | $3,007,836 | 1.0% | |
| Other (as described) | Safety Net | $20,058,751 | $20,058,751 | - | - | 0.8% |
| Pay: officers, directors, trustees, key employees | $13,818,314 | $5,526,945 | $7,386,126 | $905,243 | 0.6% | |
| Office expenses | $13,032,579 | $11,035,900 | $212,184 | $1,784,495 | 0.5% | |
| Grants outside the US | $9,547,200 | $9,547,200 | - | - | 0.4% | |
| Insurance | $8,153,085 | $93,667 | $8,059,418 | - | 0.3% | |
| Advertising and promotion | $8,133,913 | $218,664 | $7,735,078 | $180,171 | 0.3% | |
| Travel | $6,640,359 | $5,672,195 | $717,232 | $250,932 | 0.3% | |
| Pay: disqualified persons | $5,785,077 | $1,808,345 | $3,976,732 | - | 0.2% | |
| Royalties | $5,403,599 | $5,403,599 | - | - | 0.2% | |
| Conferences, conventions and meetings | $4,101,043 | $3,595,950 | $457,267 | $47,826 | 0.2% | |
| Grants to US individuals | $3,308,500 | $3,308,500 | - | - | 0.1% | |
| Fees: legal | $2,842,662 | - | $2,842,662 | - | 0.1% | |
| Fees: investment management | $2,084,560 | - | $2,084,560 | - | 0.1% | |
| Fees: accounting | $1,195,124 | - | $1,195,124 | - | 0.0% | |
| Fees: lobbying | $706,691 | - | $706,691 | - | 0.0% | |
| Fees: professional fundraisers | $456,941 | - | - | $456,941 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $361,744 | $2,165,530 | reported apart | |||
| Total | $2,405,985,717 | 100% |
2023 · Form 990 · $2,064,743,953 spent · pay $754,924,414 · grants $120,169,153 · events $8,809,032
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL & RESEARCH SUPP | $595,006,102 | $588,280,269 | $6,662,168 | $63,665 | 28.8% |
| Other salaries and wages | $582,520,121 | $480,156,555 | $90,054,756 | $12,308,810 | 28.2% | |
| Fees: other services | $221,798,315 | $202,655,418 | $16,419,864 | $2,723,033 | 10.7% | |
| Grants to US organizations and governments | $97,410,892 | $97,410,892 | - | - | 4.7% | |
| Other employee benefits | $72,486,077 | $55,520,151 | $15,651,286 | $1,314,640 | 3.5% | |
| Depreciation and depletion | $68,576,412 | $57,377,328 | $11,030,489 | $168,595 | 3.3% | |
| Occupancy | $58,153,190 | $43,501,281 | $14,602,783 | $49,126 | 2.8% | |
| Information technology | $53,405,919 | $11,755,278 | $41,560,252 | $90,389 | 2.6% | |
| Other (as described) | COLLAB. ARRANGEMENT | $50,056,494 | $50,056,494 | - | - | 2.4% |
| Payroll taxes | $47,597,912 | $38,882,347 | $7,749,046 | $966,519 | 2.3% | |
| Interest | $44,147,222 | $41,538,465 | $2,453,547 | $155,210 | 2.1% | |
| Pension plan contributions | $36,472,503 | $30,323,252 | $5,348,984 | $800,267 | 1.8% | |
| All other expenses | $21,910,053 | $7,153,717 | $11,901,974 | $2,854,362 | 1.1% | |
| Grants outside the US | $20,567,457 | $20,567,457 | - | - | 1.0% | |
| Other (as described) | EQUIP. RENTAL & MAINT. | $16,406,431 | $15,696,815 | $708,635 | $981 | 0.8% |
| Office expenses | $11,104,046 | $10,264,739 | $96,632 | $742,675 | 0.5% | |
| Pay: officers, directors, trustees, key employees | $11,061,327 | $5,416,188 | $4,809,175 | $835,964 | 0.5% | |
| Other (as described) | SAFETY NET | $10,014,691 | $10,014,691 | - | - | 0.5% |
| Advertising and promotion | $8,877,630 | $6,283,834 | $1,405,630 | $1,188,166 | 0.4% | |
| Insurance | $7,838,093 | $71,598 | $7,766,495 | - | 0.4% | |
| Conferences, conventions and meetings | $7,155,973 | $6,377,412 | $724,479 | $54,082 | 0.3% | |
| Travel | $6,196,885 | $5,412,264 | $528,203 | $256,418 | 0.3% | |
| Pay: disqualified persons | $4,786,474 | $1,291,735 | $3,494,739 | - | 0.2% | |
| Royalties | $2,829,264 | $2,829,264 | - | - | 0.1% | |
| Fees: legal | $2,659,762 | - | $2,659,762 | - | 0.1% | |
| Grants to US individuals | $2,190,804 | $2,190,804 | - | - | 0.1% | |
| Fees: investment management | $1,349,900 | - | $1,349,900 | - | 0.1% | |
| Fees: accounting | $1,161,689 | - | $1,161,689 | - | 0.1% | |
| Fees: lobbying | $713,988 | - | $713,988 | - | 0.0% | |
| Fees: professional fundraisers | $288,327 | - | - | $288,327 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $721,335 | $1,653,059 | reported apart | |||
| Total | $2,064,743,953 | 100% |
2022 · Form 990 · $1,951,660,593 spent · pay $657,862,084 · grants $149,912,745 · events $5,414,683
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $512,808,390 | $412,529,480 | $90,616,788 | $9,662,122 | 26.3% | |
| Other (as described) | MEDICAL SUPPLIES | $488,133,719 | $488,043,908 | $89,811 | - | 25.0% |
| Fees: other services | $251,246,227 | $196,545,573 | $51,075,484 | $3,625,170 | 12.9% | |
| Other (as described) | COLLAB. ARRANGEMENT | $101,613,919 | $101,613,919 | - | - | 5.2% |
| Grants to US organizations and governments | $84,461,089 | $84,461,089 | - | - | 4.3% | |
| Grants outside the US | $62,314,067 | $62,314,067 | - | - | 3.2% | |
| Other employee benefits | $57,413,718 | $46,174,066 | $10,239,518 | $1,000,134 | 2.9% | |
| Depreciation and depletion | $53,626,068 | $47,329,616 | $6,203,223 | $93,229 | 2.7% | |
| Information technology | $51,120,530 | $7,575,033 | $43,545,497 | - | 2.6% | |
| Payroll taxes | $41,938,122 | $33,607,578 | $7,604,475 | $726,069 | 2.1% | |
| Occupancy | $41,645,085 | $27,359,113 | $14,285,972 | - | 2.1% | |
| Interest | $37,980,819 | $35,243,057 | $2,585,664 | $152,098 | 1.9% | |
| Other (as described) | RESEARCH SUPPLIES | $34,280,192 | $34,280,192 | - | - | 1.8% |
| Pension plan contributions | $28,623,103 | $15,202,657 | $12,901,208 | $519,238 | 1.5% | |
| Other (as described) | MEDICAL EQUIPMENT R&M | $27,115,613 | $16,504,827 | $10,465,587 | $145,199 | 1.4% |
| Pay: officers, directors, trustees, key employees | $16,536,682 | $9,378,348 | $6,524,333 | $634,001 | 0.8% | |
| Office expenses | $15,207,325 | $8,354,457 | $5,192,641 | $1,660,227 | 0.8% | |
| Insurance | $8,670,745 | $198,825 | $8,471,920 | - | 0.4% | |
| All other expenses | $8,091,462 | $81,464,819 | -$78,304,246 | $4,930,889 | 0.4% | |
| Advertising and promotion | $5,304,965 | $5,188,652 | $113,305 | $3,008 | 0.3% | |
| Travel | $4,621,474 | $4,128,232 | $358,656 | $134,586 | 0.2% | |
| Conferences, conventions and meetings | $4,380,457 | $3,753,465 | $601,313 | $25,679 | 0.2% | |
| Fees: management | $3,653,265 | $3,638,680 | $14,585 | - | 0.2% | |
| Grants to US individuals | $3,137,589 | $3,137,589 | - | - | 0.2% | |
| Fees: legal | $2,512,602 | $840,526 | $1,672,076 | - | 0.1% | |
| Fees: professional fundraisers | $2,279,028 | - | - | $2,279,028 | 0.1% | |
| Fees: investment management | $1,240,531 | - | $1,240,531 | - | 0.1% | |
| Fees: lobbying | $635,646 | - | $635,646 | - | 0.0% | |
| Pay: disqualified persons | $542,069 | $542,069 | - | - | 0.0% | |
| Fees: accounting | $526,092 | - | $526,092 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income $305,531 | $1,034,226 | reported apart | |||
| Total | $1,951,660,593 | 100% |
2021 · Form 990 · $1,134,529,429 spent · pay $328,167,481 · grants $34,738,432 · events $1,957,610
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $405,166,992 | $405,124,347 | $42,645 | - | 35.7% |
| Other salaries and wages | $244,374,099 | $194,761,626 | $47,732,776 | $1,879,697 | 21.5% | |
| Fees: other services | $189,205,709 | $156,177,791 | $32,214,020 | $813,898 | 16.7% | |
| Information technology | $38,495,711 | $9,117,865 | $29,377,846 | - | 3.4% | |
| Depreciation and depletion | $36,525,546 | $30,133,283 | $6,409,483 | -$17,220 | 3.2% | |
| Other employee benefits | $34,896,410 | $26,213,444 | $8,158,026 | $524,940 | 3.1% | |
| Occupancy | $30,887,837 | $15,479,743 | $15,407,730 | $364 | 2.7% | |
| Grants to US organizations and governments | $27,811,433 | $27,811,433 | - | - | 2.5% | |
| Payroll taxes | $21,325,978 | $15,748,369 | $5,239,792 | $337,817 | 1.9% | |
| Pension plan contributions | $15,167,274 | $11,094,928 | $3,769,309 | $303,037 | 1.3% | |
| Pay: officers, directors, trustees, key employees | $12,403,720 | $4,079,692 | $8,324,028 | - | 1.1% | |
| Other (as described) | RESEARCH SUPPLIES | $10,342,543 | $10,342,543 | - | - | 0.9% |
| Other (as described) | BUSINESS TAXES | $9,697,061 | $5,478,234 | $4,218,827 | - | 0.9% |
| Interest | $9,232,462 | $7,629,279 | $1,587,272 | $15,911 | 0.8% | |
| Other (as described) | MEDICAL EQUIPMENT R&M | $8,850,487 | $8,831,486 | $19,001 | - | 0.8% |
| Office expenses | $7,517,306 | $3,134,381 | $2,274,105 | $2,108,820 | 0.7% | |
| Fees: management | $5,450,073 | $5,450,073 | - | - | 0.5% | |
| Grants outside the US | $5,378,847 | $5,378,847 | - | - | 0.5% | |
| All other expenses | $4,450,310 | $23,912,797 | -$16,924,599 | -$2,537,888 | 0.4% | |
| Advertising and promotion | $3,450,070 | $3,407,695 | $17,816 | $24,559 | 0.3% | |
| Fees: legal | $2,813,842 | $614,579 | $2,199,263 | - | 0.2% | |
| Insurance | $2,639,982 | $877,449 | $1,762,533 | - | 0.2% | |
| Conferences, conventions and meetings | $1,850,554 | $1,487,149 | $360,133 | $3,272 | 0.2% | |
| Grants to US individuals | $1,548,152 | $1,548,152 | - | - | 0.1% | |
| Travel | $1,507,492 | $1,365,261 | $108,571 | $33,660 | 0.1% | |
| Fees: accounting | $1,298,089 | $59,872 | $1,238,217 | - | 0.1% | |
| Fees: investment management | $720,955 | - | $720,955 | - | 0.1% | |
| Royalties | $608,250 | $608,250 | - | - | 0.1% | |
| Fees: professional fundraisers | $517,259 | - | - | $517,259 | 0.0% | |
| Fees: lobbying | $394,986 | - | $394,986 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income $0 | $107,056 | reported apart | |||
| Total | $1,134,529,429 | 100% |
2020 · Form 990 · $841,344,866 spent · pay $202,228,813 · grants $2,084,886 · events $1,197,651
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $353,285,989 | $353,262,208 | $23,781 | - | 42.0% |
| Fees: other services | $158,199,562 | $136,163,189 | $22,036,373 | - | 18.8% | |
| Other salaries and wages | $150,575,195 | $118,408,062 | $32,094,569 | $72,564 | 17.9% | |
| Information technology | $34,776,458 | $14,186,718 | $20,589,740 | - | 4.1% | |
| Depreciation and depletion | $27,836,045 | $22,858,011 | $4,955,831 | $22,203 | 3.3% | |
| Occupancy | $23,930,800 | $7,732,659 | $16,197,716 | $425 | 2.8% | |
| Other employee benefits | $20,254,249 | $16,238,090 | $4,006,259 | $9,900 | 2.4% | |
| Payroll taxes | $13,068,905 | $10,277,016 | $2,785,591 | $6,298 | 1.6% | |
| Pay: officers, directors, trustees, key employees | $9,646,383 | $2,402,835 | $7,243,548 | - | 1.1% | |
| Pension plan contributions | $8,684,081 | $6,828,915 | $1,850,981 | $4,185 | 1.0% | |
| Office expenses | $6,652,023 | $5,118,568 | $1,531,306 | $2,149 | 0.8% | |
| Other (as described) | MEDICAL EQUIPMENT R&M | $5,974,722 | $5,953,271 | $21,451 | - | 0.7% |
| Fees: management | $5,433,505 | $5,433,505 | - | - | 0.6% | |
| Other (as described) | BUSINESS TAXES | $4,910,046 | $4,731,859 | $178,187 | - | 0.6% |
| Interest | $3,804,726 | $3,804,726 | - | - | 0.5% | |
| Advertising and promotion | $2,701,909 | $2,638,383 | $5,347 | $58,179 | 0.3% | |
| All other expenses | $2,537,042 | $622,436 | $1,914,303 | $303 | 0.3% | |
| Grants to US organizations and governments | $1,424,863 | $1,424,863 | - | - | 0.2% | |
| Other (as described) | RENT MEDICAL EQUIPMENT | $1,251,724 | $1,251,724 | - | - | 0.1% |
| Conferences, conventions and meetings | $1,197,651 | $724,582 | $473,069 | - | 0.1% | |
| Insurance | $1,003,709 | $755,620 | $248,089 | - | 0.1% | |
| Fees: legal | $819,665 | $26,357 | $793,308 | - | 0.1% | |
| Royalties | $797,000 | $797,000 | - | - | 0.1% | |
| Fees: accounting | $698,244 | $60,222 | $638,022 | - | 0.1% | |
| Grants to US individuals | $660,023 | $660,023 | - | - | 0.1% | |
| Fees: investment management | $572,322 | - | $572,322 | - | 0.1% | |
| Fees: lobbying | $394,109 | - | $394,109 | - | 0.0% | |
| Fees: professional fundraisers | $189,159 | - | - | $189,159 | 0.0% | |
| Travel | $64,757 | $49,257 | $15,500 | - | 0.0% | |
| Total | $841,344,866 | 100% |
2019 · Form 990 · $735,653,659 spent · pay $179,903,521 · grants $2,660,139 · events $1,838,260
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $291,564,939 | $291,540,855 | $24,084 | - | 39.6% |
| Fees: other services | $153,448,492 | $131,928,277 | $21,520,215 | - | 20.9% | |
| Other salaries and wages | $130,778,074 | $100,928,475 | $29,794,162 | $55,437 | 17.8% | |
| Information technology | $31,769,385 | $12,573,674 | $19,195,711 | - | 4.3% | |
| Depreciation and depletion | $23,098,221 | $19,005,249 | $4,071,404 | $21,568 | 3.1% | |
| Occupancy | $22,426,460 | $8,666,244 | $13,759,338 | $878 | 3.0% | |
| Other employee benefits | $19,083,396 | $15,414,304 | $3,660,639 | $8,453 | 2.6% | |
| Pay: officers, directors, trustees, key employees | $11,648,396 | $2,830,165 | $8,818,231 | - | 1.6% | |
| Payroll taxes | $11,095,774 | $8,563,205 | $2,527,865 | $4,704 | 1.5% | |
| Pension plan contributions | $7,297,881 | $5,632,167 | $1,662,620 | $3,094 | 1.0% | |
| Office expenses | $5,361,008 | $3,245,177 | $2,114,189 | $1,642 | 0.7% | |
| Fees: management | $4,433,756 | $4,433,756 | - | - | 0.6% | |
| Other (as described) | BUSINESS TAXES | $4,169,643 | $3,969,796 | $199,847 | - | 0.6% |
| Interest | $3,312,129 | $3,312,129 | - | - | 0.5% | |
| Advertising and promotion | $2,566,889 | $2,499,186 | - | $67,703 | 0.3% | |
| All other expenses | $2,314,037 | $602,666 | $1,711,371 | - | 0.3% | |
| Grants to US organizations and governments | $2,106,746 | $2,106,746 | - | - | 0.3% | |
| Conferences, conventions and meetings | $1,722,926 | $1,117,410 | $605,516 | - | 0.2% | |
| Other (as described) | MEDICAL EQUIPMENT R&M | $1,715,501 | $1,715,501 | - | - | 0.2% |
| Other (as described) | RENT MEDICAL EQUIPMENT | $1,206,079 | $1,206,079 | - | - | 0.2% |
| Insurance | $866,074 | $553,914 | $312,160 | - | 0.1% | |
| Royalties | $778,000 | $778,000 | - | - | 0.1% | |
| Travel | $770,642 | $446,655 | $323,933 | $54 | 0.1% | |
| Grants to US individuals | $550,393 | $550,393 | - | - | 0.1% | |
| Fees: accounting | $428,193 | - | $428,193 | - | 0.1% | |
| Fees: lobbying | $354,885 | - | $354,885 | - | 0.0% | |
| Fees: investment management | $318,970 | - | $318,970 | - | 0.0% | |
| Fees: legal | $276,611 | - | $276,611 | - | 0.0% | |
| Fees: professional fundraisers | $187,159 | - | - | $187,159 | 0.0% | |
| Grants outside the US | $3,000 | $3,000 | - | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income $70,800 | $115,334 | reported apart | |||
| Total | $735,653,659 | 100% |
2018 · Form 990 · $684,323,509 spent · pay $166,269,723 · grants $3,012,177 · events $1,920,202
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $275,701,285 | $275,695,469 | $5,816 | - | 40.3% |
| Fees: other services | $123,067,865 | $116,744,096 | $6,323,769 | - | 18.0% | |
| Other salaries and wages | $119,500,512 | $89,604,422 | $29,896,090 | - | 17.5% | |
| Fees: management | $28,945,354 | $13,573,641 | $15,371,713 | - | 4.2% | |
| Depreciation and depletion | $23,610,945 | $20,056,070 | $3,551,292 | $3,583 | 3.5% | |
| Information technology | $19,859,989 | $7,342,478 | $12,517,511 | - | 2.9% | |
| Other employee benefits | $19,022,926 | $14,506,567 | $4,516,359 | - | 2.8% | |
| Occupancy | $15,299,153 | $5,989,242 | $9,309,911 | - | 2.2% | |
| Pay: officers, directors, trustees, key employees | $11,314,412 | $2,596,254 | $8,718,158 | - | 1.7% | |
| Payroll taxes | $10,118,150 | $7,586,838 | $2,531,312 | - | 1.5% | |
| Pension plan contributions | $6,313,723 | $4,622,352 | $1,691,371 | - | 0.9% | |
| Office expenses | $5,659,927 | $3,102,133 | $2,555,186 | $2,608 | 0.8% | |
| Other (as described) | BUSINESS TAXES | $4,194,770 | $3,998,943 | $195,827 | - | 0.6% |
| Interest | $3,460,387 | $3,460,387 | - | - | 0.5% | |
| Advertising and promotion | $3,280,866 | $3,224,858 | $2,185 | $53,823 | 0.5% | |
| All other expenses | $3,009,446 | $1,625,660 | $1,383,786 | - | 0.4% | |
| Grants to US organizations and governments | $2,493,871 | $2,493,871 | - | - | 0.4% | |
| Conferences, conventions and meetings | $1,806,418 | $1,085,787 | $719,640 | $991 | 0.3% | |
| Other (as described) | MEDICAL EQUIPMENT R&M | $1,495,105 | $1,495,105 | - | - | 0.2% |
| Fees: legal | $1,169,639 | - | $1,169,639 | - | 0.2% | |
| Travel | $1,103,732 | $579,633 | $522,446 | $1,653 | 0.2% | |
| Royalties | $756,998 | $756,998 | - | - | 0.1% | |
| Insurance | $752,207 | $521,715 | $230,492 | - | 0.1% | |
| Grants to US individuals | $518,306 | $518,306 | - | - | 0.1% | |
| Fees: accounting | $501,173 | - | $501,173 | - | 0.1% | |
| Fees: investment management | $426,892 | - | $426,892 | - | 0.1% | |
| Other (as described) | UBI TAXES | $423,913 | - | $423,913 | - | 0.1% |
| Fees: lobbying | $361,557 | - | $361,557 | - | 0.1% | |
| Fees: professional fundraisers | $153,988 | - | - | $153,988 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $76,400 | $113,784 | reported apart | |||
| Total | $684,323,509 | 100% |
2017 · Form 990 · $610,353,946 spent · pay $152,506,331 · grants $1,742,018 · events $2,076,705
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $226,802,062 | $226,781,789 | $20,273 | - | 37.2% |
| Fees: other services | $121,809,725 | $115,119,650 | $6,690,075 | - | 20.0% | |
| Other salaries and wages | $109,187,596 | $80,864,212 | $28,290,437 | $32,947 | 17.9% | |
| Fees: management | $27,989,979 | $11,945,657 | $16,044,322 | - | 4.6% | |
| Depreciation and depletion | $22,386,580 | $14,709,904 | $7,672,421 | $4,255 | 3.7% | |
| Other employee benefits | $18,230,696 | $13,726,059 | $4,499,097 | $5,540 | 3.0% | |
| Information technology | $15,832,187 | $4,974,529 | $10,853,788 | $3,870 | 2.6% | |
| Occupancy | $15,574,716 | $6,685,061 | $8,889,655 | - | 2.6% | |
| Pay: officers, directors, trustees, key employees | $9,912,108 | $2,067,280 | $7,844,828 | - | 1.6% | |
| Payroll taxes | $9,225,155 | $6,832,431 | $2,389,940 | $2,784 | 1.5% | |
| Office expenses | $7,061,900 | $4,492,038 | $2,524,676 | $45,186 | 1.2% | |
| Pension plan contributions | $5,950,776 | $4,378,302 | $1,570,645 | $1,829 | 1.0% | |
| Other (as described) | BUSINESS TAXES | $3,708,444 | $3,705,185 | $3,259 | - | 0.6% |
| Interest | $3,406,760 | $3,406,760 | - | - | 0.6% | |
| Advertising and promotion | $2,466,921 | $2,396,315 | $70,606 | - | 0.4% | |
| Other (as described) | BAD DEBT | $2,259,933 | $2,259,933 | - | - | 0.4% |
| Conferences, conventions and meetings | $1,953,277 | $1,225,372 | $718,011 | $9,894 | 0.3% | |
| Grants to US organizations and governments | $1,251,594 | $1,251,594 | - | - | 0.2% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $1,189,793 | $283,627 | $906,166 | - | 0.2% |
| Travel | $853,889 | $521,395 | $332,430 | $64 | 0.1% | |
| Insurance | $755,221 | $506,586 | $248,635 | - | 0.1% | |
| Fees: legal | $509,485 | - | $509,485 | - | 0.1% | |
| Grants to US individuals | $487,424 | $487,424 | - | - | 0.1% | |
| Fees: investment management | $466,722 | - | $466,722 | - | 0.1% | |
| Fees: lobbying | $334,108 | - | $334,108 | - | 0.1% | |
| Fees: accounting | $311,970 | - | $311,970 | - | 0.1% | |
| All other expenses | $225,649 | $207,916 | $17,733 | - | 0.0% | |
| Fees: professional fundraisers | $150,769 | - | - | $150,769 | 0.0% | |
| Royalties | $55,507 | $55,507 | - | - | 0.0% | |
| Grants outside the US | $3,000 | $3,000 | - | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income $45,300 | $123,428 | reported apart | |||
| Total | $610,353,946 | 100% |
2016 · Form 990 · $528,580,707 spent · pay $136,061,873 · grants $1,927,743 · events $1,909,036
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $176,387,704 | $176,219,188 | $168,516 | - | 33.4% |
| Fees: other services | $111,020,574 | $104,221,448 | $6,646,113 | $153,013 | 21.0% | |
| Other salaries and wages | $97,787,944 | $74,115,695 | $23,636,527 | $35,722 | 18.5% | |
| Fees: management | $27,023,500 | $10,006,795 | $17,016,705 | - | 5.1% | |
| Depreciation and depletion | $22,308,145 | $15,381,751 | $6,922,139 | $4,255 | 4.2% | |
| Occupancy | $16,200,734 | $6,721,930 | $9,478,804 | - | 3.1% | |
| Other employee benefits | $15,245,891 | $11,690,152 | $3,550,103 | $5,636 | 2.9% | |
| Information technology | $11,916,307 | $2,390,309 | $9,519,373 | $6,625 | 2.3% | |
| Pay: officers, directors, trustees, key employees | $9,263,825 | $2,191,011 | $7,072,814 | - | 1.8% | |
| Payroll taxes | $8,337,226 | $6,318,972 | $2,015,208 | $3,046 | 1.6% | |
| Office expenses | $7,194,581 | $3,779,336 | $3,414,002 | $1,243 | 1.4% | |
| Pension plan contributions | $5,426,987 | $4,085,819 | $1,339,144 | $2,024 | 1.0% | |
| Advertising and promotion | $3,424,892 | $3,321,289 | $42,403 | $61,200 | 0.6% | |
| Interest | $3,341,795 | $3,341,795 | - | - | 0.6% | |
| Other (as described) | BUSINESS TAXES | $2,373,166 | $2,533,015 | -$159,849 | - | 0.4% |
| Fees: legal | $1,933,002 | - | $1,933,002 | - | 0.4% | |
| Conferences, conventions and meetings | $1,779,516 | $964,147 | $811,723 | $3,646 | 0.3% | |
| Other (as described) | BAD DEBT | $1,613,012 | $1,613,012 | - | - | 0.3% |
| Grants to US organizations and governments | $1,454,052 | $1,454,052 | - | - | 0.3% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $897,560 | $159,056 | $731,386 | $7,118 | 0.2% |
| Travel | $881,454 | $459,962 | $421,396 | $96 | 0.2% | |
| Insurance | $636,160 | $138,263 | $497,897 | - | 0.1% | |
| Grants to US individuals | $473,691 | $473,691 | - | - | 0.1% | |
| Fees: investment management | $446,519 | - | $446,519 | - | 0.1% | |
| Fees: accounting | $343,547 | - | $343,547 | - | 0.1% | |
| All other expenses | $332,098 | $283,060 | $49,038 | - | 0.1% | |
| Fees: lobbying | $316,023 | - | $316,023 | - | 0.1% | |
| Royalties | $195,534 | $195,534 | - | - | 0.0% | |
| Fees: professional fundraisers | $25,268 | - | - | $25,268 | 0.0% | |
| Fundraising events Event | direct expenses; gross income $39,450 | $129,520 | reported apart | |||
| Total | $528,580,707 | 100% |
2015 · Form 990 · $475,898,010 spent · pay $120,859,920 · grants $2,007,625 · events $1,606,431
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $161,105,962 | $161,057,564 | $48,398 | - | 33.9% |
| Fees: other services | $95,869,931 | $93,889,023 | $1,980,908 | - | 20.1% | |
| Other salaries and wages | $87,793,201 | $56,309,153 | $31,457,624 | $26,424 | 18.4% | |
| Fees: management | $39,039,551 | $11,794,063 | $27,219,398 | $26,090 | 8.2% | |
| Depreciation and depletion | $21,380,276 | $13,125,423 | $8,254,853 | - | 4.5% | |
| Occupancy | $12,963,262 | $6,535,434 | $6,425,328 | $2,500 | 2.7% | |
| Other employee benefits | $11,818,045 | $7,856,561 | $3,954,197 | $7,287 | 2.5% | |
| Pay: officers, directors, trustees, key employees | $9,152,710 | $4,601,196 | $4,551,514 | - | 1.9% | |
| Payroll taxes | $7,191,360 | $4,138,715 | $3,052,645 | - | 1.5% | |
| Office expenses | $5,390,804 | $3,373,247 | $1,945,472 | $72,085 | 1.1% | |
| Pension plan contributions | $4,904,604 | $3,536,997 | $1,367,607 | - | 1.0% | |
| Advertising and promotion | $4,110,506 | $4,110,506 | - | - | 0.9% | |
| Interest | $3,306,199 | $3,306,199 | - | - | 0.7% | |
| Information technology | $2,339,737 | $319,719 | $2,019,258 | $760 | 0.5% | |
| Other (as described) | BAD DEBT | $1,968,505 | $1,968,505 | - | - | 0.4% |
| Fees: legal | $1,651,490 | - | $1,651,490 | - | 0.3% | |
| Conferences, conventions and meetings | $1,606,431 | $900,083 | $652,576 | $53,772 | 0.3% | |
| Grants to US organizations and governments | $1,337,029 | $1,337,029 | - | - | 0.3% | |
| Travel | $787,855 | $371,793 | $415,986 | $76 | 0.2% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $761,280 | $222,836 | $534,893 | $3,551 | 0.2% |
| Grants to US individuals | $670,596 | $670,596 | - | - | 0.1% | |
| Insurance | $628,971 | $200,244 | $428,727 | - | 0.1% | |
| Fees: investment management | $612,298 | - | $612,298 | - | 0.1% | |
| Fees: accounting | $492,038 | $40,000 | $452,038 | - | 0.1% | |
| All other expenses | $379,226 | $363,694 | $1,402 | $14,130 | 0.1% | |
| Fees: lobbying | $288,927 | - | $288,927 | - | 0.1% | |
| Royalties | $192,864 | $192,864 | - | - | 0.0% | |
| Fees: professional fundraisers | $48,179 | - | - | $48,179 | 0.0% | |
| Other (as described) | BUSINESS TAXES | -$1,893,827 | -$969,693 | -$924,134 | - | -0.4% |
| Total | $475,898,010 | 100% |
2014 · Form 990 · $443,892,609 spent · pay $111,034,354 · grants $1,606,020 · events $1,047,834
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $125,879,775 | $125,793,478 | $86,297 | - | 28.4% |
| Fees: other services | $81,102,742 | $78,152,046 | $2,950,696 | - | 18.3% | |
| Other salaries and wages | $80,991,547 | $51,294,142 | $29,697,405 | - | 18.2% | |
| Fees: management | $57,993,858 | $26,761,638 | $31,232,220 | - | 13.1% | |
| Depreciation and depletion | $18,917,509 | $10,328,833 | $8,588,676 | - | 4.3% | |
| Other employee benefits | $11,853,896 | $7,514,660 | $4,339,236 | - | 2.7% | |
| Other (as described) | BUSINESS TAXES | $10,072,281 | $9,540,693 | $531,588 | - | 2.3% |
| Occupancy | $7,392,524 | $884,092 | $6,508,432 | - | 1.7% | |
| Office expenses | $7,275,416 | $4,744,433 | $2,530,983 | - | 1.6% | |
| Payroll taxes | $6,801,828 | $4,059,599 | $2,742,229 | - | 1.5% | |
| Pay: officers, directors, trustees, key employees | $6,733,157 | $2,374,744 | $4,358,413 | - | 1.5% | |
| Information technology | $4,741,415 | $822,596 | $3,918,819 | - | 1.1% | |
| Pension plan contributions | $4,653,926 | $3,004,251 | $1,649,675 | - | 1.0% | |
| Interest | $4,317,808 | $4,317,808 | - | - | 1.0% | |
| Advertising and promotion | $3,838,705 | $3,817,771 | $20,934 | - | 0.9% | |
| Other (as described) | BAD DEBT | $2,728,474 | $2,728,474 | - | - | 0.6% |
| Fees: legal | $2,103,160 | - | $2,103,160 | - | 0.5% | |
| Conferences, conventions and meetings | $1,047,834 | $102,692 | $945,142 | - | 0.2% | |
| Grants to US organizations and governments | $893,796 | $893,796 | - | - | 0.2% | |
| Insurance | $722,330 | $167,054 | $555,276 | - | 0.2% | |
| Grants to US individuals | $712,224 | $712,224 | - | - | 0.2% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $667,402 | $12,092 | $655,310 | - | 0.2% |
| Travel | $656,471 | $97,390 | $559,081 | - | 0.1% | |
| Fees: accounting | $541,971 | - | $541,971 | - | 0.1% | |
| Fees: investment management | $541,522 | - | $541,522 | - | 0.1% | |
| All other expenses | $269,152 | $18,172 | $250,980 | - | 0.1% | |
| Fees: lobbying | $228,689 | - | $228,689 | - | 0.1% | |
| Royalties | $191,327 | $191,327 | - | - | 0.0% | |
| Fees: professional fundraisers | $21,870 | - | - | $21,870 | 0.0% | |
| Total | $443,892,609 | 100% |
2013 · Form 990 · $409,414,069 spent · pay $99,764,523 · grants $1,301,089 · events $893,602
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | MEDICAL SUPPLIES | $105,521,317 | $105,382,866 | $138,451 | - | 25.8% |
| Fees: other services | $77,991,071 | $75,736,154 | $2,254,917 | - | 19.0% | |
| Other salaries and wages | $74,626,928 | $48,017,361 | $26,609,567 | - | 18.2% | |
| Fees: management | $58,306,202 | $29,770,688 | $28,535,514 | - | 14.2% | |
| Depreciation and depletion | $15,915,064 | $8,059,478 | $7,855,586 | - | 3.9% | |
| Other (as described) | BUSINESS TAXES | $14,057,758 | $13,751,062 | $306,696 | - | 3.4% |
| Other employee benefits | $8,926,348 | $5,610,104 | $3,316,244 | - | 2.2% | |
| Office expenses | $7,622,255 | $4,460,670 | $3,161,585 | - | 1.9% | |
| Occupancy | $6,420,738 | $907,291 | $5,513,447 | - | 1.6% | |
| Payroll taxes | $6,350,432 | $3,837,247 | $2,513,185 | - | 1.6% | |
| Interest | $6,344,972 | $6,344,972 | - | - | 1.5% | |
| Pay: officers, directors, trustees, key employees | $5,485,059 | $1,847,337 | $3,637,722 | - | 1.3% | |
| Pension plan contributions | $4,375,756 | $2,884,235 | $1,491,521 | - | 1.1% | |
| Information technology | $4,221,819 | $676,452 | $3,545,367 | - | 1.0% | |
| Advertising and promotion | $3,046,849 | $3,016,975 | $29,874 | - | 0.7% | |
| Fees: legal | $1,978,759 | - | $1,978,759 | - | 0.5% | |
| Other (as described) | BAD DEBT | $1,682,807 | $1,682,807 | - | - | 0.4% |
| Fees: lobbying | $1,214,765 | - | $1,214,765 | - | 0.3% | |
| Insurance | $897,543 | $357,568 | $539,975 | - | 0.2% | |
| Conferences, conventions and meetings | $893,602 | $83,225 | $810,377 | - | 0.2% | |
| Grants to US individuals | $719,301 | $719,301 | - | - | 0.2% | |
| Grants to US organizations and governments | $581,788 | $581,788 | - | - | 0.1% | |
| Fees: investment management | $564,656 | - | $564,656 | - | 0.1% | |
| Travel | $545,058 | $103,922 | $441,136 | - | 0.1% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $540,822 | $6,537 | $534,285 | - | 0.1% |
| Fees: accounting | $386,874 | - | $386,874 | - | 0.1% | |
| All other expenses | $260,041 | $24,187 | $235,854 | - | 0.1% | |
| Fees: professional fundraisers | $21,405 | - | - | $21,405 | 0.0% | |
| Royalties | -$85,920 | -$85,920 | - | - | -0.0% | |
| Total | $409,414,069 | 100% |
2012 · Form 990 · $365,615,667 spent · pay $94,579,014 · grants $1,632,418 · events $752,720
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Office expenses | $96,213,305 | $93,149,079 | $3,060,338 | $3,888 | 26.3% | |
| Fees: other services | $72,629,490 | $70,400,822 | $2,228,668 | - | 19.9% | |
| Other salaries and wages | $69,272,505 | $44,382,412 | $24,890,093 | - | 18.9% | |
| Fees: management | $49,252,064 | $25,343,992 | $23,908,072 | - | 13.5% | |
| Depreciation and depletion | $15,729,495 | $8,577,627 | $7,151,868 | - | 4.3% | |
| Other employee benefits | $10,079,484 | $6,307,287 | $3,772,197 | - | 2.8% | |
| Other (as described) | BUSINESS TAXES | $9,112,678 | $8,964,676 | $148,002 | - | 2.5% |
| Interest | $6,429,938 | $6,429,938 | - | - | 1.8% | |
| Payroll taxes | $5,868,841 | $3,561,308 | $2,307,533 | - | 1.6% | |
| Occupancy | $5,833,896 | $1,120,251 | $4,713,645 | - | 1.6% | |
| Pay: officers, directors, trustees, key employees | $5,189,089 | $2,085,948 | $3,103,141 | - | 1.4% | |
| Pension plan contributions | $4,169,095 | $2,726,288 | $1,442,807 | - | 1.1% | |
| Information technology | $3,982,343 | $806,120 | $3,176,223 | - | 1.1% | |
| Advertising and promotion | $3,160,089 | $3,128,791 | $31,298 | - | 0.9% | |
| Other (as described) | BAD DEBT | $1,756,724 | $1,756,724 | - | - | 0.5% |
| Fees: legal | $1,355,377 | - | $1,355,377 | - | 0.4% | |
| Grants to US organizations and governments | $971,183 | $971,183 | - | - | 0.3% | |
| Insurance | $821,231 | $410,256 | $410,975 | - | 0.2% | |
| Conferences, conventions and meetings | $750,916 | $63,618 | $687,298 | - | 0.2% | |
| Grants to US individuals | $661,235 | $661,235 | - | - | 0.2% | |
| Fees: investment management | $556,517 | - | $556,517 | - | 0.2% | |
| Travel | $441,250 | $88,124 | $353,126 | - | 0.1% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $343,716 | $10,765 | $332,951 | - | 0.1% |
| All other expenses | $319,627 | $23,126 | $296,501 | - | 0.1% | |
| Fees: accounting | $264,574 | - | $264,574 | - | 0.1% | |
| Royalties | $204,630 | $204,630 | - | - | 0.1% | |
| Fees: lobbying | $203,345 | - | $203,345 | - | 0.1% | |
| Fees: professional fundraisers | $43,030 | - | - | $43,030 | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $1,804 | reported apart | |||
| Total | $365,615,667 | 100% |
2011 · Form 990 · $327,907,205 spent · pay $88,365,958 · grants $935,916 · events $967,345
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Office expenses | $83,919,338 | $80,968,541 | $2,950,797 | - | 25.6% | |
| Fees: other services | $64,653,432 | $62,635,531 | $2,017,901 | - | 19.7% | |
| Other salaries and wages | $64,538,638 | $41,537,671 | $23,000,967 | - | 19.7% | |
| Fees: management | $42,746,769 | $21,487,669 | $21,237,164 | $21,936 | 13.0% | |
| Depreciation and depletion | $14,616,026 | $6,901,313 | $7,714,713 | - | 4.5% | |
| Other employee benefits | $9,404,937 | $5,846,871 | $3,558,066 | - | 2.9% | |
| Other (as described) | BUSINESS TAXES | $6,724,093 | $6,575,150 | $148,943 | - | 2.1% |
| Interest | $6,504,748 | $6,504,748 | - | - | 2.0% | |
| Payroll taxes | $5,621,771 | $3,422,532 | $2,199,239 | - | 1.7% | |
| Occupancy | $5,574,647 | $1,158,526 | $4,416,121 | - | 1.7% | |
| Pay: officers, directors, trustees, key employees | $5,185,367 | $572,764 | $4,612,603 | - | 1.6% | |
| Pension plan contributions | $3,615,245 | $2,382,903 | $1,232,342 | - | 1.1% | |
| Other (as described) | BAD DEBT | $3,323,794 | $3,323,794 | - | - | 1.0% |
| Information technology | $3,028,808 | $131,122 | $2,897,686 | - | 0.9% | |
| Advertising and promotion | $2,936,737 | $2,906,352 | $19,180 | $11,205 | 0.9% | |
| Conferences, conventions and meetings | $967,345 | $43,138 | $924,207 | - | 0.3% | |
| Fees: legal | $891,880 | - | $891,880 | - | 0.3% | |
| Grants to US individuals | $661,474 | $661,474 | - | - | 0.2% | |
| Insurance | $592,505 | $356,202 | $236,303 | - | 0.2% | |
| Fees: investment management | $418,947 | - | $418,947 | - | 0.1% | |
| Travel | $360,710 | $81,240 | $279,470 | - | 0.1% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $350,204 | $19,400 | $330,804 | - | 0.1% |
| Fees: accounting | $344,580 | - | $344,580 | - | 0.1% | |
| Other (as described) | MISCELLANEOUS | $299,266 | $42,608 | $256,658 | - | 0.1% |
| Grants to US organizations and governments | $274,442 | $274,442 | - | - | 0.1% | |
| Fees: lobbying | $185,130 | - | $185,130 | - | 0.1% | |
| Royalties | $166,372 | $166,372 | - | - | 0.1% | |
| Total | $327,907,205 | 100% |
2010 · Form 990 · $301,665,248 spent · pay $79,761,116 · grants $1,122,767 · events $723,360
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Office expenses | $76,268,504 | $71,424,114 | $4,844,390 | - | 25.3% | |
| Fees: other services | $62,933,772 | $60,262,645 | $2,671,127 | - | 20.9% | |
| Other salaries and wages | $58,181,888 | $37,882,452 | $20,299,436 | - | 19.3% | |
| Fees: management | $41,203,317 | $20,352,763 | $20,850,554 | - | 13.7% | |
| Depreciation and depletion | $13,437,617 | $6,520,283 | $6,917,334 | - | 4.5% | |
| Other employee benefits | $9,296,626 | $5,862,756 | $3,433,870 | - | 3.1% | |
| Interest | $6,458,247 | $6,458,247 | - | - | 2.1% | |
| Other (as described) | BUSINESS TAXES | $5,749,031 | $5,587,210 | $161,821 | - | 1.9% |
| Payroll taxes | $5,037,372 | $3,132,086 | $1,905,286 | - | 1.7% | |
| Occupancy | $4,700,627 | $937,731 | $3,762,896 | - | 1.6% | |
| Pay: officers, directors, trustees, key employees | $3,931,391 | $520,598 | $3,410,793 | - | 1.3% | |
| Pension plan contributions | $3,313,839 | $2,190,605 | $1,123,234 | - | 1.1% | |
| Advertising and promotion | $2,619,644 | $2,605,290 | $14,354 | - | 0.9% | |
| Information technology | $1,953,419 | $169,692 | $1,783,727 | - | 0.6% | |
| Fees: legal | $1,369,770 | - | $1,369,770 | - | 0.5% | |
| Other (as described) | BAD DEBT | $788,578 | $788,578 | - | - | 0.3% |
| Grants to US individuals | $765,230 | $765,230 | - | - | 0.3% | |
| Conferences, conventions and meetings | $723,360 | $56,029 | $667,331 | - | 0.2% | |
| Insurance | $602,236 | $358,767 | $243,469 | - | 0.2% | |
| Travel | $410,184 | $147,876 | $262,308 | - | 0.1% | |
| Royalties | $373,161 | $373,161 | - | - | 0.1% | |
| Grants to US organizations and governments | $357,537 | $357,537 | - | - | 0.1% | |
| Fees: accounting | $330,229 | - | $330,229 | - | 0.1% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $312,188 | $20,902 | $291,286 | - | 0.1% |
| Other (as described) | MISCELLANEOUS | $234,725 | $4,379 | $230,346 | - | 0.1% |
| Fees: lobbying | $154,973 | - | $154,973 | - | 0.1% | |
| Fees: investment management | $88,237 | - | $88,237 | - | 0.0% | |
| Other (as described) | SHARED RESOURCES | $66,286 | $62,915 | $3,371 | - | 0.0% |
| All other expenses | $3,260 | - | $3,260 | - | 0.0% | |
| Total | $301,665,248 | 100% |
2009 · Form 990 · $263,918,776 spent · pay $71,421,408 · grants $815,215 · events $395,979
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Office expenses | $62,310,097 | $59,088,073 | $3,222,024 | - | 23.6% | |
| Fees: other services | $54,855,652 | $53,157,198 | $1,698,454 | - | 20.8% | |
| Other salaries and wages | $52,163,786 | $34,135,554 | $18,028,232 | - | 19.8% | |
| Fees: management | $39,124,212 | $18,970,278 | $20,153,934 | - | 14.8% | |
| Depreciation and depletion | $11,174,112 | $5,662,122 | $5,511,990 | - | 4.2% | |
| Other employee benefits | $8,933,070 | $5,765,680 | $3,167,390 | - | 3.4% | |
| Interest | $6,275,454 | $6,275,454 | - | - | 2.4% | |
| Occupancy | $4,770,255 | $490,818 | $4,279,437 | - | 1.8% | |
| Payroll taxes | $4,595,158 | $2,946,438 | $1,648,720 | - | 1.7% | |
| Other (as described) | BUSINESS TAXES | $4,192,677 | $4,026,903 | $165,774 | - | 1.6% |
| Pension plan contributions | $3,110,381 | $2,058,923 | $1,051,458 | - | 1.2% | |
| Pay: officers, directors, trustees, key employees | $2,619,013 | $589,526 | $2,029,487 | - | 1.0% | |
| Information technology | $1,676,050 | $48,656 | $1,627,394 | - | 0.6% | |
| Advertising and promotion | $1,633,643 | $1,611,972 | $21,671 | - | 0.6% | |
| Other (as described) | BAD DEBT | $1,563,094 | $1,563,094 | - | - | 0.6% |
| Fees: legal | $1,153,022 | - | $1,153,022 | - | 0.4% | |
| Royalties | $699,985 | $323,695 | $376,290 | - | 0.3% | |
| Grants to US individuals | $578,021 | $578,021 | - | - | 0.2% | |
| Insurance | $473,010 | $251,630 | $221,380 | - | 0.2% | |
| Conferences, conventions and meetings | $395,979 | $50,025 | $345,954 | - | 0.2% | |
| Travel | $370,004 | $159,948 | $210,056 | - | 0.1% | |
| Fees: accounting | $324,152 | - | $324,152 | - | 0.1% | |
| Other (as described) | DUES & SUBSCRIPTIONS | $276,668 | $19,576 | $257,092 | - | 0.1% |
| Grants to US organizations and governments | $237,194 | $237,194 | - | - | 0.1% | |
| Fees: lobbying | $153,519 | - | $153,519 | - | 0.1% | |
| Other (as described) | MISCELLANEOUS | $142,076 | $359 | $141,717 | - | 0.1% |
| Other (as described) | SHARED RESOURCES | $62,172 | $58,792 | $3,380 | - | 0.0% |
| Fees: investment management | $48,681 | - | $48,681 | - | 0.0% | |
| Fees: professional fundraisers | $5,874 | - | - | $5,874 | 0.0% | |
| All other expenses | $1,765 | - | $1,765 | - | 0.0% | |
| Total | $263,918,776 | 100% |
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2026 | $295,946,444 | $24,802,232 | 369 |
| 2025 | $368,037,899 | $21,579,861 | 354 |
| 2024 | $206,681,868 | $21,414,195 | 384 |
| 2023 | $278,253,706 | $22,274,494 | 342 |
| 2022 | $390,812,201 | $19,230,024 | 260 |
| 2021 | $670,061 | $0 | 2 |
| 2020 | $0 | -$3,858 | 1 |
| 2017 | $0 | -$115,753 | 2 |
| 2016 | $0 | $15,995 | 4 |
| 2015 | $0 | $30,370 | 5 |
| 2014 | $0 | $107,358 | 4 |
| 2013 | $0 | $131,475 | 8 |
| 2012 | $0 | $274,817 | 10 |
| 2011 | $0 | $67,168 | 5 |
| 2010 | $0 | $51,267 | 4 |
| 2009 | $2,328,777 | $79,778 | 9 |
| 2008 | $2,139,094 | $85,522 | 5 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS; HIV VACCINE TRIALS NETWORK | $30,761,530 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIALS NETWORK | $22,001,047 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS; HIV PREVENTION TRIALS NETWORK | $19,541,681 |
| 2026 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | HVTN LABORATORY PROGRAM | $16,568,461 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | CANCER CENTER SUPPORT GRANT (COMPREHENSIVE) | $11,389,017 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | HAWAIIAN, ASIAN AMERICAN, AND PACIFIC ISLANDER (HAAPI) COORDINATING CENTER - SUMMARY/ABSTRACT PEOPLE OF ASIAN, HAWAIIAN, OR PACIFIC ISLANDER (ASA-NHPI) ANCESTRY | $10,396,133 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | WOMEN'S HEALTH INITIATIVE (WHI) CLINICAL COORDINATING CENTER - TASK AREA A AND A2 | $10,225,386 |
| 2026 | National Institutes of Health | Contract | TELEMARKETING BUREAUS AND OTHER CONTACT CENTERS 561422 | THE NATIONAL CANCER INSTITUTE'S (NCI) CANCER INFORMATION SERVICE (CIS) IS AN EXISTING AND ESTABLISHED CRITICAL COMPONENT OF HEALTHCARE DELIVERY, PARTICULARLY IN | $9,531,636 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | SWOG STATISTICS AND DATA MANAGEMENT CENTER | $9,484,458 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER | $7,972,514 |
| 2026 | National Institutes of Health | Grant or other assistance | 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT 93.353 | NCI CANCER SCREENING RESEARCH NETWORK: COORDINATING AND COMMUNICATION CENTER - SUMMARY/ABSTRACT THIS APPLICATION IS BEING SUBMITTED IN RESPONSE TO THE NOSI IDEN | $5,419,496 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | URBAN NATIVE ELDERS (URBANE2): RISK AND PROTECTIVE FACTORS FOR ALZHEIMER’S DISEASE AND RELATED DEMENTIAS – LONGITUDINAL FOLLOW-UP - PROJECT SUMMARY/ABSTRACT ALZ | $5,178,384 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | ADULT LEUKEMIA RESEARCH CENTER | $4,395,431 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) | $4,382,631 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SELF-AMPLIFYING MRNA-BASED VACCINES TO ELICIT VRC01-CLASS BNABS - ABSTRACT OVERALL THE MAIN GOAL OF OUR IPCAVD PROGRAM GRANT IS TO EVALUATE IN HUMANS SELF-AMPLI | $3,586,525 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PERSONALIZED GUIDANCE FOR MENOPAUSAL HORMONE THERAPY - PROJECT SUMMARY/ABSTRACT MENOPAUSAL HORMONE THERAPY (MHT) IS HIGHLY EFFECTIVE IN TREATING SYMPTOMS OF MEN | $3,350,648 |
| 2026 | National Institutes of Health | Grant or other assistance | MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 | CANOE PARTNERSHIP: CANCER AWARENESS, NAVIGATION, OUTREACH, AND EQUITABLE INDIGENOUS HEALTH OUTCOMES - PROJECT SUMMARY/ABSTRACT THE CANOE PARTNERSHIP: CANCER AWA | $2,519,876 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | TRANSLATIONAL RESEARCH PROGRAM IN COLORECTAL CANCER DISPARITIES - PROJECT SUMMARY/ABSTRACT – OVERALL RACIAL AND ETHNIC DISPARITIES IN COLORECTAL CANCER (CRC) AR | $2,442,020 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | FRED HUTCHINSON CANCER RESEARCH CENTER LUNG SPORE | $2,407,128 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | THE PACIFIC NORTHWEST PROSTATE CANCER SPORE | $2,388,022 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | POLYGENIC RISK SCORES FOR DIVERSE POPULATIONS - BRIDGING RESEARCH AND CLINICAL CARE | $2,283,828 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | A COMPASS FOR THOSE WITH RELAPSED LEUKEMIA AFTER TRANSPLANT - ABSTRACT RELAPSE OF LEUKEMIA OCCURS IN NEARLY HALF OF PATIENTS AFTER HEMATOPOIETIC CELL TRANSPLANT | $2,061,389 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | EARLY AND REINFECTION IN HIGH RISK WOMEN | $2,025,340 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | PAR-4 REGULATION OF ACTOMYOSIN CONTRACTILITY AS A TUMOR SUPPRESSIVE MECHANISM IN BREAST CANCER - PROJECT SUMMARY/ABSTRACT TUMOR PROGRESSION – INCLUDING RESISTAN | $1,796,329 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | NRF2 SUPPRESSION OF INFLAMMATORY SIGNALING AND ITS ROLE IN TUMOR PROGRESSION - PROJECT SUMMARY/ABSTRACT TUMOR METASTASIS IS RESPONSIBLE FOR THE VAST MAJORITY O | $1,766,401 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | CAUSES AND CONSEQUENCES OF GENOMIC INSTABILITY IN MYELODYSPLASIA - PROJECT SUMMARY/ABSTRACT MYELODYSPLASTIC SYNDROMES (MDS) ARE A GROUP OF AGE-RELATED MARROW FA | $1,612,564 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SEATTLE VACCINE TRIALS UNIT | $1,598,150 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DISSECTING THE IMMUNOMODULATORY EFFECTS OF NK CELLS ON IMMUNE RESPONSES TO CANCER - PROJECT SUMMARY CURRENT IMMUNOTHERAPIES, SUCH AS ANTI-PD-1 IMMUNOTHERAPY, HA | $1,591,211 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DEVELOPMENT OF INNOVATIVE RESOURCES TO ADVANCE MDS RESEARCH - (PLEASE KEEP IN WORD, DO NOT PDF) ENTER THE TEXT HERE THAT IS THE NEW ABSTRACT INFORMATION FOR YOU | $1,574,993 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CONTROL 93.399 | UNDERSTANDING ADENOMA PROGRESSION: INTERPLAY AMONG TISSUE MICROENVIRONMENT, CLONAL ARCHITECTURE, AND GUT MICROBIOME - SUMMARY COLORECTAL CANCER (CRC) AFFECTS ~1 | $1,519,091 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CONTROL 93.399 | STATISTICS AND DATA MANAGEMENT CENTER (SDMC) FOR THE NCI CANCER SCREENING RESEARCH NETWORK (CSRN) - MULTI-CANCER DETECTION ASSAYS OFFER NEW OPPORTUNITIES TO SCR | $1,496,598 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CENTERS SUPPORT GRANTS 93.397 | PARTNERSHIP FOR THE ADVANCEMENT OF CANCER RESEARCH: NMSU-FHCRC (2 OF 2) | $1,415,560 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROMOTING T CELL RECONSTITUTION AFTER HEMATOPOIETIC CELL TRANSPLANTATION - PROJECT SUMMARY THE THYMUS, WHICH IS THE PRIMARY SITE OF T CELL GENERATION, IS EXTRE | $1,171,635 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS OF TRANSCRIPTIONAL REGULATION AND TRANSCRIPTION FACTOR SPECIFICITY - SUMMARY PRECISE REGULATION OF TRANSCRIPTION IS REQUIRED FOR MANY CELLULAR PROCES | $1,105,868 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER | $1,101,225 |
| 2026 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | PROJECT TITLE: AIR POLLUTION DURING DEPLOYMENT AND LIVER CANCER RISK AMONG UNITED STATES VETERANS | $1,092,877 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | A PATIENT-CENTRIC APPROACH TO ADVANCE FUNCTIONAL PRECISION ONCOLOGY - PROJECT SUMMARY/ABSTRACT THE DEVELOPMENT OF DRUG RESISTANCE IS A MAJOR CAUSE OF CANCER TRE | $1,060,954 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE ROLE AND MECHANISM OF ALTERNATIVE RNA SPLICE VARIANTS AND GENE FUSIONS AS DRIVERS OF CANCER - ABSTRACT MY LAB HAS BEEN THE LEADER IN THE FIELD OF MOUSE MODE | $1,055,493 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DETERMINANTS OF RESPONSE TO CANCER IMMUNOTHERAPY - PROJECT SUMMARY/ABSTRACT WHILE IMMUNOTHERAPY IS TRANSFORMING CANCER TREATMENT, THE MAJORITY OF PATIENTS DO NO | $1,055,426 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MODELING AND ANALYTICS FOR CANCER DIAGNOSTICS: TRAVERSING THE DATA-EVIDENCE DIVIDE - THE FIELD OF CANCER DIAGNOSTICS IS IN A RAPIDLY EXPANDING GROWTH PHASE THAT | $1,055,236 |
| 2026 | National Institute of Food and Agriculture | Grant or other assistance | AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI) 10.310 | SEATTLE DIETARY BIOMARKER DEVELOPMENT CENTER | $1,050,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | BREAST-CANCER FOCUSED BIOMARKER CHARACTERIZATION CENTER EMPLOYING TARGETED MASS SPEC ASSAYS IN A CLIA ENVIRONMENT - PROJECT SUMMARY/ABSTRACT (OVERALL COMPONENT, | $1,025,401 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | IDENTIFYING VULNERABILITIES IN THE LONG-LIVED HIV RESERVOIR TO ACCELERATE ITS DECAY - PROJECT SUMMARY LATENTLY INFECTED CD4+ T CELLS HARBORING INTEGRATED AND RE | $982,072 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | SYSTEMIC METABOLOMIC DYSREGULATION LINKING ENDOMETRIOSIS TO SUBSEQUENT CARDIOVASCULAR DISEASE - ABSTRACT CARDIOVASCULAR DISEASE (CVD) IS THE NUMBER ONE CAUSE OF | $947,180 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | TARGETING MICROBIAL TRIGGERS OF GAMMOPATHY FOR IMMUNOPREVENTION - ABSTRACT: MULTIPLE MYELOMA (MM) IS AN INCURABLE PLASMA CELL TUMOR PRECEDED BY A DEFINED PRENEO | $945,368 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MODELING TO SUPPORT DECISIONS IN AN EVOLVING LANDSCAPE OF PROSTATE CANCER CONTROL - PROJECT SUMMARY/ABSTRACT PROSTATE CANCER IS THE MOST COMMON SOLID TUMOR AND | $917,987 |
| 2026 | National Institutes of Health | Grant or other assistance | RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 | ACUPUNCTURE TO DECREASE SYMPTOM BURDEN IN PATIENTS WITH METASTATIC BREAST CANCER - ABSTRACT DUE TO ADVANCES IN TREATMENT, THE NUMBER OF PEOPLE LIVING WITH METAS | $916,473 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | NOVEL GENE EDITING APPROACHES FOR HEMOGLOBINOPATHIES | $904,885 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MUCOSAL REGULATORY T CELLS MODULATE THE RECALLED MEMORY T CELL RESPONSE - PROJECT SUMMARY TISSUE RESIDENT MEMORY T CELL RESPONSES (TRM) ARE WELL KNOWN FOR THEIR | $879,998 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAPPING THE B-CELL REPERTOIRE INDUCED BY HIV VACCINATION: A BIOINFORMATICS PLATFORM FOR INTEGRATED ANALYSIS OF B-CELL RECEPTOR SEQUENCES AND ANTIBODY FUNCTIONS | $879,407 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | CORE CENTER FOR STEM CELL AND TRANSPLANTATION BIOLOGY | $877,378 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GUIDING THE MATURATION OF ANTI-CD4-BS BNABS THROUGH SEQUENTIAL HETEROLOGOUS ENV IMMUNIZATION - PROJECT SUMMARY / ABSTRACT AN EFFECTIVE HIV-1 VACCINE WILL BE ONE | $876,168 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | ACTIFY! AN MHEALTH MOOD MANAGEMENT TOOL TO IMPROVE POPULATION-LEVEL SMOKING CESSATION - PROJECT SUMMARY CIGARETTE SMOKING IS RESPONSIBLE FOR OVER 480,000 DEATHS | $874,044 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | NEXT GENERATION METABOLIC SIGNATURES OF INFECTIOUS CAUSES OF VAGINITIS: SMALL MOLECULE METABOLITE-BASED BIOMARKERS FOR DIAGNOSIS, TEST-OF-CURE, AND PREDICTION O | $867,869 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLE OF LOCAL ANTIBODIES IN CONTROL OF CHRONIC GENITAL HERPES - PROJECT SUMMARY/ABSTRACT INFECTION WITH HERPES SIMPLEX VIRUS 2 (HSV-2) FOR WHICH THERE IS NO VAC | $865,722 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CROSS TALK BETWEEN KERATINOCYTES AND SKIN-RESIDENT T-CELLS INFLUENCES HSV RECURRENCE - PROJECT SUMMARY/ABSTRACT KERATINOCYTES, THE MAJOR BUILDING BLOCK OF SKIN | $862,878 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PREVENTING GVHD BY INHIBITION OF ALLOANTIGEN PRESENTATION IN THE GUT | $861,225 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHC | $860,779 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS) | $858,711 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEFINING THE PROTECTIVE EFFICACY OF ANTIBODIES AGAINST THE EBV GH/GL GLYCOPROTEIN COMPLEX | $857,804 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MOLECULAR BASIS AND PROTECTIVE EFFICACY OF CROSS-NEUTRALIZING ANTIBODIES AGAINST FOUR MAJOR RESPIRATORY VIRUSES - PROJECT SUMMARY/ABSTRACT TENS OF THOUSANDS OF | $857,757 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | PHYLODYNAMIC MECHANISMS OF HIV RESERVOIR SEEDING AND MAINTENANCE - PROJECT SUMMARY THE HIV RESERVOIR IS A POPULATION OF LATENTLY HIV INFECTED CELLS THAT PERSIST | $857,037 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | AN INTEGRATIVE OMICS APPROACH TO INVESTIGATE GENE-ENVIRONMENT INTERACTION IN COLORECTAL CANCER RISK - PROJECT SUMMARY/ABSTRACT COLORECTAL CANCER (CRC) REMAINS | $851,399 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | OPTIMIZING CLINIC-DELIVERED HIV PRE-EXPOSURE PROPHYLAXIS SERVICES WITH SELF-TESTING - ABSTRACT KENYA AND OTHER AFRICAN COUNTRIES ARE FACING SEVERAL CHALLENGES T | $850,388 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | METABOLITE- AND CYTOKINE-MEDIATED SIGNALS INTERACT TO CONTROL HUMAN CD8 T CELL RESPONSES IN TISSUES - PROJECT SUMMARY INHIBITORY MECHANISMS AND NEGATIVE FEEDBAC | $849,176 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SELECTIVE TARGETING OF THE PD-1+ HIV/SIV RESERVOIR WITH NOVEL ANTI-PD-1 CHIMERIC ANTIGEN RECEPTOR T CELLS - PROJECT SUMMARY/ABSTRACT HUMAN IMMUNODEFICIENCY VIRU | $843,750 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A NEW HUMANIZED MOUSE MODEL TO STUDY HBV GENE EDITING - PROJECT SUMMARY CHRONIC HEPATITIS B VIRUS (HBV) INFECTION (CHB) AFFECTS HUNDREDS OF MILLIONS OF PEOPLE A | $843,440 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEEP LEARNING-BASED PROTEIN DESIGN OF HIV-1 ENV GP120 CORE IMMUNOGENS FOR CD4 BINDING SITE GERMLINE TARGETING - PROJECT SUMMARY/ABSTRACT THIS RESEARCH PROPOSAL | $841,429 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEVELOPMENT OF MEASURES TO SCREEN FOR FINANCIAL HARDSHIP IN ALZHEIMER'S DISEASE AND DEMENTIA - PROJECT ABSTRACT/SUMMARY ALZHEIMER'S DISEASE AND RELATED DEMENTIA | $832,535 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | PROTEOGENOMIC STUDIES TO UNDERSTAND MECHANISMS AND DRIVERS OF RESISTANCE TO IMMUNOTHERAPIES - PROJECT SUMMARY/ABSTRACT MELANOMA IS THE DEADLIEST FORM OF SKIN CA | $829,054 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EARLY INTERVENTION WITH ANTI-PROLIFERATIVE THERAPY CLOSE TO ART INITIATION TO LIMIT LONG-TERM SIV PERSISTENCE - PROJECT SUMMARY HIV PERSISTS DESPITE DECADES OF | $828,228 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | CONSORTIUM ON TRANSLATIONAL RESEARCH IN EARLY DETECTION OF LIVER CANCER: DATA MANAGEMENT AND COORDINATING CENTER (DMCC) | $820,192 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPING DURABLE, ENV-BOOSTED CAR T CELLS FOR HIV CURE - PROJECT SUMMARY/ABSTRACT MODIFICATION OF AUTOLOGOUS T CELLS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) MOLE | $819,721 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS AND FUNCTIONS OF GLOBAL CHROMATIN CONTROL - PROJECT SUMMARY/ABSTRACT THE LONG TERM GOAL OF THE PROPOSED STUDY IS TO DETERMINE, AT THE MOLEC | $813,090 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | ACT ON VAPING: DIGITAL THERAPEUTIC FOR YOUNG ADULT VAPING CESSATION - ALMOST ONE IN TEN YOUNG ADULTS REPORT CURRENT E-CIGARETTE USE, PUTTING THEM AT RISK OF DEV | $812,783 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | BIOMARKERS FOR OPTIMIZING RISK PREDICTION AND EARLY DETECTION OF CANCERS OF THE COLON AND ESOPHAGUS - PROJECT SUMMARY GASTROINTESTINAL (GI) CANCERS ARE A MAJOR | $807,974 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEEPLY ANALYZING MHC CLASS I-RESTRICTED PEPTIDE PRESENTATION MECHANISTICS ACROSS ALLELES, PATHWAYS, AND DISEASE COUPLED WITH TCR DISCOVERY/CHARACTERIZATION - PR | $804,206 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | CLINICAL TRANSLATION OF A NEXGEN PLATFORM FOR QUANTIFYING PROTEIN NETWORKS IN HUMAN BIOSPECIMENS | $801,862 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | IMMUNE AGING AND OUTCOMES IN ADULT SURVIVORS OF CHILDHOOD CANCER - SUMMARY: CHILDHOOD CANCER SURVIVORS CARRY A HIGH BURDEN OF MORBIDITY RESULTING IN A SIGNIFICA | $798,501 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | PRECOMPETITIVE COLLABORATION ON LIQUID BIOPSY FOR EARLY CANCER ASSESSMENT: DATA MANAGEMENT AND COORDINATING UNIT - PROJECT SUMMARY LIQUID BIOPSY IS A CLINICAL T | $792,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | BASE-EDITED HEMATOPOIETIC STEM AND PROGENITOR CELLS TO ENABLE SAFE USE OF HIGHLY POTENT CD33-TARGETED RADIOIMMUNOTHERAPY - ABSTRACT ANTIGEN-SPECIFIC THERAPIES H | $790,449 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN AGING AND EXCEPTIONAL LONGEVITY IN OLDER WOMEN - THIS APPLICATION IS RESPONSIVE TO NOTICE OF SPECIAL INTEREST | $785,867 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEFINING PROTECTIVE CMV IMMUNITY AFTER TRANSPLANTATION - PROJECT SUMMARY/ABSTRACT CYTOMEGALOVIRUS (CMV) INFECTION IS A FREQUENT AND LIFE-THREATENING COMPLICATIO | $774,089 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DEFINING CRITICAL SITES OF VULNERABILITY AND CORRELATES OF PROTECTION TO KAPOSI SARCOMA ASSOCIATED HERPESVIRUS TO INFORM VACCINE DESIGN - PROJECT SUMMARY KAPOSI | $767,887 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | GENETIC AND MOLECULAR BASIS FOR SRSF2 MUTATIONS IN MYELODYSPLASIA | $764,771 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | METABOLOMIC MECHANISMS CONTRIBUTING TO PROSTATE CANCER RISK ACROSS MULTIPLE POPULATIONS - 1 2 PROSTATE CANCER (PCA) IS THE MOST COMMON CANCER AND SECOND LEADIN | $760,396 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | QUITQUEST: FULL SCALE RANDOMIZED TRIAL OF A NOVEL SMARTPHONE APPLICATION TO HELP TEENS STOP VAPING - PROJECT SUMMARY/ABSTRACT (DESCRIPTION) DESPITE RECENT DECL | $758,490 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | CD90-TARGETED NANOPARTICLES FOR IN VIVO HEMATOPOIETIC STEM CELL GENE THERAPY - PROJECT SUMMARY/ABSTRACT PATIENTS WITH GENETIC BLOOD DISEASES AND DISORDERS ARE C | $756,008 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DECIPHERING TUMOR HETEROGENEITY, METASTATIC SPREAD, AND TREATMENT RESISTANCE IN ADVANCED BLADDER CANCER - PROJECT SUMMARY/ABSTRACT METASTATIC BLADDER CANCER (MB | $752,751 |
| 2026 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | LEVERAGING TELEHEALTH TO OPTIMIZE PREP AND PEP DELIVERY AT PHARMACIES IN KENYA - ABSTRACT HIGHLY EFFECTIVE HIV PRE- AND POST-EXPOSURE PROPHYLAXIS (PREP AND PEP) | $750,792 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FORECASTING INFLUENZA EVOLUTION ON A HETEROGENEOUS IMMUNE LANDSCAPE - PROJECT SUMMARY INFLUENZA VIRUS EVOLVES RAPIDLY TO ESCAPE IMMUNITY ELICITED BY PRIOR INFEC | $744,369 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MEASURING PROVIDER AND INTERVENTION CHARACTERISTIC DETERMINANTS OF EVIDENCE-BASED CANCER CARE - PROJECT SUMMARY/ABSTRACT OVER THE LAST SEVERAL DECADES, NUMEROUS | $737,945 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | NONGENOTOXIC CONDITIONING FOR GENE THERAPY AND ALLOGENEIC TRANSPLANTATION IN FANCONI ANEMIA | $736,867 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | INVESTIGATING PTGES3 AS A NOVEL THERAPEUTIC TARGET IN ADVANCED PROSTATE CANCER - PROJECT SUMMARY / ABSTRACT THE ANDROGEN RECEPTOR (AR) IS A CENTRAL DRIVER OF PR | $736,383 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROBING HUMAN HSC GENESIS IN A FLOW-DIRECTED 3D HEMOGENIC VASCULAR NICHE MODEL - TITLE: PROBING HUMAN HSC GENESIS IN A FLOW-DIRECTED 3D HEMOGENIC VASCULAR NICHE | $729,547 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | USING A SMART DESIGN TO EVALUATE REMOTELY DELIVERED, CULTURALLY TAILORED WEIGHT LOSS INTERVENTIONS AMONG LATINA BREAST CANCER SURVIVORS - PROJECT SUMMARY / ABST | $728,300 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DISTINCTIVE FEATURES OF THE TUMOR-ASSOCIATED MICROBIOME IN EARLY-ONSET RECTAL CANCERS: ELUCIDATING THE MICROENVIRONMENT OF AN EMERGING DISEASE - PROJECT SUMMARY | $727,971 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | LONGITUDINAL IMPACT OF RESPIRATORY VIRUSES ON BRONCHIOLITIS OBLITERANS SYNDROME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS - PROJECT SUMMARY/ABSTRAC | $725,389 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DELINEATING THE ROLE OF 5’ UNTRANSLATED REGIONS IN PROSTATE CANCER CLONALITY - ABSTRACT PROSTATE CANCER IS A HIGHLY HETEROGENEOUS DISEASE EVEN WITHIN INDIVIDUAL | $723,547 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DEVELOPING CVD PREDICTION MODELS FOR WOMEN WITH EARLY STAGE BREAST CANCER - ABSTRACT IN A RENEWAL APPLICATION OF THE PATHWAYS HEART STUDY (R01CA214057), WE EXTE | $720,060 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | PROVIDING NICOTINE REPLACEMENT THERAPY TO ENHANCE THE EFFICACY OF A SMOKING CESSATION SMARTPHONE APP FOR HISPANIC ADULTS - PROJECT SUMMARY/ABSTRACT (DESCRIPTION | $719,916 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | SYNTHETIC INTRONS FOR SELECTIVE TARGETING OF RNA SPLICING FACTOR-MUTANT LEUKEMIA - SUMMARY MANY CANCERS CARRY RECURRENT, CHANGE-OF-FUNCTION MUTATIONS AFFECTING | $719,415 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | OPTIMIZING CD45-TARGETED ASTATINE-211-RADIOIMMUNOTHERAPY FOR MALIGNANT AND NON-MALIGNANT BLOOD DISORDERS - ABSTRACT CD45 IS EXPRESSED ON ALMOST ALL NORMAL AND N | $716,319 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | LUNG CANCER SUBTYPE RISK STRATIFICATION: VALIDATION IN REAL WORLD COHORTS - SUMMARY LUNG CANCER SCREENING (LCS) USING LOW DOSE COMPUTED TOMOGRAPHY (CT) CAN REDU | $714,192 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMPACT OF KEAP1/NRF2 ON THERAPY RESPONSE IN LUNG NEUROENDOCRINE CANCERS - SUMMARY SCLC IS EXQUISITELY SENSITIVE TO CHEMOTHERAPY BUT RAPID EMERGENCE OF CHEMORESI | $712,569 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | CLONAL HEMATOPOIESIS IN THE WOMENS HEALTH INITIATIVE MEMORY STUDY | $707,028 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DEEP MOLECULAR AND CELLULAR PROFILING OF COLORECTAL CANCER TUMOR AND IMMUNE MICROENVIRONMENT IN ALASKA NATIVE PEOPLE - PROJECT SUMMARY ALASKA NATIVE PEOPLE HAVE | $705,202 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | LEVERAGING METABOLOMICS TO IDENTIFY FACTORS CONTRIBUTING TO HEALTH DISPARITIES IN NATIVE HAWAIIAN INDIVIDUALS - 1 2 NATIVE HAWAIIAN INDIVIDUALS REPRESENT ONE O | $701,442 |
| 2026 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | IN VIVO GENE EDITING OF B CELLS WITH NICE-AAV VECTORS - ABSTRACT HIV-SPECIFIC GENE THERAPIES ARE A POWERFUL AND PROMISING MEANS TO ACHIEVE HIV CURE/STABLE REMIS | $699,738 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | OPTIMIZING THE DOSING OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION - PROJECT SUMMARY ALLOGENEIC HEMATOPOIETIC CELL TR | $695,155 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | EXAMINATION OF FACTORS INFLUENCING THE RACIAL DISPARITY IN FIBROID INCIDENCE - PROJECT SUMMARY UTERINE FIBROIDS ARE THE MOST COMMON PELVIC TUMORS IN WOMEN OF R | $694,699 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING THE TUMOR MICROENVIRONMENT WITH ENGINEERED CD4+ T CELLS - ABSTRACT NOVEL IMMUNE THERAPIES ARE NEEDED TO HELP THE MAJORITY OF PATIENTS WITH MELANOMA AN | $693,882 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | THE MYC TRANSCRIPTION FACTOR NETWORK: ELUCIDATING ONCOGENIC AND TUMOR SUPPRESSIVE PATHWAYS - PROJECT SUMMARY/ABSTRACT THIS APPLICATION IS FOCUSED ON THE MYC NET | $692,368 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMPROVING IMMUNE MODULATION FOR SMOLDERING MYELOMA - SUMMARY ALL CASES OF MULTIPLE MYELOMA (MM) ARE PRECEDED BY PRECURSOR STATE TERMED AS MONOCLONAL GAMMOPATHY | $687,233 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | RATIONAL VACCINE DESIGN TO PREVENT HIV-ASSOCIATED LYMPHOMA - PROJECT SUMMARY/ABSTRACT RELATIVE TO THE GENERAL POPULATION, HIV-INFECTED INDIVIDUALS HAVE A 60–20 | $685,055 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HEMATOPOPIETIC STEM CELL TRANSPLANTATION | $683,225 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | DEVELOPING METHODS FOR ADVANCING THE EARLY DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA LEVERAGING ELECTRONIC MEDICAL RECORDS DATA - PROJECT SUMMARY PANCREATIC | $674,211 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | AUGMENTING PSMA EXPRESSION TO ENHANCE PSMA DIRECTED THERAPEUTIC EFFICACY - PROJECT SUMMARY/ABSTRACT DESPITE TREATMENT ADVANCES OVER THE PAST DECADE, METASTATIC | $667,980 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMMUNO AND EPIGENETICS OF HEMATOPOIETIC CELL TRANSPLANTATION | $666,880 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | DLK1 REGULATES HSC QUIESCENCE THROUGH PHASE SEPARATION MEDIATED INHIBITION OF RECEPTOR SIGNALING - PROJECT SUMMARY: WHILE MUCH IS KNOWN ABOUT FACTORS THAT STIMU | $666,715 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | HUTCHINSON CENTER AS LEAD ACADEMIC PARTICIPATING SITE (UG1) | $657,177 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | ROLE OF NECROSIS IN THE EVOLUTION OF HIGHLY METASTATIC AND CHEMO-RESISTANT BREAST CANCERS - HIGH-GRADE, FAST-GROWING BREAST CANCERS OFTEN DISPLAY NECROSIS, USUA | $650,494 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | BREASTMILK ANTIBODIES REGULATE NEONATAL IMMUNITY TO THE MICROBIOTA - PROJECT SUMMARY TO MAINTAIN HEALTH, THE HOST MUST AVOID GENERATING INFLAMMATORY RESPONSES T | $648,715 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | MAPK-DRIVEN KINETOCHORE STRESS IN CANCER - SUMMARY KINETOCHORES (KTS) ARE LARGE PROTEIN STRUCTURES ASSEMBLED UPON CENTROMERES DURING MITOSIS THAT BIND TO MICROT | $646,440 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MEMBRANE CURVATURE SENSING MECHANISMS FOR SYNAPTIC VESICLE ENDOCYTOSIS | $638,385 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | FECAL MICROBIOTA TRANSPLANTATION AND FIBER FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION - PROJECT SUMMARY ALLOGENEIC | $627,095 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | NOVEL APPROACHES TO CD33-DIRECTED RADIOIMMUNOTHERAPY | $618,999 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | PLANAR CELL POLARITY CONTROL OF AXON GUIDANCE - PROJECT SUMMARY MIDLINE CROSSING BY DORSAL COMMISSURAL AXONS IS A PROMINENT FEATURE OF VERTEBRATE AND INVERTEBRA | $616,225 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | BIOPHYSICAL AND STRUCTURAL STUDIES OF PROTEIN AND ENZYME MECHANISM, EVOLUTION, AND ENGINEERING - PROJECT SUMMARY/ABSTRACT AMONG THE SEVERAL ONGOING REVOLUTIONS | $616,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS OF DYNAMIC CYTOSKELETON AND MEMBRANE INTERACTIONS - PROJECT SUMMARY/ABSTRACT DYNAMIC INTERACTIONS BETWEEN INTERCELLULAR MEMBRANES AND THE CORTICAL CY | $613,838 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DISSECTING MCPYV ALTO TRANSCRIPTION AND TUMOR SUPPRESSION - PROJECT SUMMARY/ABSTRACT MERKEL CELL CARCINOMA (MCC) IS A DEADLY SKIN CANCER THAT IS PRIMARILY CAUSE | $610,984 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MOLECULAR MECHANISMS BY WHICH GLIA ENGULF NEURON-ENDINGS - PROJECT SUMMARY GLIA, WHICH IN HUMAN BRAINS APPROXIMATE NEURONS IN NUMBER, INTERACT WITH NEURONS TO | $609,484 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | MODULATION OF SIGNALING FROM DAMAGE-ASSOCIATED MOLECULAR PATTERNS TO IMPROVE RADIATION-INDUCED THYMIC DYSFUNCTION - PROJECT SUMMARY THE THYMUS, WHICH IS THE PR | $606,406 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | EVALUATING PROSTATE CANCER PHENOTYPE AND GENOTYPE CLASSIFICATION FROM CIRCULATING TUMOR DNA AS BIOMARKERS FOR PREDICTING TREATMENT OUTCOMES - PROJECT SUMMARY/AB | $602,496 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TRANSLATING AUTOANTIBODIES INTO CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY FOR SMALL CELL LUNG CANCER - ABSTRACT FOR THE LAST 30 YEARS, THE 5-YEAR SURVIVAL RATE O | $602,150 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | PROACT: PROMOTING FOLLOW-UP OF ABNORMAL COLORECTAL CANCER SCREENING TESTS THROUGH MULTILEVEL INTERVENTIONS - PROJECT SUMMARY/ABSTRACT COLORECTAL CANCER (CRC) DE | $601,829 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | AUTOANTIBODIES TO TUMOR-DERIVED NEOEPITOPES AS BIOMARKERS AND IMMUNOPET AGENTS FOR THE EARLY DETECTION OF SMALL CELL LUNG CANCER - PROJECT SUMMARY/ABSTRACT SMA | $597,523 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | NEUTROPHIL DERIVED PROTEINASES ABOLISH THE IFNG SIGNATURE IN NSCLC - ABSTRACT ALTHOUGH IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY HAS BEEN A TREMENDOUS CLINICAL | $584,823 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | INTERROGATING ROLES FOR REST IN SMALL CELL LUNG CANCER THERAPY RESPONSE AND RESISTANCE - SUMMARY SMALL CELL LUNG CANCER (SCLC) IS A LETHAL TUMOR TYPE CHARACTERI | $582,076 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MECHANISMS AND CONSEQUENCE OF HELICAL SHAPE GENERATION IN HELICOBACTER PYLORI | $578,926 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | TRANSCRIPTIONAL-TRANSLATIONAL CONFLICT IN BLADDER EPITHELIAL HOMEOSTASIS AND CANCER - ABSTRACT CHROMATIN REMODELING AND PROTEIN SYNTHESIS ARE TIGHTLY REGULATED | $569,061 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | EVALUATING CENTRALIZING INTERVENTIONS TO ADDRESS LOW ADHERENCE TO LUNG CANCER SCREENING FOLLOW-UP IN DECENTRALIZED SETTINGS - PROJECT SUMMARY/ABSTRACT LUNG CAN | $562,948 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMPROVING CAR-T EFFICACY AGAINST SOLID TUMORS BY EXPANDING LYMPH NODE RESERVOIRS OF ?STEM-LIKE? CAR-T CELLS - PROJECT SUMMARY/ABSTRACT IMMUNOTHERAPY USING CAR-T | $555,917 |
| 2026 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | STATISTICAL METHODS FOR INFERRING GENE-PHENOTYPE ASSOCIATIONS USING OMIC DATA FROM GENE KNOCKOUT AND HUMAN PHENOTYPE STUDIES - PROJECT SUMMARY THE PHASE 1 OF TH | $551,382 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | INTERROGATING A NOVEL AXIS OF TUMOR SUPPRESSION IN SMALL CELL LUNG CANCER - SUMMARY SMALL CELL LUNG CANCER (SCLC) IS AN AGGRESSIVE CANCER TYPE WITH NO TARGETED | $548,915 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | IMMUNOGLOBULIN REPLACEMENT THERAPY AND INFECTIOUS COMPLICATIONS AFTER CD19-TARGETED CAR-T-CELL THERAPY - PROJECT SUMMARY/ABSTRACT CHIMERIC ANTIGEN RECEPTOR T CE | $545,260 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | OPTIMIZING PANCREATIC CANCER MANAGEMENT WITH NEXT GENERATION IMAGING AND LIQUID BIOPSY - PROJECT SUMMARY: PANCREATIC DUCTAL ADENOCARCINOMA (PDA) WILL BECOME TH | $544,053 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GENETIC REQUIREMENTS OF HELICOBACTER PYLORI INFECTION | $543,827 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | DEFINING THE CONTRIBUTION OF HIV DIVERSITY TO INFANT IMMUNITY - ABSTRACT DEVELOPING AN EFFECTIVE HIV VACCINE HAS BEEN REMARKABLY CHALLENGING IN PART BECAUSE ATT | $536,918 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | EXPANDING THE CANCER PARALOG GENETIC INTERACTION MAP TO ENABLE PRECISION ONCOLOGY - PROJECT SUMMARY/ABSTRACT RECENT ADVANCES IN TARGETED THERAPIES HAVE PROLONGE | $530,439 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | IDENTIFYING AND UNDERSTANDING DRIVERS OF CHEMORESISTANCE IN SMALL CELL LUNG CANCER - SUMMARY SMALL CELL LUNG CANCER (SCLC) IS AN AGGRESSIVE AND LETHAL NEUROENDO | $530,048 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ENHANCING DATA SCIENCE SKILLS THROUGH BIO-OCS - BIOMEDICAL OPEN CASE STUDIES - PROJECT SUMMARY/ABSTRACT DRAMATIC ADVANCES IN ARTIFICIAL INTELLIGENCE, SINGLE CEL | $525,148 |
| 2026 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | DIFFERENTIATION BALANCES ONCOGENE-DRIVEN PROLIFERATION TO MAINTAIN EPIDERMAL HOMEOSTASIS | $518,607 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | SIGNALING PATHWAYS THAT MODULATE NEURONAL ACTIVITY | $512,963 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DECIPHERING LONG-TERM VIRUS EVOLUTION THROUGH THE RECONSTRUCTION OF PAST VIRAL GENOMES - PROJECT SUMMARY VIRUSES HAVE IMPOSED A SIGNIFICANT GLOBAL BURDEN OF MOR | $509,299 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | TISSUE MECHANISMS OF AGING IN THE GENETIC MODEL C. ELEGANS - PROJECT SUMMARY/ABSTRACT THE NEMATODE C. ELEGANS IS A LEADING EXPERIMENTAL AND GENETIC MODEL FOR AG | $506,014 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | STATISTICAL METHODS FOR PRECISION PREVENTION - PROJECT SUMMARY/ABSTRACT PREVENTION HOLDS THE GREATEST POTENTIAL FOR REDUCING CANCER BURDEN IN THE POPULATION. R | $505,613 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS | $497,934 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | HARNESSING LARGE BIOBANKS TO DECIPHER CANCER PLEIOTROPY - PROJECT SUMMARY GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE IDENTIFIED NUMEROUS PLEIOTROPIC CANCER RIS | $487,902 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | SEER*EDUCATE BASE AWARD | $486,001 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MAPPING AND PREDICTION OF EPISTATIC ENHANCER INTERACTIONS IN GENE REGULATION - PROJECT SUMMARY GENE REGULATION IS A FUNDAMENTAL BIOLOGICAL PROCESS THROUGH WHICH | $484,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING MECHANISMS THAT UNDERLIE WELL-CONTROLLED TRANSLATION INITIATION - PROJECT SUMMARY TRANSLATION INITIATION DETERMINES THE IDENTITY AND AMOUNT OF A SYNTHE | $484,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | VISUALIZATION OF NATIVE CHROMATIN-ASSOCIATED COMPLEXES TO ELUCIDATE CHROMATIN REGULATORY MECHANISMS - PROJECT SUMMARY CHROMATIN ORGANIZES INTO DISTINCT FUNCTION | $484,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETING PLK1 SIGNALING FOR THE TREATMENT OF FIBROLAMELLAR CARCINOMA - PROJECT SUMMARY FIBROLAMELLAR CARCINOMA (FLC) IS A CHILDHOOD LIVER CANCER WITH A HIGH CA | $473,280 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | UNDERSTANDING AND EXPLOITING NOVEL THERAPEUTIC VULNERABILITIES OF RIT1-DRIVEN LUNG CANCER - PROJECT SUMMARY/ABSTRACT RECENT ADVANCES IN TARGETED THERAPIES HAVE | $467,377 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE FBW7 UBIQUITIN LIGASE NETWORK: NORMAL AND NEOPLASTIC FUNCTIONS - THIS APPLICATION FOCUSES ON FBW7, AN E3 UBIQUITIN LIGASE AND TUMOR SUPPRESSOR, AND ON ITS S | $461,553 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MECHANISM OF MODULATION OF INTESTINAL IMMUNE RESPONSES BY DIETARY SIGNALS - PROJECT SUMMARY THE INTESTINE SERVES BOTH AS A CONDUIT FOR THE UPTAKE OF FOOD-DERIV | $455,407 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | STATISTICAL METHODS TO LEVERAGE IMMUNOLOGIC BIOMARKERS AND COMPLEX MOLECULAR TESTING DATA FOR RESPIRATORY DISEASES VACCINES DEVELOPMENT - PROJECT SUMMARY/ABSTRA | $448,573 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | TOPOGRAPHIC MAPPING BY CRANIAL MOTOR NEURONS | $443,010 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | STATISTICAL METHODS FOR ANALYZING OBJECTIVELY MEASURED PHYSICAL ACTIVITY DATA | $442,520 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISTIC CHARACTERIZATION OF THE REPLICATION STRESS RESPONSE - PROJECT SUMMARY ACCURATE DNA REPLICATION IS A FUNDAMENTAL PROCESS THAT GOVERNS THE SURVIVAL OF | $440,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UNDERSTANDING METABOLIC FUNCTIONS OF MITOCHONDRIA IN PROLIFERATING CELLS - PROJECT SUMMARY CELL METABOLISM IS THE COLLECTION OF BIOCHEMICAL PROCESSES THAT SUPPO | $440,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | THE MOLECULAR BASIS FOR INTEGRIN-MEDIATED BIDIRECTIONAL SIGNALING - LEUKOCYTES ARE ESSENTIAL IMMUNE COMPONENTS PROTECTING THE BODY AGAINST FOREIGN INVADERS. ADH | $440,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | DORMANCY-DEPENDENT DETERMINATION OF HEMATOPOIETIC STEM CELL FATE FROM HEMOGENIC ENDOTHELIUM - TITLE: DORMANCY-DEPENDENT DETERMINATION OF HEMATOPOIETIC STEM CELL | $440,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | METHODS FOR MICROSIMULATION MODEL CALIBRATION - PROJECT SUMMARY MICROSIMULATION MODELING IS A POWERFUL TOOL FOR USING SCIENTIFIC EVIDENCE TO INFORM HEALTH POLIC | $439,639 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | IMMUNOGENETICS OF OUTCOMES DISPARITIES AFTER ALLOGENEIC HCT | $438,973 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | STRATEGIES TO ENHANCE ADOPTIVE TRANSFER T CELL CLONES | $435,730 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | PATHWAYS TO CANCER RESEARCH | $432,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DATA ANALYSIS TOOLS FOR LEVERAGING MASSIVE PUBLIC DATA TO IMPROVE HYPOTHESIS-DRIVEN RESEARCH - PROJECT SUMMARY THERE IS A CRISIS OF REPRODUCIBILITY AND REPLICAB | $431,963 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | INVESTIGATING HOW CELLULAR MECHANISMS INTERFACE TO MAINTAIN ENERGY BALANCE | $426,793 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | COMPUTATIONAL MODELING OF LINEAGE DECISIONS USING SINGLE-CELL DATA - PROJECT SUMMARY CELLULAR DIFFERENTIATION IS A FUNDAMENTAL BIOLOGICAL PROCESS THROUGH WHICH | $424,868 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | STATISTICAL METHODS FOR ADVANCING HIV PREVENTION - PROJECT SUMMARY/ABSTRACT ANTIRETROVIRAL-BASED HIV PROPHYLAXIS IS HIGHLY EFFECTIVE AT PREVENTING ACQUISITION | $419,125 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | STATISTICAL METHODS FOR RNA-SEQ DATA ANALYSIS | $413,604 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | OPTIMIZING PRE-ANALYTICAL VARIABLES FOR RELIABLE MASS SPECTROMETRY-BASED QUANTIFICATION OF IMMUNOMODULATORY PROTEINS IN CEREBROSPINAL FLUID IN PEDIATRIC NEURO-O | $405,509 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DISPARITIES IN FINANCIAL AND CLINICAL OUTCOMES AMONG COMMERCIALLY-INSURED CANCER PATIENTS FOLLOWING THE AFFORDABLE CARE ACT - PROJECT SUMMARY/ABSTRACT DEMOGRAPH | $402,600 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | ROLE OF TUMOR CELL CLUSTER-INDUCED SIGNALING IN BREAST CANCER METASTASIS | $402,600 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | TARGETING VULNERABILITIES EXPOSED BY CANCER TREATMENT-INDUCED LINEAGE PLASTICITY - SUMMARY/ABSTRACT THE AR MAY BE THE EARLIEST KNOWN EXAMPLE OF A LINEAGE ONCOGE | $402,600 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | ACCELERATING BIOMARKER DEVELOPMENT THROUGH NOVEL STATISTICAL METHODS FOR ANALYZING PHASE III/IV STUDIES - PROJECT SUMMARY/ABSTRACT THE MULTITUDE OF CANDIDATE CA | $401,719 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | STATISTICAL METHODS FOR NETWORK-BASED INTEGRATIVE ANALYSIS OF MICROBIOME DATA - PROJECT SUMMARY THE PAST DECADE HAS SEEN SUBSTANTIAL PROGRESS IN THE DISCOVERY O | $356,046 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | PEDIARIC ONCOLOGY RESEARCH TRAINING PROGRAM | $353,645 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS UNDERLYING CHROMOSOME SEGREGATION - PROJECT SUMMARY ACCURATE CELL DIVISION IS ESSENTIAL FOR THE DEVELOPMENT OF ALL ORGANISMS. DURING EACH CELL CYCLE, | $352,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TRANSLATIONAL EPIGENOMICS IN GASTROINTESTINAL CANCER | $345,951 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | A PROTEOMICS RESEARCH SPECIALIST IN DEVELOPING TARGETED MASS SPECTROMETRY METHODS FOR QUANTIFYING PROTEINS IMPORTANT IN CANCER | $310,761 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | STATISTICAL METHODS FOR ENHANCED MAPPING OF MICROBIOME RELATIONSHIPS - PROJECT SUMMARY/ABSTRACT THE HUMAN MICROBIOME IS INTEGRALLY RELATED TO A VAST RANGE OF HU | $295,702 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ASSESSING THE LONGITUDINAL IMPACT OF VRC01 PROPHYLAXIS ON VIRAL POPULATIONS AND AUTOLOGOUS ANTIBODY RESPONSES IN BREAKTHROUGH INFECTIONS - SUMMARY DESPITE SIGNI | $278,333 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MULTIPLEX BINDING ANTIBODY ASSAY FOR CONFIRMATORY HSV-1/2 SEROLOGICAL DIAGNOSIS - PROJECT SUMMARY/ABSTRACT HERPES SIMPLEX VIRUS TYPES 1 AND 2 (HSV-1/2) ARE MAJO | $270,591 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | BLOOD & MARROW CLINICAL TRIALS NETWORK- HUTCHINSON CENTER AS CORE CLINICAL SITE | $264,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CLONAL LINEAGE TRACING OF HIV SPECIFIC NK MEMORY CELLS - ABSTRACT IMMUNE MEMORY IS A CRITICAL ASPECT OF ADAPTIVE IMMUNITY. THE PRESENCE OF ANTIGEN-SPECIFIC MEMO | $264,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | EDYNAMIC - FREDHUTCH - EDYNAMIC (EXTRACHROMOSOMAL DNA IN CANCER) HUMAN GENES ARE ARRANGED ON 23 PAIRS OF CHROMOSOMES, BUT IN CANCER, TUMOUR-PROMOTING GENES CAN | $263,616 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | HARNESSING EXERCISE TO ENHANCE IMMUNITY AND BOOST IMMUNOTHERAPY OUTCOMES IN PATIENTS WITH LUNG CANCER - PROJECT SUMMARY OVERVIEW: 1.8 MILLION PEOPLE DIE OF LUNG | $249,000 |
State business registration
- FRED HUTCHINSON CANCER CENTER, INC. FL, Foreign nonprofit corporation (FORNP), Active, formed 2020-11-17
The same business name in the same state, from the state’s official registry data.
Patents
81 US patents filed in the last 20 years; 2 security interests recorded against them.
- Fred Hutchinson Cancer Center 81 patents, 2022-06-14 to 2026-10-13 EXACT high confidence: identical full name and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12760361 | Compositions and methods for accurately identifying mutations | 2026-10-13 | PTBLXML, file of 2026-10-13 |
| US 12758614 | Augmenting antigen-negative cell death in antigen-targeted immunotherapies | 2026-10-13 | PTBLXML, file of 2026-10-13 |
| US 12758582 | Anti-CD33 antibodies and uses thereof | 2026-10-13 | PTBLXML, file of 2026-10-13 |
| US 12747473 | Compositions and methods for accurately identifying mutations | 2026-09-29 | PTBLXML, file of 2026-09-29 |
| US 12741001 | Compositions and methods for providing hematopoietic function without HLA matching | 2026-09-22 | PTBLXML, file of 2026-09-22 |
| US 12714722 | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor | 2026-08-25 | PTBLXML, file of 2026-08-25 |
| US 12662546 | Human anti-CD33 antibodies and uses thereof | 2026-06-23 | PTBLXML, file of 2026-06-23 |
| US 12653886 | T-cell immunotherapy specific for WT-1 | 2026-06-16 | PTBLXML, file of 2026-06-16 |
| US 12624396 | Methods for alleviating facioscapulohumeral dystrophy (FSHD) by an antisense nucleic acid molecule inhibiting the expression of double homeobox 4 (DUX4) | 2026-05-12 | PTBLXML, file of 2026-05-12 |
| US 12600801 | Single-domain antibodies that bind ROR1 | 2026-04-14 | PTBLXML, file of 2026-04-14 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Trademarks
9 US trademarks, 7 live.
- Fred Hutchinson Cancer Center 9 marks, WA EXACT high confidence: identical full name and state
| Mark | Serial | Filed | Status | Source |
|---|---|---|---|---|
| LOOK BEYOND | 98192620 | 2023-09-22 | Pending application | TRTDXFAP, file of 2026-10-16 |
| CURE CANCER FASTER | 98063687 | 2023-06-28 | Registered | TRTYRAP, file of 2026-04-03 |
| H FRED HUTCH CANCER CENTER | 97522830 | 2022-07-27 | Registered | TRTYRAP, file of 2026-04-03 |
| H | 97522720 | 2022-07-27 | Abandoned | TRTYRAP, file of 2026-04-03 |
| H | 97522434 | 2022-07-27 | Registered | TRTYRAP, file of 2026-04-03 |
| FRED HUTCH CANCER CENTER | 97437754 | 2022-06-01 | Registered | TRTYRAP, file of 2026-04-03 |
| LIFE BEYOND CANCER | 97374524 | 2022-04-21 | Abandoned | TRTYRAP, file of 2026-04-03 |
| FRED HUTCH | 86282740 | 2014-05-15 | Registered and renewed | TRTYRAP, file of 2026-04-03 |
| OBLITERIDE | 85696976 | 2012-08-07 | Registered and renewed | TRTYRAP, file of 2026-04-03 |
The newest marks of the trademark owners above, matched to this record by name (and state).
Comments